Public Summary Documents by Product

Page last updated: 10 November 2023

A | B | C | D | E | F | G | H | I | J K L | M | N | O | P | Q | R | S | T | U V W | X Y Z |

A

• Abacavir sulfate with Lamivudine, tablet, 600 mg (base) - 300 mg, Kivexa®, July 2005
• Abatacept: 125mg SC injection (auto-injector and pre-filled syringe) and 250mg vial for IV infusion; Orencia® - March 2018
• Abatacept: 125mg/mL injection, 4 x 1mL autoinjector; Orencia® - November 2015
• Abatacept, powder for I.V. infusion, 250 mg, Orencia® - July 2011
• Abatacept, powder for I.V. infusion, 250 mg, Orencia®, November 2007
• Abemaciclib: Tablet 50 mg, Tablet 100 mg, Tablet 150 mg; Verzenio® - March 2023
• Abemaciclib: Tablet 50 mg, Tablet 100 mg, Tablet 150 mg; Verzenio™ - March 2022
•  Abemaciclib: Tablet 150 mg, Tablet 100 mg, Tablet 50 mg; Verzenio® - March 2021
• Abemaciclib: Tablet 50 mg, Tablet 100 mg, Tablet 150 mg; Verzenio® - March 2019
• Abiraterone and methylprednisolone: Pack containing 120 tablets abiraterone (as acetate) 125 mg and 30 tablets methylprednisolone 4 mg; Yonsa Mpred® - July 2023
• Abiraterone and Methylprednisolone: Pack containing 120 tablets abiraterone (as acetate) 125 mg and 60 tablets methylprednisolone 4 mg; Yonsa® Mpred™ - November 2022
• Abiraterone and methylprednisolone: Pack containing 120 tablets abiraterone (as acetate) 125 mg and 60 tablets methylprednisolone 4 mg; Yonsa® MPRED - March 2022
• Abiraterone: Tablet 500 mg; Zytiga® - July 2017
• Abiraterone: Tablet 250 mg; Zytiga® - March 2017
• Abiraterone Acetate, tablet, 250 mg, Zytiga®, Janssen-Cilag Pty Ltd - July 2014
• Abiraterone tablet, 250 mg (as acetate), Zytiga® - November 2012
• Abiraterone ,tablet, 250 mg (as acetate), Zytiga® - July 2012
• Abiraterone, tablet, 250 mg (as acetate), Zytiga® - March 2012
• Abiraterone, tablet, 250 mg (as acetate), Zytiga®, November 2011
• Acalabrutinib: Tablet 100 mg; Calquence® - July 2023
• Acalabrutinib: Capsule 100 mg; Calquence® - March 2023
• Acalabrutinib: Capsule 100 mg; Calquence® – December 2022
• Acalabrutinib: Capsule 100 mg; Calquence® - November 2021
• Acalabrutinib: Capsule 100 mg; Calquence® - July 2021
• Acalabrutinib: Capsule 100 mg; Calquence® - July 2020
• Acalabrutinib: Capsule 100 mg; Calquence® - March 2020
• Aciclovir: Eye ointment 30 mg per g, 4.5 g; Xorox® - March 2021
• Aciclovir; 30mg/g (3%) eye ointment, 4.5g; Acivision® - July 2015
• Aclidinium Bromide, 400 microgram/actuation inhalation: powder for, 60 actuations, Bretaris® Genuair® - March 2014
• Aclidinium bromide with eformoterol fumarate dehydrate; aclidinium 340 microgram/actuation + eformoterol 12 microgram/actuation inhalation: powder for, 60 actuations; Brimica® Genuair® - July 2015
• Adalimumab: Injection 40 mg in 0.4 mL pre-filled pen, Injection 40 mg in 0.4 mL pre-filled syringe, Injection 80 mg in 0.8 mL pre-filled syringe; Ardalicip® - July 2023
• Adalimumab: Injection 20 mg in 0.2 mL pre-filled syringe, Injection 40 mg in 0.4 mL pre-filled pen, Injection 40 mg in 0.4 mL pre-filled syringe, Injection 80 mg in 0.8 mL pre-filled pen, Injection 80 mg in 0.8 mL pre-filled syringe; Humira® and Upadacitinib: Tablet 15 mg; Rinvoq® - November 2022
• Adalimumab: Injection 40 mg in 0.4 mL pre-filled pen, Injection 40 mg in 0.4 mL pre-filled syringe; Yuflyma® - July 2022
• Adalimumab: Injection 80 mg in 0.8 mL pre-filled syringe; Humira® - November 2021
• Adalimumab: Injection 40 mg in 0.8 mL pre-filled pen, Injection 40 mg in 0.8 mL pre-filled syringe; Hulio® - November 2021
• Adalimumab: Injection 20 mg in 0.4 mL pre-filled syringe, Injection 40 mg in 0.8 mL pre-filled syringe, Injection 40 mg in 0.8 mL pre-filled pen; Abrilada® - July 2021
• Adalimumab: Injection 40 mg in 0.8 mL pre-filled syringe, Injection 40 mg in 0.8 mL single dose autoinjector; Hadlima® - November 2020
• Adalimumab: Injection 40 mg in 0.8 mL pre-filled pen, Injection 40 mg in 0.8 mL pre-filled syringe, Injection 40 mg in 0.8 mL vial; Idacio® - November 2020
•  Adalimumab: Injection 40 mg in 0.8 mL pre-filled syringe, Injection 40 mg in 0.8 mL single dose autoinjector; Hadlima® - July 2020
• Adalimumab: Injection 40 mg in 0.8 ml pre-filled syringe, 2; Injection 40 mg in 0.8 ml pre-filled pen, 2; Injection 40 mg in 0.8 ml pre-filled syringe, 6; Injection 40 mg in 0.8 ml pre-filled pen, 6; Hyrimoz® - March 2020
• Adalimumab: Injection 80 mg in 0.8 mL pre-filled pen, Injection 80 mg in 0.8 mL pre-filled syringe; Humira® - November 2019
• Adalimumab: Injection 20 mg in 0.4 mL pre-filled syringe; Injection 40 mg in 0.8 mL pre-filled syringe; Injection 40 mg in 0.8 mL pre-filled pen; Amgevita® - July 2018
• Adalimumab: Injection 40 mg in 0.8 mL pre-filled syringe; Injection 40 mg in 0.8 mL single dose autoinjector; Hadlima® - July 2018
• Adalimumab: Injection 20 mg in 0.2 mL pre-filled syringe; Injection 80 mg in 0.8 mL pre-filled pen; Humira® - July 2018
• Adalimumab: Injection 40 mg in 0.4 mL pre-filled syringe and Injection 40 mg in 0.4 mL pre-filled pen; Humira® - December 2017
• Adalimumab: Injection 40 mg in 0.8 mL vial; Humira® - July 2017
• Adalimumab: Injection 40 mg in 0.8 mL pre-filled syringe, Injection 40 mg in 0.8 mL pre-filled pen; Humira® - March 2017
• Adalimumab: Injection 40 mg in 0.8 mL pre-filled pen, Injection 40 mg in 0.8 mL pre-filled syringe; Humira® - November 2016
• Adalimumab; 20 mg/0.4 ml injection, 2 x 0.4 ml syringes, 40 mg/0.8 ml injection, 2 x 0.8 ml cartridges, 40 mg/0.8 ml injection, 2 x 0.8 ml syringes, 40 mg/0.8 ml injection, 6 x 0.8 ml cartridges, 40 mg/0.8 ml injection, 6 x 0.8 ml syringes; Humira® - November 2014
• Adalimumab: 40 mg/0.8 mL injection, 2 × 0.8 mL cartridges, 40 mg/0.8 mL injection, 2 × 0.8 mL syringes, 40 mg/0.8 mL injection, 6 × 0.8 mL cartridges, 40 mg/0.8 mL injection, 6 × 0.8 mL syringes, Humira® - July 2016
• Adalimumab: 40 mg/0.8 mL injection, 2 x 0.8 mL cartridges 40 mg/0.8 mL injection, 2 x 0.8 mL syringes 40 mg/0.8 mL injection, 6 x 0.8 mL cartridges 40 mg/0.8 mL injection, 6 x 0.8 mL syringes, Humira® - March 2016
• Adalimumab: 40 mg/0.8 mL injection, 2 x 0.8 mL cartridges 40 mg/0.8 mL injection, 2 x 0.8 mL syringes 40 mg/0.8 mL injection, 6 x 0.8 mL cartridges 40 mg/0.8 mL injection, 6 x 0.8 mL syringes , Humira® - March 2016
• Adalimumab: 40 mg/0.8 mL injection, 2 x 0.8 mL cartridges; 40 mg/0.8 mL injection, 2 x 0.8 mL syringes; 40 mg/0.8 mL injection, 6 x 0.8 mL cartridges;40 mg/0.8 mL injection, 6 x 0.8 mL syringes, Humira® - November 2015
• Adalimumab; 40 mg/0.8 mL injection, 2 x 0.8 mL cartridges; 40 mg/0.8 mL injection, 2 x 0.8 mL syringes; 40 mg/0.8 mL injection, 6 x 0.8 mL cartridges; 40 mg/0.8 mL injection, 6 x 0.8 mL syringes; Humira® - July 2015
• Adalimumab, 40 mg/0.8 mL injection, 2 x 0.8 mL cartridges and 2 x 0.8 mL syringes, 40 mg/0.8 mL injection, 6 x 0.8 mL cartridges and 6 x 0.8 mL syringes, Humira® - July 2014
• Adalimumab, 40mg/0.8mL injection, 0.8 mL cartridges and 0.8mL syringes, Humira® - November 2013
• Adalimumab, injection, 40 mg in 0.8 mL pre-filled syringe, 40 mg in 0.8 mL pre-filled pen, Humira® - March 2013
• Adalimumab, injection, 20 mg in 0.4 mL, 40 mg in 0.8 mL, pre-filled syringe, Humira® - March 2010
• Adalimumab, 40 mg in 0.8 mL pre-filled syringe, packs of 2 and 6, Humira®, Adalimubab Pen, 40 mg solution in 0.8 mL pre-filled pen, packs of 2 and 6, Humira Pen®, November 2007
• Adalimumab, injection, 40 mg in 0.8 mL pre-filled syringe, 40 mg in 0.8 mL pre-filled pen, Humira®, July 2008
• Adalimumab, injection, 40 mg in 0.8 mL pre-filled syringe, Humira®, November 2006
• Adalimumab, pre-filled syringe, 40 mg per 0.8 mL, Humira , March 2006
• Adalimumab, injection, 40 mg in 0.8 mL, pre-filled syringe, pre-filled pen, Humira®, November 2010
• Adapalene with benzoyl peroxide, gel, 1 mg – 25 mg per g (0.1%-2.5%), 30 g, Epiduo®, November 2010
• Adefovir Dipivoxil, tablet, 10 mg, Hepsera®, Nov 2006
• Adefovir Dipivoxil, tablet, 10 mg, Hepsera®, July 2006
• Adefovir Dipivoxil, tablet, 10 mg, Hepsera®, March 2007
• Adefovir Dipivoxil, tablet, 10 mg, Hepsera®, November 2007
• Adrenaline: I.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector; I.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injector; I.M. injection 500 micrograms in 0.3 mL single dose syringe auto-injector; Anapen® - November 2020
• Adrenaline: I.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector, I.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injector, Adrenaline Auto Inject Sun-JV® - July 2016
• Adrenaline: I.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector and I.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injector; AdrenaJect® - March 2018
• Adrenaline: I.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector and I.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injector; Emerade® - March 2018
• Adrenaline: 300 microgram/0.3 mL injection, 1 x 0.3 mL syringe 150 microgram/0.3 mL injection, 1 x 0.3 mL syringe, EpiPen®, EpiPen Jr. ® - March 2016
• Aflibercept: Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL) vial, Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe; Eylea® - July 2019
• Aflibercept, 2 mg/0.05 mL injection, 1 x 0.05 mL vial and 2 mg/0.05 mL injection, 1 x 0.05 mL syringe, Eylea® - March 2014
• Aflibercept: 4 mg/0.1 mL injection, 1 x 0.1 mL vial, 4 mg/0.1 mL injection, 1 x 0.09 mL syringe; Eylea® - November 2015
• Aflibercept, injection, 4 mg/0.1 mL, Eylea® - July 2013
• Aflibercept, solution for IV injection, 100 mg/4 mL and 200 mg/8 mL, Zaltrap® - July 2013
• Aflibercept; 4 mg/0.1 mL injection, 1 x 0.1 mL vial, 4 mg/0.1 mL injection, 1 x 0.09 mL syringe; Eylea® (DME)
• Aflibercept; 4 mg/0.1 mL injection, 1 x 0.1 mL vial, 4 mg/0.1 mL injection, 1 x 0.09 mL syringe; Eylea® (CRVO)
• Aflibercept; 4 mg/0.1 mL injection, 1 x 0.1 mL vial, 4 mg/0.1 mL injection, 1 x 0.09 mL syringe; Eylea® - March 2015
• Afatinib dimaleate; 20 mg tablet, 28; 30 mg tablet, 28; 40 mg tablet, 28; 50 mg tablet, 28; Giotrif® - July 2015
• Afatinib, tablets, 20mg, 30mg, 40mg and 50mg, (as dimaleate), Giotrif® (first line) - July 2013
• Afatinib, tablets, 20 mg, 30 mg, 40 mg and 50 mg, (as dimaleate) Giotrif® (second or third line) - July 2013
• Aflibercept, solution for IV injection, 100 mg/4 mL and 200 mg/8 mL, Zaltrap® - July 2013
• Aflibercept, solution for intravitreal injection, 40 mg per mL, Eylea® - March 2012
• Agalsidase alfa (ghu) and beta (rch) infusions, literature review; Replagal®, Fabrazyme®, November 2009
• Age restrictions on inhaled corticosteroid (ICS) + long-acting beta2 agonist (LABA) fixed dose combination (FDC) products Correspondence from Clinician, December 2019
• Agomelatine, tablet, 25mg, Valdoxan® - March 2012
• Agomelatine, tablet, 25 mg, Valdoxan®, July 2011
• Agomelatine, tablet, 25 mg, Valdoxan®, November 2010
• Alectinib: Capsule 150 mg; Alecensa®; Crizotinib: Capsule 200 mg; Capsule 250 mg; Xalkori® - November 2019
• Alectinib: Capsule 150 mg; Alecensa® - July 2017
• Alectinib: Capsule 150 mg; Alecensa® - March 2019
• Alefacept, powder for injection, 7.5 mg and 15 mg, Amevive® November 2005
• Alemtuzumab: Solution concentrate for I.V. infusion 12 mg in 1.2 mL; Lemtrada® - November 2018
• Alemtuzumab, solution for infusion, 10 mg/ mL, Lemtrada® - July 2014
• Alemtuzumab; solution for infusion, 10 mg/ mL; Lemtrada® - November 2014
• Alendronate: 70 mg tablet: effervescent, 4, Binosto® - July 2016
• Alendronate Sodium, tablet equivalent to 70 mg alendronic acid, Fosamax® Once Weekly, July 2011
• Alendronate sodium, tablet equivalent to 70 mg alendronic acid, Fosamax Once Weekly®, Alendronate Sodium with Colecalciferol, tablet equivalent to 70 mg alendronic acid with 70 micrograms colecalciferol, Fosamax Plus®,March 2008
• Alendronate sodium with Colecalciferol (vitamin D3), tablet, 70 mg-70 micrograms (2800 i.u.), Fosamax® Plus, March 2006
• Alendronate sodium, tablet, 70 mg Fosamax® Once Weekly, Alendronate sodium with Colecalciferol, tablet, 70 mg – 70 micrograms, Fosamax Plus®, July 2006
• Alendronate Sodium, tablet equivalent to 70 mg alendronic acid, Fosamax Once Weekly®, ALENDRONATE SODIUM with COLECALCIFEROL tablet equivalent to 70 mg alendronic acid with 70 micrograms colecalciferol, Fosamax Plus®, ALENDRONATE SODIUM with COLECALCIFEROL tablet equivalent to 70 mg alendronic acid with 140 micrograms colecalciferol, Fosamax Plus 70 mg/140 mcg®, ALENDRONATE SODIUM with COLECALCIFEROL and CALCIUM CARBONATE, pack containing 4 tablets containing the equivalent of 70 mg alendronic acid with 140 micrograms colecalciferol and 48 tablets calcium carbonate 1.25 g (equivalent to 500 mg calcium), Fosamax Plus D-Cal® - July 2010
• Alglucosidase alfa-rch, powder for I.V. infusion, 50 mg, Myozyme®, March 2013
• Alglucosidase alfa-rch, powder for I.V. infusion, 50 mg, Myozyme® - November 2012
• Alglucosidase Alfa, powder for I.V. infusion, 50 mg, Myozyme®, July 2011
• Alglucosidase alfa, powder for I.V. infusion, 50 mg, Myozyme®, July 2008
• Alglucosidase alfa, powder for I.V. infusion, 50 mg, Myozyme®, March 2009
• Alglucosidase alfa, powder for I.V. infusion, 50 mg, Myozyme®, November 2009
• Alglucosidase alfa, powder for I.V. infusion, 50 mg, Myozyme®, November 2010
• Alirocumab: Injection 300 mg in 2 mL single dose autoinjector; Praluent® - March 2023
• Alirocumab: Injection 75 mg in 1 ml single dose pre-filled pen injection 150 mg in 1 ml single dose pre-filled pen; Praluent® - March 2020
• Alirocumab: Injection 75 mg in 1 mL single dose pre-filled pen, Injection 150 mg in 1 mL single dose pre-filled pen; Praluent® - March 2019
• Alirocumab: Injection 75 mg in 1 mL single dose pre-filled pen, Injection 150 mg in 1 mL single dose pre-filled pen; Praluent® - November 2017
• Aliskiren, tablets, 150 mg and 300 mg (as hemifumarate), Rasilez®, July 2010
• Alogliptin, tablets, 6.25 mg, 12.5 mg, 25 mg Nesina® - July 2013
• Alogliptin with Metformin, tablet, 12.5mg/500mg, 12.5mg/850mg, 12.5mg/ 1000mg, Nesina Met® - November 2013
• Ambrisentan, tablets, 5 mg and 10 mg, Volibris®, July 2009
• Amifampridine: Tablet 10 mg; Ruzurgi® - March 2022
• Amifampridine: Tablet 10 mg; Ruzurgi® - November 2021
• Amino acid formula with vitamins and minerals, without methionine and supplemented with arachidonic acid and docosahexaenoic acid: Sachets containing oral powder 12.5 g, 30 (HCU explore5); HCU explore5™- March 2023
• Amino acid formula with vitamins and minerals, without phenylalanine and tyrosine and supplemented with arachidonic acid and docosahexaenoic acid: Sachets containing oral powder 12.5 g, 30 (TYR explore5); TYR explore5™ - March 2023
• Amino acid formula with vitamins and minerals without valine, leucine and isoleucine and supplemented with arachidonic acid and docosahexaenoic acid: Sachets containing oral powder 12.5 g, 30 (MSUD explore5); MSUD explore5™- March 2023
• Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids: Oral powder 400 g (EleCare LCP); EleCare® LCP – March 2023
• Amino Acid Formula with Vitamins and Minerals without Phenylalanine: Oral gel 85 g, 30 (PKU Squeezie); PKU Squeezie® - November 2022
• Amino Acid Synthetic Formula Supplemented with Long Chain Polyunsaturated Fatty Acids, Medium Chain Triglycerides, 2’- Fucosyllactose and Lacto-N-Neotetraose: Oral powder 400 g; Alfamino® - November 2022
• Amino acid formula with vitamins and minerals without methionine: Sachets containing oral powder 25 g, 30; HCU Express 15® - July 2021
• Amino acid formula with vitamins and minerals without phenylalanine: Sachets containing oral powder 34 g, 30; PKU Express 20® - July 2021
• Amino acid formula with vitamins and minerals without phenylalanine: Sachets containing oral powder 25 g,30; PKU Express 15® - July 2021
• Amino acid formula with vitamins and minerals without phenylalanine and tyrosine: Sachets containing oral powder 25 g,30; TYR Express 15® - July 2021
• Amino acid formula with vitamins and minerals without valine, leucine and isoleucine: Sachets containing oral powder 25 g, 30; MSUD Express 15® - July 2021
• Amino acid formula with fat, carbohydrate, vitamins, minerals, trace element and medium chain tryglycerides: Oral powder 800 g; Essential Care Jr®- March 2021
• Amino acid formula with vitamins and minerals without lysine and low in tryptophan: Sachets containing oral powder 24 g, Sachets containing oral powder 25 g; GA Gel®; GA Express 15® - November 2020
• Amino acid formula with carbohydrate, vitamins, minerals and trace elements without phenylalanine, supplemented with docosahexaenoic acid: Sachets containing oral powder 33 g, 30; PKU Synergy® - July 2020
• Amino acid formula with vitamins and minerals without methionine: Sachets containing oral powder 28 g, 30; HCU Lophlex® - July 2020
• Amino acid formula with vitamins and minerals without phenylalanine and tyrosine: Sachets containing oral powder 28 g, 30; TYR Lophlex® - July 2020
• Amino acid formula with vitamins and minerals without valine, leucine and isoleucine: Sachets containing oral powder 28 g, 30; MSUD Lophlex® - July 2020
• Amino acid formula with vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine, 2. Amino acid formula with vitamins and minerals without phenylalanine and tyrosine, 3. Amino acid formula with vitamins and minerals without lysine and low in tryptophan, 4. Amino acid formula with vitamins and minerals without methionine, threonine and valine and low in isoleucine, 5. Amino acid formula with vitamins and minerals without methionine, 6. Amino acid formula with vitamins and minerals without valine, leucine and isoleucine: Oral powder 400 g; 1. PKU Anamix Infant®, 2. TYR Anamix Infant®, 3. GA1 Anamix Infant®, 4. MMA/PA Anamix Infant®, 5. HCU Anamix Infant®, 6. MSUD Anamix Infant® - July 2020
• Amino acid formula with vitamins and minerals without phenylalanine: Sachets containing oral powder 27.8 g, 30; PKU Lophlex® - March 2020
• Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids: Oral powder 400 g; (Neocate® LCP); Amino acid formula supplemented with prebiotics, probiotics and long chain polyunsaturated fatty acids: Oral powder 400g; Neocate® Syneo - March 2020
• Amino acid formula with carbohydrate without phenylalanine: Tablet 1.25 g, 462; PKU Easy Tablet® - November 2019
• Amino acid formula with fat, carbohydrate without methionine: Tablets 0.91g, 462; HCU Easy® - November 2019
• Amino acid formula with fat, carbohydrate without phenylalanine and tyrosine: Tablets 0.91g, 462; TYR Easy® - November 2019
• Amino acid formula with fat, carbohydrate without valine, leucine and isoleucine: Tablets 1.25 g, 462; MSUD Easy Tablet® - November 2019
• Amino acid formula with vitamins and minerals without valine, leucine and isoleucine: Sachet containing oral powder 12.5 g, 30; MSUD explore5® - November 2019
• Amino acid formula with vitamins and minerals, low phenylalanine and supplemented with docosahexaenoic acid and arachidonic acid: Sachets containing oral powder 12.5 g, 30, Sachets containing oral powder 25 g, 30; PKU Explore® 5 and PKU Explore® 10 - July 2019
• Amino acid formula with carbohydrate, vitamins, minerals and trace elements without phenylalanine,supplemented with docosahexaenoic acid: Sachets containing oral powder 33 g, 30; PKU Synergy® - July 2017
• Amino acid formula supplemented with prebiotics, probiotics and long chain polyunsaturated fatty acids: Oral powder, 400g; Neocate Syneo® - July 2017
• Amino acid formula with vitamins and minerals without lysine and low in tryptophan, oral liquid: powder for, 30 x 18 g sachets; GA1 Anamix Junior® - November 2015
• Amino acid formula with vitamins and minerals without lysine and low in tryptophan; oral liquid: powder for, 500 g; XLYS LOW TRY Maxamum® – March 2015
• Amino acid formula with vitamins and minerals without methionine oral liquid: powder for, 30 x 36 g sachets; HCU Anamix Junior® - November 2015
• Amino acid formula with vitamins and minerals without methionine, threonine, and valine and low in isoleucine oral liquid: powder for, 30 x 18 g sachets; MMA/PA Anamix Junior® - November 2015
• Amino acid formula with vitamins and minerals without valine, leucine and isoleucine: Oral liquid, 87 mL, 30 (MSUD Cooler 10); oral liquid, 130 mL, 30 (MSUD Cooler 15); oral liquid, 174 mL, 30 (MSUD Cooler 20); MSUD Cooler® 10, MSUD Cooler® 15, MSUD Cooler® 20. Amino acid formula with vitamins and minerals without phenyalanine and tyrosine: oral liquid, 87 mL, 30 (TYR Cooler 10); oral liquid, 130 mL, 30 (TYR Cooler 15); oral liquid, 174 mL, 30 (TYR Cooler 20); TYR Cooler® 10, TYR Cooler® 15, TYR Cooler® 20. Amino acid formula with vitamins and minerals without methionine: oral liquid, 87 mL, 30 (HCU Cooler 10); oral liquid, 130 mL, 30 (HCU Cooler 15); oral liquid, 174 mL, 30 (HCU Cooler 20); HCU Cooler® 10, HCU Cooler® 15, HCU Cooler® 20 - March 2018
• Amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides: Oral powder 400 g; Neocate Junior® - March 2017
• Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine, 2. Amino acid formula with fat, carbohydrate without phenylalanine, 3. Protein formula with amino acids, carbohydrates, vitamins and minterals without phenylalanine, and supplemented with docosahexaenoic acid (PKU Easy): 1. Bottles containing oral powder 34 g, 2. Tablet: modified release, 70.8 g protein per 100 g, 3. Oral liquid 130 mL; "1. PKU Easy Shake & Go, 2. PKU EASY® Microtabs, 3. PKU Easy® - November 2016
• Amino acid formula with vitamins, minerals and long chain polyunsaturated fatty acids, without phenylalanine: Oral powder 400 g (PKU Start); PKU Start® - November 2017
• Amino acid formula with vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine: oral liquid, 20 x 500 mL, PKU Baby® - March 2016
• Amino acid formula with vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine: 10 g protein oral liquid, 500 mL bottle, 20, PKU Baby® - November 2015
• Amino acid formula with vitamins and minerals without phenylalanine: Oral liquid 87 mL, 30, Oral liquid 130 mL, 30, Oral liquid 174 mL, 30; PKU Cooler® - March 2017
• Amino acid formula with vitamins and minerals without phenylalanine: oral liquid: powder for, 30 x 20 g sachets, PKU Go® - March 2016
• Amino acid formula with vitamins and minerals without phenylalanine, PKU Go® - November 2015
• Amino acid formula with vitamins and minerals without phenylalanine, 15g protein equivalent oral liquid: powder, 30 x 34 g bottles, PKU Easy Shake & Go® - November 2015
• Amino acid formula with vitamins and minerals without phenylalanine, oral liquid: powder for, 30 x 130mL cans, PKU Easy Liquid® - November 2015
• Amino acid formula with vitamins and minerals, without phenylalanine: Oral liquid 125 mL, 30; PKU Lophlex LQ 20®: Sachets containing oral powder 27.8 g, 30; PKU Lophlex® - July 2017
• Amino Acid Formula with Vitamins and Minerals without Phenylalanine oral liquid, 30 x 125 mL cans, PKU Lophlex LQ 20® - July 2014
• Amino Acid Formula with Vitamins and Minerals without Valine, oral liquid: powder for, 30 x 6 g sachets, MSUD amino5® - July 2014
• Amino acid formula with vitamins and minerals without phenylalanine: Oral liquid 130 mL, 30, Oral liquid 174 mL, 30; PKU Air® - March 2017
• Amino acid formula with vitamins and minerals without phenylalanine; oral liquid, 30 x 130 mL & 30 x 174 mL pouch; PKU Air® - November 2014
• Amino acid formula with vitamins and minerals without phenylalanine, oral liquid, 30 x 130 mL & 30 x 174 mL pouch, PKU Air® - March 2015
• Amino acid formula with vitamins and minerals without phenylalanine, oral liquid: powder for, 30 x 36 g sachets, PKU Anamix Junior®; – March 2015
• Amino acid formula with vitamins and minerals without phenylalanine; oral liquid: powder for, 30 x 36 g sachets; PKU Anamix Junior® - November 2014
• Amino acid formula with fat, carbohydrate, vitamins, mineral and trace elements without phenylalanine and tyrosine: 34 g bottle, powder for oral liquid, 30, TYR Easy Shake & Go® - July 2016
• Amino acid formula with vitamins and minerals without phenylalanine and tyrosine: Sachets containing oral powder 34 g, 30; TYR Express20® - March 2017
• Amino acid formula with vitamins and minerals without phenylalanine and tyrosine, oral liquid: powder for, 30 x 36 g sachets, TYR Anamix Junior® - March 2015
• Amino acid formula with vitamins and minerals without phenylalanine and tyrosine; oral liquid: powder for, 30 x 36 g sachets, TYR Anamix Junior® - November 2014
• Amino acid formula with vitamins and minerals without valine, leucine and isoleucine, oral liquid: powder for, 30 x 36 g sachets, MSUD Anamix Junior®; – March 2015
• Amino acid formula with vitamins and minerals without valine, leucine and isoleucine; oral liquid: powder for, 30 x 36 g sachets; MSUD Anamix Junior® - November 2014
• Amino acid formula with vitamins and minerals, without phenylalanine, and supplemented with docosahexaenoic acid and arachidonic acid: Sachets containing oral powder 12.5 g, 30; PKU Anamix First Spoon® - March 2017
• Amino acid formula without phenylalanine, 110g modified release tablet x 4, bottle; PKU Easy Microtabs® - November 2015
• Amino Acids-Synthetic, Formula: Oral powder 400 g (Neocate Junior Vanilla); Neocate Junior® Vanilla - November 2018
• Amino acid synthetic formula; oral liquid: powder for, 400 g; Alfamino® Junior – March 2015
• Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides oral liquid: powder for, 400 g, Alfamino® and Alfamino® Junior - November 2015
• Amlodipine (as besylate) with Valsartan and Hydrochlothiazide, tablets, 5 mg-160 mg-12.5 mg, 5 mg-160 mg-25 mg, 10 mg-160 mg-12.5 mg, 10 mg-160 mg-25 mg, and 10 mg-320 mg-25 mg, Exforge HCT® - July 2010
• Amlodipine besylate with Valsartan, tablet, 5 mg-80 mg, 5 mg-160 mg, 10 mg-160 mg, Exforge® 5/80, Exforge®5/160, Exforge®10/160, July 2008
• Anakinra: Injection 100 mg in 0.67 mL single use pre-filled syringe; Kineret® - July 2017
• Anakinra; anakinra 100 mg/0.67 mL injection, 28 x 0.67 mL syringes; Kineret® - July 2015
• Anakinra; 100 mg/0.67 mL, 28 X 0.67 mL syringes; Kineret® - November 2014
• Anastrozole; everolimus; exemestane; goserelin; letrozole - November 2014
• Anastrozole, tablets, 1 mg, Arimidex®, July 2005
• Anecortave acetate, depot suspension, 15 mg in 0.5 ml, Retaane®, Nov 2006
• Anecortave acetate, depot suspension, 15 mg in 0.5 mL, Retaane® March 2006
• Antibiotic Repeats on the Pharmaceutical Benefits Scheme - August 2019
• Anti-Glaucoma drugs; (various) – March 2015
• Antipsychotics - DUSC Review on the Utilisation of Antipsychotics - August 2013
• Anifrolumab: Solution concentrate for I.V. infusion 300 mg in 2 mL vial; Saphnelo®  - March 2023
• Anifrolumab: Solution concentrate for I.V. infusion 300 mg in 2 mL; Saphnelo®
• Apalutamide: Tablet 60 mg; Erlyand® - July 2022
• Apalutamide (mHSPC): Tablet 60 mg; Erlyand® - November 2021
• Apalutamide (m0CRPC): Tablet 60 mg; Erlyand® - November 2021
• Apalutamide: Tablet 60 mg; Erlyand® - November 2020
• Apalutamide: Tablet 60 mg; Erlyand® - July 2019
• Apalutamide: Tablet 60 mg; Erlyand® - November 2018
• Apixaban, tablet, 2.5 mg and 5 mg, Eliquis®, March 2013
• Apixaban, tablet, 2.5 mg and 5 mg, Eliquis® - Nov 2012
• Apixaban, tablet 2.5 mg, Eliquis®, July 2011
• Apixaban; 2.5 mg tablet 60, 5 mg tablet 28, 5 mg tablet 60; Eliquis® – March 2015

• Apomorphine: Solution for subcutaneous infusion containing apomorphine hydrochloride hemihydrate 50 mg in 10 mL pre-filled syringe; Movapo PFS® - November 2020

• Apomorphine: Injection containing apomorphine hydrochloride hemihydrate 100 mg in 20 ml, Solution for subcutaneous injection containing apomorphine hydrochloride 30 mg in 3 ml pre-filled pen; Apomine® Solution for infusion and Apomine® Intermittent - March 2020
• Apomorphine: Injection containing apomorphine hydrochloride 30 mg in 3 ml cartridge; Apomine® Intermittent - July 2018
• Apomorphine: Injection containing apomorphine hydrochloride 30 mg in 3 mL pre-filled pen; Movapo®Pen - March 2018
• Apomorphine: Injection containing apomorphine (as hydrochloride) 100 mg in 20 mL; Apomine® - November 2016
• Apomorphine: 50 mg/10 mL solution for subcutaneous infusion, 5 × 10 mL syringe, MOVAPO® PFS – July 2016
• Apomorphine; Injection, 10 mg in 1 mL, Apomine® - November 2014
• Apremilast: Tablet 30 mg, Pack containing 4 tablets of 10 mg, 4 tablets of 20 mg, 19 tablets of 30 mg; Otezla®  - March 2023
• Apremilast: Tablet 30 mg, Pack containing 4 tablets 10 mg, 4 tablets 20 mg and 19 tablets 30 mg; Otezla® – May 2022
• Apremilast: Tablet 30 mg, Pack containing 4 tablets of 10 mg, 4 tablets of 20 mg and 19 tablets of 30 mg; Otezla® - July 2020
• Apremilast: Pack containing 4 tablets of 10 mg, 4 tablets of 20 mg and 19 tablets of 30; Tablet 30 mg; Otezla® - March 2018
• Apremilast: Tablet 30 mg, Pack containing 4 tablets of 10 mg , 4 tablets of 20 mg and 19 tablets of 30 mg; Otezla® - November 2017
• Apremilast: Tablet 30 mg, Pack containing 4 tablets 10 mg, 4 tablets 20 mg and 19 tablets 30 mg; Otezla® - March 2017
• Apremilast: Tablet 30 mg, Pack containing 4 tablets 10 mg, 4 tablets 20 mg and 19 tablets 30 mg; Otezla® - November 2016
• Apremilast: tablets, 10 mg, 20 mg, 30 mg, Otezla® - November 2015
• Apremilast; 30 mg tablet 56, Starter Pack (10 mg tablet 4; 20 mg tablet 4; and 30 mg tablet 19); Otezla® - March 2015
• Apremilast; 30 mg tablet 56, Starter Pack (10 mg tablet 4; 20 mg tablet 4; and 30 mg tablet 19); Otezla® - March 2015
• Aprepitant: Capsule 165 mg; Apotex® Aprepitant - July 2019
• Aprepitant: 165 mg capsule, 1, Emend® - March 2016
• Aprepitant: oral capsule, 165 mg, Emend® - November 2015
• Aprepitant, pack containing 1 capsule 125 mg and 2 capsules 80 mg, Emend® - March 2010
• Aprepitant, pack containing 1 capsule 125 mg and 2 capsules 80 mg, Emend®, November 2009
• Aprepitant, capsule, 1 x 125 mg and 2 x 80 mg Tri - pack, Emend® March 2006
• Arginine: Tablet 500 mg; Arginine Easy® - November 2017
• Aripiprazole: Powder for injection 400 mg (as monohydrate) with diluent, pre-filled syringe; Abilify Maintena® - July 2018
• Aripiprazole, 300 mg injection: modified release [1 x 300 mg vial] (&) inert substance diluent [2 x 3 mL syringe], 400 mg injection: modified release [1 x 400 mg vial] (&) inert substance diluent [2 x 3 mL syringe], Abilify Maintena® - July 2014
• Armodafinil and Modafinil: armodafinil: Tablet 50 mg, Tablet 150 mg, Tablet 250 mg; modafinil: Tablet 100 mg; Various brands – May 2022
• Armodafinil and Modafinil: modafinil: Tablet 100 mg; armodafinil: Tablet 50 mg, Tablet 150 mg, Tablet 250 mg; Various brands - July 2020
• Armodafinil: 50 mg tablet, 30, 150 mg tablet, 30, 250 mg tablet, 30, Nuvigil® - March 2016
• Armodafinil: tablets, 50 mg, 150 mg and 250 mg, 30, Nuvigil® - November 2015
• Arsenic trioxide: injection, 10mg in 10mL; Phenasen® - November 2015
• Arsenic trioxide, solution for I.V. infusion, 10mg in 10mL, Phenasen® , March 2009
• Asciminib: Tablet 20 mg, Tablet 40 mg; Scemblix® - November 2022
• Asciminib: Tablet 20 mg, Tablet 40 mg; Scemblix® - July 2022
• Asenapine, sublingual wafer, 5 mg and 10 mg (as maleate), Saphris®, July 2011
• Asenapine, sublingual wafer, 5 mg and 10 mg (as maleate), Saphris®, July 2011
• Asfotase alfa: Injection 18 mg in 0.45 mL, vial, Injection 28 mg in 0.7 mL, vial, Injection 40 mg in 1 mL, vial, Injection 80 mg in 0.8 mL, vial; Strensiq® - July 2017
• Asfotase alfa rch: Injection, 18 mg in 0.45 mL, 28 mg in 0.7 mL, 40 mg in 1 mL and 80 mg in 0.8 mL, vial; Strensiq® - March 2018
• Asunaprevir; 100 mg capsule 56; Sunvepra® - March 2015
• Atazanavir with cobicistat: atazanavir 300 mg + cobicistat 150 mg; fixed dose combination tablets 30; Evotaz ® - November 2015
• Atezolizumab: Solution concentrate for I.V. infusion 840 mg in 14 mL, Solution concentrate for I.V. infusion 1200 mg in 20 mL; Tecentriq® -July 2022
• Atezolizumab: Solution concentrate for I.V. infusion 840 mg in 14 mL; Tecentriq®- March 2021
• Atezolizumab and Bevacizumab: atezolizumab: Solution concentrate for I.V. infusion 1200 mg in 20 mL, Solution concentrate for I.V. infusion 840 mg in 14 mL; bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Tecentriq® and Avastin® - July 2020

• Atezolizumab (TNBC): Solution concentrate for I.V. infusion 840 mg in 14 ml; Tecentriq® - March 2020

• Atezolizumab (SCLC): Solution concentrate for I.V. infusion 840 mg in 14 ml; Tecentriq® - March 2020
• Atezolizumab: Solution concentrate for I.V. infusion 840 mg in 14 mL; Tecentriq® - November 2019
• Atezolizumab: Solution concentrate for I.V. infusion 1200 mg in 20 mL; Tecentriq® - November 2019
• Atezolizumab: Solution concentrate for I.V. infusion 1200 mg in 20 mL; Tecentriq® - November 2017
• Atezolizumab and Bevacizumab: atezolizumab: Solution concentrate for I.V. infusion 1200 mg in 20 mL; bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Tecentriq® and Avastin® - March 2019
• Atezolizumab: Solution concentrate for I.V. infusion 1200 mg in 20 mL; Tecentriq®
• Atogepant: Tablet 60 mg; Aquipta® - July 2023
• Atomoxetine hydrochloride, capsules, 10 mg, 18 mg, 25 mg, 40 mg and 60 mg, Strattera®, Nov 2006
• Atomoxetine hydrochloride, capsules, 10 mg, 18 mg, 25 mg, 40 mg and 60 mg, Strattera®, July 2006
• Atomoxetine hydrochloride, capsules, 10 mg, 18 mg, 25 mg, 40 mg and 60 mg, Strattera®, November 2005
• Atomoxetine hydrochloride, capsules, 80 mg and 100 mg, Strattera®, July 2008
• Authorised Nurse Practitioner prescribing for Hepatitis B, Hepatitis C and Human Immunodeficiency Virus medicines under the Highly Specialised Drugs (HSD) Program – November 2019
• Auranofin: Tablet 3 mg; Ridaura® - July 2017
• Auranofin: Tablet, 3 mg, 100, Riadura® - July 2016
• Avacopan: Capsule 10 mg; Tavneos® - July 2023
• Avalglucosidase alfa: Powder for injection 100 mg in 10 mL; Nexviazyme® - November 2021
• Avatrombopag: Tablet 20 mg; Doptelet® - November 2022
• Avelumab: Solution concentrate for I.V. infusion 200 mg in 10 mL; Bavencio® - March 2022
• Avelumab (renal cell carcinoma): Solution concentrate for I.V. infusion 200 mg in 10 mL; Bavencio®- March 2021
• Avelumab (urothelial carcinoma): Solution concentrate for I.V. infusion 200 mg in 10 mL; Bavencio®- March 2021
• Avelumab: Solution concentrate for I.V. infusion 200 mg in 10 ml; Bavencio® - March 2020
• Avelumab: Solution concentrate for I.V. infusion 200 mg in 10 mL; Bavencio® - July 2018
• Axitinib, tablet, 1 mg and 5 mg, Inlyta® - November 2013
• Axitinib; tablets, 1 mg & 5 mg; Inlyta® - November 2014
• Azacitidine: Tablet 200 mg, Tablet 300 mg; Onureg® – July 2022 – September 2022
• Azacitidine, powder for injection, 100 mg, Vidaza®July 2009
• Aztreonam, powder for inhalation, 75 mg, with diluent, Cayston® - July 2012
• Aztreonam, powder for inhalation, 75 mg (as lysine), with diluent, Cayston®, November 2010
  Top of page

B

• Baclofen: Intrathecal injection 40 mg in 20mL; Sintetica Baclofen Intrathecal® - July 2017
• Balsalazide: Capsule containing balsalazide sodium 750 mg; Colazide® - July 2017
• Baricitinib: Tablet 2 mg, Tablet 4 mg; Olumiant® - July 2021
• Baricitinib; Tablet 2 mg, Tablet 4 mg, Olumiant® - July 2017
• Baricitinib: Tablet 2 mg, Tablet 4 mg; Olumiant® - November 2017
• Baricitinib: Tablet 2 mg, Tablet 4 mg; Olumiant® - March 2018
• bDMARDs for the treatment of severe active rheumatoid athritis
• Beclometasone with formoterol: Pressurised inhalation containing beclometasone dipropionate 200 micrograms and formoterol fumarate dihydrate 6 micrograms per dose, 120 doses; Fostair® - July 2022
• Beclometasone with formoterol and glycopyrronium: Pressurised inhalation containing beclometasone dipropionate 100 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses, Pressurised inhalation containing beclometasone dipropionate 200 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses; Trimbow® - March 2022
• Beclometasone with formeterol: Pressurised inhalation containing beclometasone dipropionate 100 micrograms and formoterol fumarate dihydrate 6 micrograms per dose, 120 dose; Fostair® - March 2022
• Beclometasone dipropionate with Formoterol fumarate dehydrate and Glycopyrronium: Pressurised inhalation containing Beclometasone dipropionate 100 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses; Trimbow® - November 2020
• Beclometasone dipropionate with Formoterol fumarate dihydrate: Powder for oral inhalation in breath actuated device containing beclometasone dipropionate 100 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses; Fostair® - July 2020
• Bee venom, paper wasp venom and yellow jacket venom - March 2016
• Belimumab: Injection 200 mg in 1 mL pre-filled pen; Benlysta® - July 2020
• Belimumab: Injection 200 mg in 1 mL pre-filled pen; Benlysta®  - November 2019
• Bendamustine Hydrochloride; 25 mg injection: powder for, 1 vial, 100 mg injection: powder for, 1 vial; Ribomustin® - March 2015
• Bendamustine; powder for injection 100 mg vial, 1; powder for injection 25 mg vial, 1; Ribomustin® - July 2015
• Benralizumab: Injection 30 mg in 1 ml pre-filled pen; Fasenra Pen® - March 2020
• Benralizumab: 30 mg in 1 mL injection; Fasenra® - March 2018
• Benralizumab: 30 mg in 1 mL solution for injection prefilled syringe; Fasenra® - March 2018
• Benzathine Benzylpenicillin: Injection 517 mg in 1.17 mL single use pre-filled syringe; Bicillin L-A® - March 2019
• Benztropine mesylate: solution for injection 2 mg/2 mL vial, Benztropine Omega® - November 2015
• Betaine, 1 g/g oral liquid: powder for, 180 g, Cystadane® - March 2014
• Bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Bevaciptin® - March 2022
• Bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Abevmy® - November 2021
• Bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Mvasi®- March 2021
• Bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V infusion 400 mg in 16 mL; Zirabev® - July 2020
• Bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Mvasi® - November 2020
• Bevacizumab: Solution for intravenous infusion, 100 mg in 4 mL, 400 mg in 16 mL; Avastin® - May 2019
• Bevacizumab: 100 mg/4 mL injection, 1 x 4 mL vial 400 mg/16 mL injection, 1 x 16 mL vial, Avastin® - March 2016
• Bevacizumab: solution for I.V. use, 100 mg in 4 mL and 400 mg in 16 mL, Avastin® - November 2015
• Bevacizumab, 100 mg/4 mL injection, 1 x 4mL vial and 400 mg/16 mL injection, 1x16 mL vial, Avastin®, Roche Products Pty Limited - March 2014
• Bevacizumab, solution for IV use, 100mg in 4mL and 400mg in 16mL, Avastin® - November 2013
• Bevacizumab, solution for I.V. infusion, 100 mg in 4 mL and 400 mg in 16 mL, Avastin®, March 2011
• Bevacizumab, solution for intravenous infusion, 100 mg in 4 mL and 400 mg in 16 mL, Avastin®, November 2010
• Bevacizumab, solution for I.V. infusion, 100 mg in 4 mL, 400 mg in 16 mL, Avastin®, July 2008
• Bevacizumab, solution for I.V. infusion, 100 mg in 4 mL, 400 mg in 16 mL, Avastin®, March 2008
• Bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Avastin® - March 2019
• Bezlotoxumab: Solution concentrate for I.V. infusion 1000 mg in 40 ml; Zinplava® - March 2020
• Bezlotoxumab: Solution concentrate for I.V. infusion 1000 mg in 40 mL; Zinplava® - July 2019
• Bezlotoxumab: Solution concentrate for I.V. infusion 1000 mg in 40 ml; Zinplava® - July 2018
• Bezlotoxumab: Solution concentrate for I.V. infusion 1000 mg in 40 mL; Zinplava® - November 2017
• Bictegravir + emtricitabine + tenofovir alafenamide fixed dose combination: Tablet containing tenofovir alafenamide 25 mg with emtricitabine 200 mg and bictegravir 50 mg; Biktarvy® - March 2018
• Bimatoprost: 300 micrograms per mL, 3 mL; Vizo-PF Bimatoprost® - July 2020
• Bimatoprost with Timolol maleate, eye drops, 0.3 mg - 5 mg (base) per mL (0.03%-0.5%), 3 mL, Ganfort® , March 2009
• Bimekizumab: Injection 160 mg in 1 mL single use pre-filled syringe, Injection 160 mg in 1 mL single use pre-filled pen; Bimzelx® - March 2023
• Bimekizumab: Solution for injection 160 mg in 1 mL pre-filled pen, Solution for injection 160 mg in 1 mL pre-filled syringe; Bimzelx® - March 2022
• Biosimilar medicines: considering brand equivalence /substitution –March 2018
• Blinatumomab: Powder for I.V. infusion 38.5 micrograms; Blincyto® - July 2019
• Blinatumomab: Powder for I.V. infusion, 38.5 micrograms; Blincyto® - May 2019
• Blinatumomab: Injection 38.5 microgram [1 vial] and inert substance solution [10 mL vial]; Blincyto® - November 2016
• Blinatumomab: Injection 38.5 microgram [1 vial] (&) inert substance solution [10 mL vial], 1 pack, Blincyto® - July 2016
• Blinatumomab: Powder for I.V. infusion 38.5 micrograms; Blincyto® - July 2018
• Blinatumomab: powder for IV infusion, 38.5 µg, Blincyto® - November 2015
• Blinatumomab: Powder for I.V. infusion 38.5 micrograms; Blincyto® - March 2019
• Blood beta-ketone, electrode strips, MediSense Optium® Ketone Blood ?-Ketone Electrodes® March 2006
• Boceprevir, capsule, 200 mg, Victrelis® - July 2012
• Boceprevir, capsule, 200 mg, Victrelis® - March 2012
• Boceprevir, capsule 200 mg, Victrelis® - July 2011
• Boceprevir with Peginterferon Alfa-2B and Ribavirin, packs containing boceprevir 200 mg capsules, ribavirin 200 mg capsule and peginterferon alfa-2b, Victrelis Pegatron® Combination Therapy - November 2012
• Bortezomib: Solution for Injection 2.5 mg, Solution for Injection 3.5 mg; Bortezomib Ever Pharma® - March 2022
• Bortezomib: Powder for injection 1 mg, Powder for injection 2.5 mg, Powder for injection 3 mg, Powder for injection 3.5 mg: DBL Bortezomib® - July 2021
• Bortezomib: Powder for injection 2.5 mg; Bortezomib Juno® - July 2021
• Bortezomib, powder for injection 1 mg (solvent required), Velcade® - March 2012
• Bortezomib, powder for injection, 1 mg (solvent required), Velcade®, July 2011
• Bortezomib, powder for injection, 1 mg (solvent required), Velcade®, March 2011
• Bortezomib, powder for injection, 1 mg, Velcade®, March 2010
• Bortezomib: 3 mg injection, 3 mg vial, Velcade® - March 2016
• Bortezomib, powder for injection, 3.5 mg, 1 mg, Velcade®, July 2009
• Bortezomib, powder for I.V. injection, 3.5 mg, Velcade®, Nov 2006
• Bortezomib, powder for I.V. injection, 3.5 mg, Velcade® March 2006
• Bortezomib, powder for injection, 3.5 mg, Velcade®, July 2007
• Bosentan; epoprostenol; macitentan; bosentan 62.5 mg tablet, 60; bosentan 125 mg tablet, 60; epoprostenol 500 microgram injection vial, 1; epoprostenol 1.5 mg injection vial, 1; macitentan 10 mg tablet, 30; Tracleer®; Veletr®; Opsumit® - July 2015
• Bosentan monohydrate, tablets, 62.5 mg and 125 mg (base), Tracleer®, March 2008
• Botulinum toxin type A purified neurotoxin complex: Lyophilised powder for injection 100 units; Botox® - November 2019
• Botulinum Toxin Type A: Lyophilised powder for injection 100 units; Botox® - November 2018
• Botulinum toxin type A: Lyophilised powder for injection 100 units; Botox®- July 2018
• Botulinum toxin type A: Lyophilised powder for injection 100 units; Botox® - March 2017
• Botulinum Toxin Type A: Lyophilised powder for injection 100 units; Botox® - March 2019
• Botulinum toxin type A, 100 units injection, vial, Botox® - November 2013
• Botulinum Toxin Type A, injection, 100 units/vial, Botox® - July 2013
• Botulinum toxin type a purified neurotoxin complex, lyophilised powder for injection, 100 units, Botox® (urinary incontinence) - July 2012
• Botulinum toxin type A purified neurotoxin complex, lyophilised powder for injection, 100 units, Botox® (migraine) - July 2012
• Botulinum toxin type A purified neurotoxin complex: Lyophilised powder for injection, 100 units; Botox® - March 2018
• Botulinum toxin type A purified neurotoxin complex, lyophilised powder for I.M injection, 100 units, Botox® - November 2011
• Botulinum toxin type A purifed neurotoxin complex, lyophilised powder for IM injection, 100 units, Botox® - March 2010
• Botulinum toxin type A purified neurotoxin complex, lyophilised powder for I.M. injection, 100 units, Botox®, November 2009
• Botulinum toxin type A purified neurotoxin complex, lyophilised powder for IM injection, 100 units vial, Botox®, November 2008
• Botulinum toxin type A purified neurotoxin complex, lyophilised powder for IM injection, 100 units vial, Botox®, July 2008
• Botulinum toxin type A purified neurotoxin complex, lyophilised powder for IM injection, 100 units vial, Botox®, July 2008
• Botulinum toxin type A purified neurotoxin complex, lyophilised powder for I.M. injection 100 units vial, Botox®, July 2006
• Botulinum toxin type A purified neurotoxin complex, lyophilised powder for IM injection, 100 units, Botox® November 2005
• Brentuximab vedotin: Powder for I.V. infusion 50 mg; Adcetris®- March 2021
• Brentuximab Vedotin: Powder for I.V. infusion 50 mg; Adcetris® - November 2018
• Brentuximab vedotin: Powder for I.V. infusion 50 mg; Adcetris® - July 2018
• Brentuximab vedotin (post-ASCT): Powder for I.V. infusion 50 mg; Adcetris® - November 2016
• Brentuximab vedotin (ASCT naïve): Powder for I.V. infusion 50 mg; Adcetris® - November 2016
• Brentuximab Vedotin; 50 mg injection: powder for, 1 vial; Adcetris® - March 2015
• Brentuximab Vedotin, injection, 50 mg, Adcetris® - July 2014
• Brentuximab Vedotin, 50 mg injection, 1 x 50 mg vial Adcetris® - March 2014
• Brexpiprazole: Tablet 1 mg, Tablet 2 mg, Tablet 3 mg, Tablet 4 mg; Rexulti® - March 2017
• Brigatinib : Tablet 30 mg, Tablet 90 mg, Tablet 180 mg, Pack containing 7 tablets containing brigatinib 90 mg and 21 tablets containing brigatinib 180 mg; Alunbrig® - November 2019
• Brinzolomide with brimonidine tartrate; suspension containing brinzolamide 10 mg/mL + brimonidine 2 mg/mL, 5 mL; Simbrinza® - July 2015
• Brinzolamide with timolol maleate, eye drops, 10 mg -5 mg (base) per mL, (1%-0.5%), Azarga® - March 2010
• Brivaracetam: Tablet 25 mg, Tablet 50 mg, Tablet 75 mg, Tablet 100 mg, Oral solution 10mg per mL, 300 mL; Briviact® - November 2019
• Brivaracetam: Tablet 25 mg, Table 50 mg, Tablet 75 mg, Tablet 100 mg, Oral suspension 10 mg per mL, 300 mL; Briviact® - March 2017
• Brivaracetam: 25 mg tablet, 56, 50 mg tablet, 56, 75 mg tablet, 56, 100 mg tablet, 56, 10 mg/mL, 300 mL, Briviact® - July 2016
• Brivaracetam: Tablet 25 mg, Table 50 mg, Tablet 75 mg, Tablet 100 mg, Oral suspension 10 mg per mL, 300 mL; Briviact® - November 2017
• Broad PBS subsidy listing for PD-(L)1 checkpoint inhibitors for non-small cell lung cancer - August 2019
• Brolucizumab: Solution for intravitreal injection 19.8 mg in 0.165 mL pre-filled syringe; Beovu®- March 2021
• Brolucizumab: Solution for intravitreal injection 19.8 mg in 0.165 mL pre-filled syringe; Beovu® - July 2020
• Brolucizumab:   Solution for intravitreal injection 19.8 mg in 0.165 ml pre-filled syringe; Beovu® - March 2020
• Brolucizumab: Solution for intravitreal injection 19.8 mg in 0.165 mL pre-filled syringe; Beovu® - November 2019
• Budesonide: Tablet 500 micrograms (orally disintegrating), Tablet 1 mg (orally disintegrating); Jorveza® - March 2023 - July 2023
• Budesonide with Glycopyrronium and Formoterol: Pressurised inhalation containing budesonide 160 micrograms with glycopyrronium 7.2 micrograms and formoterol fumarate dihydrate 5 micrograms per dose, 120 doses; Breztri Aerosphere® DFP-EvoCap - November 2022 – OOS June 2023
• Budesonide + glycopyrronium + formoterol: Pressurised inhalation containing budesonide 160 micrograms with glycopyrronium 7.2 micrograms (as bromide) and formoterol fumarate dihydrate 5 micrograms per dose, 120 doses; Breztri Aerosphere® - July 2021
• Budesonide: Tablet (orally disintegrating) 0.5 mg Tablet (orally disintegrating) 1 mg; Jorveza® - November 2021
• Budesonide: Tablet (orally disintegrating) 1 mg; Jorveza®- March 2021
• Budesonide: Capsule (modified release) 3 mg; Entocort® - July 2018
• Budesonide: Capsule (modified release) 3 mg; Entocort® - November 2017
• Budesonide: Tablet 9 mg; Cortiment® - July 2017
• Budesonide, foam enema, 2 mg, Budenofalk® - July 2013
• Budesonide with eformoterol: Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses; Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with eformoterol fumarate dihydrate 12 micrograms per dose, 120 dosesDuoResp® Spiromax®, Teva Pharma Australia Pty Limited - August 2018
• Budesonide with eformoterol: Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses;  Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with eformoterol fumarate dihydrate 12 micrograms per dose, 120 doses; DuoResp®, Spiromax - July 2017
• Budesonide with Formoterol: Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses, Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses; Symbicort Turbuhaler® 200/6; Symbicort Rapihaler® 100/3 - November 2019
• Budesonide with Formoterol: Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses, Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses; Symbicort® Turbuhaler® 200/6 and Symbicort® Rapihaler® 100/3 - July 2019
• Budesonide with eformoterol: Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses, Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with eformoterol fumarate dihydrate 12 micrograms per dose, 120 doses; DuoResp® Spiromax® - November 2017
• Budesonide with eformoterol fumarate dihydrate, oral pressurised inhalation, 50 micrograms – 3 micrograms per dose, 100 micrograms – 3 micrograms per dose, 200 micrograms – 6 micrograms per dose, Symbicort Rapihaler® - July 2013
• Budesonide with Eformoterol Fumarate Dihydrate, powder for oral inhalation in breath actuated device, 100 micrograms-6 micrograms per dose, 200 micrograms-6 micrograms per dose Symbicort Turbuhaler®, March 2007
• Budesonide with eformoterol fumarate dihydrate, powder for oral inhalation, fixed dose combination, 400 micrograms-12 micrograms per dose, Symbicort Turbuhaler 400/12®, November 2010
• Budesonide: Capsule (modified release) 3 mg; Budenofalk® - March 2019
• Budesonide: Capsule (modified release) 3 mg; Entocort® - March 2019
• Buprenorphine: Injection (modified release) 8 mg in 0.16 mL pre-filled syringe, Injection (modified release) 16 mg in 0.32 mL pre-filled syringe, Injection (modified release) 24 mg in 0.48 mL pre-filled syringe, Injection (modified release) 32 mg in 0.64 mL pre-filled syringe; Buvidal® Weekly; Injection (modified release) 64 mg in 0.18 mL pre-filled syringe, Injection (modified release) 96 mg in 0.27 mL pre-filled syringe, Injection (modified release) 128 mg in 0.36 mL pre-filled syringe, Injection (modified release) 160 mg in 0.45 mL pre-filled syringe; Buvidal® Monthly - November 2021
• Buprenorphine with Naloxone: Tablet (sublingual) containing 0.7 mg buprenorphine hydrochloride with 0.18 mg naloxone hydrochloride, Tablet (sublingual) containing 1.4 mg buprenorphine hydrochloride and 0.36 mg naloxone hydrochloride, Tablet (sublingual) containing 2.9 mg buprenorphine hydrochloride and 0.71mg naloxone hydrochloride, Tablet (sublingual) containing 5.7 mg buprenorphine hydrochloride and 1.4 mg naloxone hydrochloride, Tablet (sublingual) containing 8.6 mg and 2.1mg naloxone hydrochloride, Tablet (sublingual) containing 11.4 mg buprenorphine hydrochloride and 2.9 mg naloxone hydrochloride; Zubsolv® - March 2020
• Buprenorphine: Injection (modified release) 100 mg in 0.5 mL pre-filled syringe, Injection (modified release) 300 mg in 1.5 mL pre-filled syringe; Sublocade® - November 2019
• Buprenorphine: Injection 8 mg in 0.16 mL pre-filled syringe, Injection 16 mg in 0.32 mL pre-filled syringe, Injection 24 mg in 0.48 mL pre-filled syringe, Injection 32 mg in 0.64 mL pre-filled syringe, Injection 64 mg in 0.18 mL pre-filled syringe, Injection 96 mg in 0.27 mL pre-filled syringe, Injection 128 mg in 0.36 mL pre-filled syringe; Buvidal® - November 2018
• Buprenorphine: 5 μg/hour patch, 10 μg/hour patch, 15 μg/hour patch, 20 μg/hour patch, 25 μg/hour patch, 30 μg/hour patch, 40 μg/hour patch, Norspan® - July 2016
• Buprenorphine: 5 microgram/hour patch, 10 microgram/hour patch, 20microgram/hour patch, Norspan® - November 2015
• Buprenorphine: 15 microgram/hour patch, 25 microgram/hour patch, 30 microgram/hour patch, 40 microgram/hour patch; Norspan® - November 2015
• Buprenorphine; 15 microgram/hour patch, 2; 25 microgram/hour patch, 2; 30 microgram/hour patch, 2; 40 microgram/hour patch, 2; Norspan® - July 2015
• Buprenorphine; 15 microgram/hour patch 2, 25 microgram/hour patch 2,30 microgram/hour patch, 2,40 microgram/hour patch, 2; Norspan® - March 2015
• Buprenorphine hydrochloride with naloxone hydrochloride, sublingual tablets, 2 mg (base) - 500 micrograms and 8 mg (base) – 2 mg, Suboxone®, November 2005
• Buprenorphine, transdermal patch, 5 mg, 10 mg and 20 mg (releasing 5 micrograms, 10 micrograms and 20 micrograms per hour respectively), Norspan®, July 2005
• Buprenorphine + naloxone; 4mg/1mg film: sublingual, 12mg/3mg film: sublingual, Suboxone® - November 2014
• Buprenorphine: Injection (modified release) 100 mg in 0.5 mL pre-filled syringe, Injection (modified release) 300 mg in 1.5 mL pre-filled syringe; Sublocade® - March 2019
• Buprenorphine with Naloxone: Tablet (sublingual) containing 0.7 mg buprenorphine hydrochloride with 0.18 mg naloxone hydrochloride, Tablet (sublingual) containing 1.4 mg buprenorphine hydrochloride and 0.36 mg naloxone hydrochloride, Tablet (sublingual) containing 2.9 mg buprenorphine hydrochloride and 0.71mg naloxone hydrochloride, Tablet (sublingual) containing 5.7 mg buprenorphine hydrochloride and 1.4 mg naloxone hydrochloride, Tablet (sublingual) containing 8.6 mg and 2.1mg naloxone hydrochloride, Tablet (sublingual) containing 11.4 mg buprenorphine hydrochloride and 2.9 mg naloxone hydrochloride; Zubsolv®  - November 2019
• Buprenorphine: Injection 8 mg in 0.16 mL pre-filled syringe, Injection 16 mg in 0.32 mL pre-filled syringe, Injection 24 mg in 0.48 mL pre-filled syringe, Injection 32 mg in 0.64 mL pre-filled syringe, Injection 64 mg in 0.18 mL pre-filled syringe, Injection 96 mg in 0.27 mL pre-filled syringe, Injection 128 mg in 0.36 mL pre-filled syringe; Buvidal® - March 2019
• Burosumab: Injection 10 mg in 1 mL, Injection 20 mg in 1 mL, Injection 30 mg in 1 mL; Crysvita® – May 2022
• Burosumab: Injection 10 mg in 1 mL, Injection 20 mg in 1 mL, Injection 30 mg in 1 mL; Crysvita® - March 2022
• Burosumab: Injection 10 mg in 1 mL, Injection 20 mg in 1 mL, Injection 30 mg in 1 mL; Crysvita® - March 2021
• Top of page

C

• Cabazitaxel: Solution concentrate for I.V. infusion 60 mg in 3 mL; Cabazitaxel Accord® - March 2022
• Cabazitaxel: Concentrated injection 60 mg (as acetone solvate) in 1.5 mL, with diluent; Cabazitaxel Ever Pharma®- March 2021
• Cabazitaxel, injection set containing 1 single use vial concentrate for I.V. infusion, 60 mg (anhydrous) in 1.5 mL with diluent, Jevtana® - November 2011
• Cabazitaxel, injection set containing 1 single use vial concentrate for I.V. infusion, 60 mg (anhydrous) in 1.5 mL with 1 single use vial diluent 4.5 mL, Jevtana® - July 2011
• Cabotegravir, cabotegravir and rilpivirine: Tablet containing cabotegravir 30 mg; Vocabria®; Pack containing 1 injection of cabotegravir 600 mg in 3 mL and 1 injection of rilpivirine 900 mg in 3 mL; Cabenuva® - November 2021
• Cabotegravir: Suspension for injection, 600 mg in 3 mL; Apretude® - July 2023
• Cabotegravir and rilpivirine: Pack containing 1 injection of cabotegravir 600 mg in 3 mL and 1 injection of rilpivirine 900 mg in 3mL; Cabenuva®- March 2021
• Cabozantinib: Tablet 20 mg, Tablet 40 mg, Tablet 60 mg; Cabometyx® - November 2020
• Cabozantinib: Tablet 20 mg, Tablet 40 mg, Tablet 60 mg; Cabometyx® - March 2020
• Cabozantinib: Tablet 20 mg, Tablet 40 mg, Tablet 60 mg; Cabometyx® - July 2019
• Cabozantinib: Tablet 20 mg, 40 mg and 60 mg; Cabometyx® - December 2017
• Cabozantinib: Tablet 20 mg, Tablet 40 mg, Tablet 60 mg; Cabometyx® - March 2019
• Calcipotriol with betamethasone: Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g; Enstilar® - November 2016
• Calcipotriol with betamethasone: Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g; Enstilar® - July 2023
• Calcipotriol with betamethasone dipropionate: Gel containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g; Daivobet® - March 2018
• Calcipotriol + betamethasone dipropionate gel 50/500, 30g and 60g; Daivobet® - November 2015
• Calcipotriol with betamethasone dipropionate, ointment, 50 micrograms-500 micrograms (base) per g, Daivobet®, July 2009
• Calcium: Tablet, chewable, 500 mg (as carbonate); Cal-500® - March 2019
• Cannabidiol: Oral liquid 100 mg per mL, 100 mL; Epidyolex® – September 2022
• Cannabidiol: Oral liquid 100 mg per mL, 100 mL; Epidyolex® - July 2022
• Cannabidiol: Oral liquid 100 mg per mL, 100 mL; Epidyolex® - March 2022
• Cannabidiol: Oral solution, 100 mg per mL, 100 mL; Epidyolex® – July 2020
• Canagliflozin, tablet, 100 mg and 300 mg, Invokana® - July 2013
• Canakinumab; 150 mg injection: powder for, 1 vial, 150 mg injection: powder for, 4 vials; Ilaris® – March 2015
• Canakinumab: Powder for injection 150 mg with solvent, Solution for injection 150 mg in 1 mL; Ilaris® - November 2017
• Capecitabine, tablet, 150 mg and 500 mg, Xeloda® - March 2011
• Capecitabine, tablet, 150 mg and 500 mg, Xeloda® - March 2010
• Capecitabine tablets, 150 mg and 500 mg, Xeloda®, July 2009
• Capecitabine tablets, 150mg and 500 mg, Xeloda®, November 2005
• Capecitabine; megestrol; toremifene; vinorelbine - November 2014
• Caplacizumab: Injection set containing 1 vial powder for injection 10 mg and 1 pre-filled syringe solvent 1 mL; Cablivi® - July 2020
• Carbohydrate, fat, vitamins, minerals and trace elements: Oral powder 400 g; Energivit® - July 2020
• Carbohydrate formula with minerals: Sachet containing oral powder 21 g, Sachet containing oral powder 31 g, Sachet containing oral powder 42 g, Sachet containing oral powder 52 g; SOS10®, SOS15®, SOS20®, SOS25® - November 2016
• Carfilzomib: Powder for injection 10 mg, Powder for injection 30 mg, Powder for injection 60 mg; Kyprolis® - March 2022
• Carfilzomib: Powder for injection 10 mg, Powder for injection 30 mg, Powder for injection 60 mg; Kyprolis® - July 2020
• Carfilzomib: Powder for injection 30 mg, Powder for injection 60 mg; Kyprolis® - November 2018
• Carfilzomib: Powder for I.V. infusion 10 mg; Kyprolis® - March 2018
• Carfilzomib: Powder for I.V. infusion 30 mg and 60 mg; Kyprolis® - July 2017
• Carfilzomib: Powder for I.V. infusion 30 m, Powder for I.V. infusion 60 mg; Kyprolis® - November 2016
• Carglumic acid; 200 mg dispersible tablet, 5; 200 mg dispersible tablet, 60; Carbaglu® - July 2015

• Cariprazine: Capsule 1.5 mg, Capsule 3 mg, Capsule 4.5 mg, Capsule 6 mg; Reagila® - November 2020

• Ceritinib: Capsule 150 mg; Zykadia® - November 2016
• Certolizumab pegol: Injection 200 mg in 1 mL single use pre-filled syringe, Solution for injection 200 mg in 1 mL pre-filled pen; Cimzia® - November 2019
• Carmellose with glycerin and with hyaluronic acid: Eye drops containing carmellose sodium 5 mg with glycerin 9 mg and with hyaluronic acid 1 mg per mL, 10 mL; Optive Fusion® - March 2023 - May 2023
• Carmellose and Hypromellose: Eye drops containing carmellose sodium 5 mg per mL, 10 mL (Evolve carmellose); Eye drops containing hypromellose 3 mg per mL, 10 mL (Evolve hypromellose); Evolve® carmellose and Evolve®  hypromellose - July 2019
• Carmellose sodium hypromellose: Eye drops containing carmellose sodium 5 mg per ml, 10 ml (Evolve carmellose); Eye drops containing hypromellose, 3 mg per ml, 10 ml (Evolve hypromellose); Evolve® carmellose, Evolve® hypromellose - July 2018
• Carmustine, implant, 7.7 mg, 8, Gliadel ®, July 2008
• Carmustine, implant, 7.7 mg, Gliadel®, March 2007
• Carmustine, implant, 7.7 mg, Gliadel®, March 2006
• Carmustine, implant, 7.7 mg, Gliadel®, November 2005
• Cationic ophthalmic emulsion, preservative free: Eye drops containing heavy mineral oil 0.5% and light mineral oil 0.5%, 10 mL; Cationorm® - July 2020
• Cefuroxime: oral suspension, 125 mg per 5 mL, 100 mL; tablets, 250 mg, 20, Zinnat® - November 2015
• Cemiplimab: Solution for I.V. infusion 350 mg in 7 mL; Libtayo® - March 2022
• Cemiplimab: Solution for I.V. infusion 350 mg in 7 mL; Libtayo® - November 2021
• Cemiplimab: Solution for I.V. infusion 350 mg in 7 mL; Libtayo® - November 2020
• Cerliponase alfa: Solution for infusion 150 mg with flushing solution; Brineura® - July 2018
• Certolizumab pegol: Solution for injection 200mg in 1 mL pre-filled pen, Solution for injection 200 mg in 1 mL single use pre-filled syringe; Cimzia® - November 2019
• Certolizumab pegol: Injection 200 mg in 1 mL single dose auto-injector; Cimzia® - March 2017
• Certolizumab pegol: 200 mg/mL injection, 2 x 1 mL syringes, Cimzia® - March 2016
• Certolizumab Pegol, 200 mg/mL injection, 2 x 1 mL syringes, Cimzia® - March 2014
• Certolizumab Pegol, injection, 200 mg in 1 mL, single use pre-filled syringe, Cimzia® - March 2010
• Certolizumab pegol; 200 mg/mL injection, 2 x 1 mL syringes; Cimzia® - November 2014
• Certolizumab Pegol: Injection 200 mg in 1 mL pre-syringe pen, Solution for injection 200 mg in 1 mL pre-filled pen; Cimzia® - March 2019
• Cetuximab: Injection 100 mg in 20 mL, Injection 500 mg in 100 mL; Erbitux® - November 2016
• Cetuximab: 100 mg/20 mL injection, 1 x 20 mL vial 500 mg/100 mL injection, 1 x 100 mL vial , Erbitux® - March 2016
• Cetuximab: Solution for I.V. infusion 100 mg in 20 mL, Solution for I.V. infusion 500 mg in 100 mL; Erbitux® - March 2018
• Cetuximab, solution for IV infusion, 100 mg in 20 mL, 100 mg in 50 mL and 500 mg in 100 mL, Erbitux® - March 2010
• Cetuximab, solution for IV infusion, 100 mg in 20 mL, 100 mg in 50 mL and 500 mg in 100 mL, Erbitux®, March 2009
• Cetuximab, solution for IV infusion, 100 mg in 20 mL, 100 mg in 50 mL and 500 mg in 100 mL, Erbitux®, November 2008
• Cetuximab, solution for IV infusion, 100 mg in 20 mL and 500 mg in 100 mL, Erbitux® - July 2010
• Cetuximab, solution for IV infusion, 100 mg in 50 mL, Erbitux®, March 2007
• Cetuximab, solution for IV infusion, 100 mg in 50 mL, Erbitux®, November 2005
• Cetuximab; solution for intravenous (IV) infusion, 100 mg in 20 mL & 500 mg in 100 mL; Erbitux® - November 2014
• Chlormethine hydrochloride: 0.016% (160 microgram/g) gel; Ledaga® - March 2023
• Chorionic gonadotropin: Injection set containing 3 vials powder for injection 1,500 units and 3 vials diluent 1 mL, Injection set containing 1 vial powder for injection 5,000 units and 1 vial diluent 1 mL; Pregnyl® - March 2017
• Ciclosporin: Eye drops 900 micrograms per mL, single dose units, 0.25 mL, 60; Cequa® - March 2022
• Ciclosporin: Eye drops 0.1%, single dose units 0.4 mL, 30; Ikervis®- March 2021
• Cilostazol, tablets, 50 mg and 100 mg, Pletal® July 2010
• Cilostazol, tablets, 50 mg and 100 mg, Pletal®July 2009
• Cinacalcet: Tablet 30 mg, 60 mg, 90 mg; Pharmacor Cinacalcet® - July 2019
• Cinacalcet, tablets, 30 mg, 60 mg and 90 mg, Sensipar® - March 2014
• Cinacalcet, tablets, 30 mg, 60 mg and 90 mg, Sensipar® - November 2013
• Cinacalcet hydrochloride, tablets, 30 mg, 60 mg and 90 mg, Sensipar July 2009
• Cinacalcet hydrochloride, tablets, 30 mg, 60 mg and 90mg, Sensipar®, November 2007
• Cinacalcet hydrochloride, tablets, 30 mg, 60 mg and 90mg, Sensipar®, July 2006
• Cinacalcet hydrochloride, tablets, 30 mg, 60 mg, 90 mg, Sensipar®, November 2005
• Ciprofloxacin, ear drops, 3 mg per mL (0.3%), 5 mL Ciloxan® , July 2006
• Citrulline: 1 g tablet, 300, Citrulline Easy Tablets® - November 2015
• Cladribine: Tablet 10 mg; Mavenclad® - November 2021
• Cladribine: Tablet 10 mg; Mavenclad® - July 2018
• Cladribine, tablet, 10 mg, Movectro®, March 2011
• Cladribine: Tablet 10 mg; Mavenclad® - November 2017  
• Cladribine: Tablet, 10 mg; Mavenclad® - March 2018
• Clindamycin phosphate with benzoyl peroxide, gel, 10 mg (base) - 50 mg per gm (1% – 5%), 25 gm, Duac® Once Daily Gel, March 2009
• Clobetasol Propionate, shampoo, 500 microgram per mL, 125mL - November 2013
• Clopidogrel hydrogen sulfate, tablet, 75 mg (base), Iscover®, Plavix®, March 2009
• Clopidogrel hydrogen sulfate, tablet 75 mg (base), Plavix®, Iscover®, March 2008

• Clostridium botulinum type A toxin-haemagglutinin complex: Lyophilised powder for I.M. injection 300 units, Lyophilised powder for I.M. injection 500 units; Dysport® - July 2020

• Clostridium Botulinum Type A Toxin-Haemagglutinin Complex: Lyophilised powder for I.M. injection 300 units, Lyophilised powder for I.M. injection 500 units; Dysport® - July 2019
• Clostridium Botulinum Type A Toxin – Haemagglutinin C Complex (Lower Limb): Lyophilised powder for I.M. injection 300 units, Lyophilised powder for I.M. injection 500 units; Dysport® - November 2018
• Clostridium Botulinum Type A Toxin – Haemagglutinin C Complex (Upper Limb): Lyophilised powder for I.M. injection 300 units, Lyophilised powder for I.M. injection 500 units; Dysport® - November 2018
• Clostridium botulinum type A toxin haemagglutinin complex, lyophilised powder for I.M. injection, 300 units and 500 units, Dysport®, July 2011
• Clostridium botulinum type A toxin-haemagglutinin complex, lyophilised powder for I.M. injection, 500 units/vial, Dysport®, November 2007
• Clostridium Botulinum Type A Toxin – Haemagglutinin C Complex: Lyophilised powder for I.M. injection 300 units, Lyophilised powder for I.M. injection 500 units; Dysport® - March 2019
• Clozapine; Oral liquid 50 mg per mL, 100 mL; Versacloz® - July 2018
• Coal Tar Prepared , emulsion, 10 mg per g (1%), Exorex® July 2005
• Coal tar prepared; 2% (20 mg/g), foam aerosol, 100 g; Scytera® Foam - November 2014
• Cobicistat + elvitegravir + emtricitabine + tenofovir, cobicistat 150 mg, elvitegravir 150 mg, emtricitabine 200 mg, tenofovir 300 mg, Stribild®, March 2013
• Cobicistat, tablet (film coated), 150mg, Tybost®, March 2013
• Cobimetinib + vemurafenib: cobimetinib 20 mg tablet, 63 + vemurafenib 240 mg tablet, 56, Cotellic® Zelboraf® - March 2016
• Colistimethate sodium, powder for nebuliser solution, 1 million IU (equivalent to 80 mg colistimethate sodium), Tadim®, March 2011
• Collagenase Clostridium Histolyticum, 900 microgram injection [1 x 900 microgram vial] (&) inert substance [1 x 3 mL vial], Xiaflex® - July 2014
• Collagenase clostridium histolyticum, lyophilised powder for injection, 900 micrograms powder for injection, Xiaflex® - July 2013
• Continued Dispensing Arrangements - November 2021
• Corifollitropin alfa, solution for injection, 150 microgram in 0.5 mL pre-filled syringe, Elonva ®, March 2013
• Corifollitropin Alfa, solution for injection, 100 micrograms in 0.5 mL pre-filled syringe, 150 micrograms in 0.5 mL pre-filled syringe, Elonva®, July 2011
• Corifollitropin alfa, solution for injection, 100 micrograms in 0.5 mL, 150 micrograms in 0.5 mL, pre-filled syringe, Elonva®, November 2010
• Cost-effectiveness review of pneumococcal vaccines for the National Immunisation Program: Pre-filled syringe, 0.5 mL; Prevenar 13® (pneumococcal polysaccharide conjugate 13-valent adsorbed vaccine) and Pneumovax 23® (pneumococcal polysaccharide 23-valent adsorbed vaccine) - July 2019
• Crisaborole: Ointment 2%, 30 g; Ointment 2%, 60 g; Staquis® - November 2020
• Crisaborole: Ointment containing crisaborole 20 mg per g, 60 g; Staquis® - November 2018
• Crizotinib: Capsule 200 mg; Capsule 250 mg; Xalkori® - July 2018
• Crizotinib: Capsule 200 mg, Capsule 250 mg; Xalkori® - November 2017
• Crizotinib: Capsule 200 mg, Capsule 250 mg; Xalkori® - March 2017
• Crizotinib, 200 mg capsule, 60 and 250 mg capsule, 60, Xalkori®, Pfizer Australia Pty Ltd - March 2014
• Crizotinib; 200 mg capsule, 60 and 250 mg capsule, 60; Xalkori® - November 2014
• Crizotinib, 200 mg and 250 mg, capsule, Xalkori® - November 2013
  Top of page

D

• Dabigatran etexilate, capsules, 110 mg and 150 mg (as mesilate), Pradaxa®, March 2013
• Dabigatran etexilate, capsules, 110 mg and 150 mg (as mesilate), Pradaxa® - July 2012
• Dabigatran etexilate, capsules, 110 mg and 150 mg (as mesilate), Pradaxa® , March 2011
• Dabigatran etexilate mesilate, capsules, 75 mg, 110 mg (base), Pradaxa® , March 2009
• Dabigatran etexilate mesilate, capsules, 75 mg and 110 mg (base), Pradaxa®, November 2009
• Dabrafenib and Trametinib: dabrafenib: Capsule 50 mg, Capsule 75 mg; trametinib: Tablet 500 microgram, Tablet 2 mg; Tafinlar® and Mekinist® - July 2019
• Dabrafenib: capsule, 50 mg & 75 mg, Tafinlar® and Trametinib: tablet, 500 microgram & 2 mg, Mekinist® - November 2015
• Dabrafenib, capsules, 50 mg and 75 mg Tafinlar® - July 2013
• Dabrafenib, capsule, 50 mg and 75 mg, Tafinlar® - March 2013
• Dabrafenib and Trametinib: dabrafenib: Capsule 50 mg, Capsule 75 mg; trametinib: Tablet 500 micrograms, Tablet 2 mg; Tafinlar® and Mekinist® - March 2019
• Daclatasvir: tablet, 60mg or 30mg, Daklinza® - November 2015
• Daclatasvir; 60mg or 30mg, tablets; Daklinza® – March 2015
• Daclizumab: Injection 150 mg in 1 mL pre-filled syringe injection 150 mg in 1 mL pre-filled injection device; Zinbryta® - November 2016
• Daclizumab: 150 mg/mL solution for injection, 1 mL pen-filled pen 150 mg/mL solution for injection, 1 mL syringe, Zinbryta® - July 2016
• Dactylis glomerata with poa pratensis, lolium perenne, anthoxanthum odoratum and phleum pratense: 100 IR tablet: sublingual, 3 + 300 IR tablet: sublingual, 28; 300 IR tablet: sublingual, 30, Oralair® - July 2016
• Dalteparin sodium (low molecular weight heparin sodium-porcine mucous), injection, 7,500 units (anti-Xa) in 0.75 mL, 10,000 units (anti-Xa) in 1 mL, 12,500 units (anti-Xa) in 0.5 mL, 15,000 units (anti-Xa) in 0.6 mL and 18,000 units (anti-Xa) in 0.72 mL, single dose pre-filled syringe, Fragmin®, November 2010
• Dapagliflozin: Tablet 10 mg; Forxiga® - July 2023
• Dapagliflozin: Tablet 10 mg; Forxiga® - March 2022
• Dapagliflozin: Tablet 10 mg; Forxiga® - November 2021
• Dapagliflozin (chronic kidney disease): Tablet 10 mg; Forxiga® - September 2021
• Dapagliflozin (heart failure): Tablet 10 mg; Forxiga® - September 2021
• Dapagliflozin (chronic kidney disease): Tablet 10 mg; Forxiga® - July 2021
• Dapagliflozin (heart failure): Tablet 10 mg; Forxiga® - July 2021
• Dapagliflozin: Tablet 10 mg; Forxiga® - November 2020
• Dapagliflozin: Tablet 10 mg (as propanediol monohydrate); Forxiga® - July 2017
• Dapagliflozin; 10 mg tablet 28; Forxiga® – March 2015
• Dapagliflozin, 10 mg tablet, Forxiga®, AstraZeneca Pty Ltd - July 2014
• Dapagliflozin; tablet, 10 mg; Forxiga® - November 2014
• Dapagliflozin with metformin: Tablet (modified release) containing 5 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride, Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 500 mg metformin hydrochloride, Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride; Xigduo® XR - July 2017
• Dapagliflozin, 2. Dapagliflozin with metformin, 3. Dapagliflozin with saxagliptin: 1. Tablet 10 mg (as propanediol monohydrate), 2. Tablet (modified release) containing 5 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride, Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 500 mg metformin hydrochloride, Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride, 3. Tablet containing 10 mg dapagliflozin (as propanediol monohydrate) with 5 mg saxagliptin; 1. Forziga®, 2. Xigduo® XR, 3. Qtern® - November 2017 
• Dapagliflozin and metformin XR; Xigduo® XR - July 2015
• Dapagliflozin and Metformin XR (FDC), modified release tablets, 10 mg/500 mg, 10 mg/1000 mg, 5 mg/1000 mg, Xigduo XR® - July 2014
• Dapagliflozin, tablet, 10 mg, Forxiga® - July 2013
• Dapagliflozin, tablet, 10 mg, (as propanediol monohydrate), Forxiga® (dual oral) - March 2012
• Daratumumab: Solution for I.V. infusion 100 mg in 5 mL vial, Solution for I.V. infusion 400 mg in 20 mL vial, Solution for S.C. injection 1,800 mg in 15 mL vial; Darzalex® - March 2023
• Daratumumab: Solution for subcutaneous injection 1,800 mg in 15 mL vial; Darzalex SC® – May 2022
• Daratumumab: Solution for subcutaneous injection 1,800 mg in 15 mL vial; Darzalex® - July 2021
• Daratumumab: 100 mg/5 mL injection, 5 mL vial, 400 mg/20 mL injection, 20 mL vial; Darzalex® - July 2020
• Daratumumab: Solution concentrate for I.V infusion 100 mg in 5 mL, Solution concentrate for I.V infusion 400 mg in 20 mL; Darzalex® - November 2019
• Dapagliflozin, tablet, 10 mg, (as propanediol monohydrate), Forxiga® (insulin) - March 2012
• Daratumumab: Solution for subcutaneous injection 1,800 mg in 15 mL vial; Darzalex SC® - November 2021
• Daratumumab: Solution concentrate for I.V infusion 100 mg in 5 mL, Solution concentrate for I.V infusion 400 mg in 20 mL; Darzalex® - November 2017
• Daratumumab: Solution concentrate for I.V infusion 100 mg in 5 mL, Solution concentrate for I.V infusion 400 mg in 20 mL; Darzalex® - March 2019  
• Darbepoetin alfa, injection, 200 micrograms/0.4 mL, 300 micrograms/0.6 mL and 500 micrograms/1 mL, Aranesp® and Aranesp SureClick®, November 2007
• Darbepoetin Alfa: Injection 200 micrograms in 0.4 mL pre-filled syringe, Injection 300 micrograms in 0.6 mL pre-filled syringe, Injection 500 micrograms in 1 mL pre-filled syringe; Aranesp® - March 2019
• Darolutamide: Tablet 300 mg; Nubeqa® - November 2022 - May 2023
• Darolutamide: Tablet 300 mg; Nubeqa® - July 2021
• Darolutamide: Tablet 300 mg; Nubeqa®- March 2021
• Darolutamide: Tablet 300 mg; Nubeqa® - July 2020
• Darunavir with Cobicistat with Emtricitabine and Tenofovir alafenamide: Tablet containing darunavir 800 mg with cobicistat 150 mg with emtricitabine 200 mg and tenofovir alafenamide 10 mg; Symtuza® - November 2019
• Darunavir + cobicistat: darunavir 800 mg + cobicistat 150 mg tablet, 30, Prezcobix® - March 2016
• Darunavir + cobicistat: fixed-dose combination tablet, 30, darunavir 800 mg + cobicistat 150 mg, Prezcobix® - November 2015
• Darunavir, tablet, 400 mg (as ethanolate), Prezista®, July 2010
• Darunavir Ethanolate, film-coated tablets, 300 mg (base), Prezista®, July 2007
• Darunavir, tablets, 150 mg and 300 mg (as ethanolate), Prezista®, November 2009
• Dasatinib: 20 mg tablet, 60, 50 mg tablet, 60, 70 mg tablet, 60, 100 mg tablet, 30, Sprycel® - July 2016
• Dasatinib, tablets, 20 mg, 50 mg, 70 mg and 100 mg, Sprycel®, Bristol Myers Squibb Australia Pty Ltd - July 2014
• Dasatinib, tablets, 20 mg, 50 mg, 70 mg and 100 mg, Sprycel®, July 2011
• Dasatinib, tablets, 20 mg, 50 mg and 70 mg, Sprycel®, July 2007
• Dasatinib, tablets, 20 mg, 50 mg and 70 mg, Sprycel®, (ALL), March 2007
• Dasatinib, tablets, 20 mg, 50 mg and 70 mg, Sprycel®, (CML), March 2007
• Dasatinib: Tablet 20 mg, Tablet 50 mg, Tablet 70 mg, Tablet 100 mg; Sprycel® - March 2019
• Daunorubicin with cytarabine: Powder for I.V. infusion containing daunorubicin 44 mg and cytarabine 100 mg; Vyxeos® - July 2023
• Decitabine with cedazuridine: Tablet containing decitabine 35 mg + cedazuridine 100 mg; Inqovi® - July 2021
• Decitabine and cedazuridine: Tablet containing decitabine 35 mg + cedazuridine 100 mg; Inqovi®- March 2021
• Deferasirox: Dispersible tablet 125 mg, Dispersible tablet 250 mg, Dispersible tablet 500 mg; Deferasirox Juno® - November 2020
• Deferasirox: Tablet 90 mg; Tablet 180 mg; Tablet 360 mg; Jadenu® - July 2018
• Deferasirox; 125 mg dispersible tablet, 28; 250 mg dispersible tablet, 28; 500mg dispersible tablet, 28; Exjade® - July 2015
• Deferasirox, dispersible tablet, 125 mg, 250 mg and 500 mg, Exjade®, July 2006
• Deferiprone: Tablet 1000 mg; Ferriprox® - November 2017
• Degarelix: Powder for injection 80 mg (as acetate), injection set, Powder for injection 120 mg (as acetate), injection set; Firmagon® - March 2017
• Degarelix, powder for subcutaneous injection (modified release), 80 mg and 120 mg, (as acetate) with solvent, syringe and needles, Firmagon®- July 2010
• Denosumab: Injection 120 mg in 1.7 mL; Xgeva® - November 2018
• Denosumab: Injection 120 mg in 1.7 mL; Xgeva® - July 2019
• Denosumab: Injection 120 mg in 1.7 mL; Xgeva® - July 2018
• Denosumab: 120 mg/1.7 mL injection, 1 × 1.7 mL vial, Xgeva® - July 2016
• Denosumab: 120 mg/1.7 mL injection, 1 x 1.7 mL vial, XGEVA® - March 2016
• Denosumab, solution for injection, 120 mg in 1.7 mL, Xgeva® - November 2013
• Denosumab: 60 mg/mL injection, 1 × 1 mL syringe, Prolia® - July 2016
• Denosumab, injection, 60 mg/mL, Prolia® - July 2013
• Denosumab, injection 60 mg in 1 mL pre-filled syringe, Prolia® - March 2012
• Denosumab, solution for subcutaneous injection, 120 mg in 1.7 mL, Xgeva® , July 2011
• Denosumab, injection, 60 mg in 1 mL, single use pre-filled syringe, Prolia® - July 2010
• Desvenlafaxine succinate, tablet, (extended release), 50 mg and 100 mg (base), Pristiq®, November 2008

• Deucravacitinib: Tablet 6 mg; Sotyktu®- November 2022 - March 2023

• Deutetrabenazine: Tablet 6 mg, Tablet 9 mg, Tablet 12 mg; Austedo®- March 2021
• Dexamethasone: Intravitreal injection 700 micrograms; Ozurdex® - March 2018
• Dexamethasone: 700 microgram implant, 1, Ozurdex® - March 2016
• Dexamethasone; 700 µg implant; Ozurdex® - March 2015
• Dexamethasone: Intravitreal injection 700 micrograms; Ozurdex® - November 2017
• Diclofenac sodium with misoprostol, tablet, 50 mg–200 micrograms, Arthrotec® 50, November 2009
• Difelikefalin: Solution for I.V. injection 50 mcg in 1 mL vial; Korsuva® - March 2023
• Dimethyl fumarate: Capsule (modified release) 120 mg, Capsule (modified release) 240 mg; Tecfidera® - November 2019
• Dimethyl Fumarate: 120 mg capsules, Tecfidera® - July 2016
• Dimethyl Fumarate, capsules, 120 mg and 240 mg, Tecfidera® - July 2013
• dTpa Vaccine: Single dose vial containing 0.5 mL of vaccine; Adacel® - March 2017
• dTpa Vaccine: 0.5 mL injection, Boostrix® - July 2016
• Diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and haemophilus influenzae type b conjugate vaccine (DTPa-HB-IPV-Hib): 0.5 mL pre-filled syringe; Vaxelis™ - March 2022
• Diphtheria-tetanus-acellular pertussis (dTpa) vaccine, 0.5 mL in pre-filled syringe, Boostrix®, July 2011
• Diphtheria + tetanus + acellular pertussis (DTPa) vaccine; Infanrix® - November 2014
• Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (DTPa-HepB-IPV-Hib); 0.5 mL pre-filled syringe; Hexaxim® – March 2015
• Diroximel fumarate: Capsule 231 mg; Vumerity® - March 2022
• Docetaxel: Solution concentrate for I.V. infusion 160 mg in 8 Ml; Docetaxel Accord® - July 2017
• Docetaxel, injection set containing 1 single use vial concentrate for I.V. infusion 20 mg (anhydrous) in 0.5 mL and 1 single use vial solvent 1.5 mL and injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL and 1 single use vial solvent 6 mL, Taxotere®, November 2009
• Docetaxel, injection set containing 1 single use vial concentrate for I.V. infusion 20 mg (anhydrous) in 0.5 mL and 1 single use vial solvent 1.5 mL, injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL and 1 single use vial solvent 6 mL, Taxotere®, July 2008
• Docetaxel, injection set containing 1 single use vial concentrate for I.V. infusion 20 mg (anhydrous) in 0.5 mL and 1 single use vial solvent 1.5 mL and injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL and 1 single use vial solvent 6 mL, Taxotere®, July 2007
• Docetaxel, injection set containing 1 single use vial concentrate for I.V. infusion 20 mg (anhydrous) in 0.5 mL and 1 single use vial solvent 1.5 mL and injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL and 1 single use vial solvent 6 mL, Taxotere®, November 2006
• Docetaxel, injection set containing 1 single use vial concentrate for I.V. infusion, 20 mg (anhydrous) in 0.5 mL and 1 single use vial solvent 1.5 mL and 80 mg (anhydrous) in 2 mL and 1 single use vial solvent 6 mL, Taxotere® March 2006
• Docetaxel, injection set containing 1 single use vial concentrate for I.V. infusion, 20 mg (anhydrous) in 0.5 mL and 1 single use vial solvent 1.5 mL and 80 mg (anhydrous) in 2 mL and 1 single use vial solvent 6 mL, Taxotere®, July 2005.
• Docetaxel, injection set containing 1 single use vial concentrate for I.V. infusion, 20 mg (anhydrous) in 0.5 mL and 1 single use vial solvent 1.5 mL and 80 mg (anhydrous) in 2 mL and 1 single use vial solvent 6 mL, Taxotere, July 2005

• Dolutegravir with Lamivudine: Tablet containing dolutegravir 50 mg (as sodium) with lamivudine 300 mg; Dovato® - July 2020

• Dolutegravir with Lamivudine, Tablet containing dolutegravir 50 mg (as sodium) with lamivudine 300 mg, Dovato®, ViiV Health Care Pty Ltd - August 2019
• Dolutegravir with Lamivudine: Tablet containing dolutegravir 50 mg (as sodium) with lamivudine 300 mg; Dovato® - July 2019
• Dolutegravir, tablet, 50 mg, Tivicay® - November 2013
• Dolutegravir + abacavir + lamivudine; dolutegravir 50 mg + abacavir 600 mg + lamivudine 300 mg tablet, 30; Triumeq® - November 2014
• Dolutegravir + rilpivirine: Tablet containing dolutegravir 50 mg with rilpivirine 25 mg; Juluca® - July 2018
• Dorzolamide with timolol: Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL; VIzo-PF Dorzolatim® - March 2022
• Dorzolamide hydrochloride with timolol maleate, eye drops 20 mg (base)-5 mg (base) per mL (2%-0.5%), single dose units 0.6 mL, 60, Cosopt® Preservative Free Eye Drops - July 2012
• Dostarlimab: Solution concentrate for I.V. infusion 500 mg in 10 mL; Jemperli®- November 2022-March 2023
• Dostarlimab: Solution concentrate for I.V. infusion 500 mg in 10 mL; Jemperli® - March 2022
• Doxorubicin hydrochloride, pegylated liposomal, suspension for I.V. infusion, 20 mg in 10 mL and 50 mg in 25 mL, Caelyx®, July 2008
• Dronedarone hydrochloride, tablet, 400 mg, Multaq®, November 2010
• Drugs for the Treatment of Hepatitis C Stakeholder Meeting Outcomes December 2018 (various) - March 2019
• Dulaglutide: Injection 1.5 mg in 0.5 mL single dose pre-filled pen (s19A); Trulicity® (Netherlands) – OOS 2022
• Dulaglutide: Injection 3 mg in 0.5 mL single dose pre-filled pen, Injection 4.5 mg in 0.5 mL single dose pre-filled pen; Trulicity® – May 2022
• Dulaglutide: Injection 1.5 mg in 0.5 mL single dose pre-filled pen; Trulicity® - July 2020
• Dulaglutide: Injection 1.5 mg in 0.5 mL single dose pre-filled pen; Trulicity® - November 2019
• Dulaglutide: Injection 1.5 mg in 0.5 mL single dose pre-filled pen; Trulicity® - November 2017
• Duloxetine hydrochloride, capsule, 30 mg and 60 mg, Cymbalta®, July 2007
• Duloxetine Hydrochloride, capsules, 30 mg and 60 mg (base), Cymbalta®, March 2008
• Dupilumab: Injection 200 mg in 1.14 mL single dose pre filled syringe, Injection 300 mg in 2 mL single dose pre filled syringe; Dupixent® - July 2023
• Dupilumab: Injection 300 mg in 2 mL single dose autoinjector, Injection 200 mg in 1.14 mL single dose autoinjector; Dupixent® - November 2022
• Dupilumab: Injection 200 mg in 1.14 mL single dose pre-filled syringe, Injection 300 mg in 2 mL single dose pre-filled syringe; Dupixent® - July 2022
• Dupilumab: Injection 200 mg in 1.14 mL single dose pre-filled syringe, Injection 300 mg in 2 mL single dose pre-filled syringe; Dupixent® - March 2022
• Dupilumab (atopic dermatitis): Injection 200 mg in 1.14 mL single dose prefilled syringe, Injection 300 mg in 2 mL single dose prefilled syringe; Dupixent® - November 2020
• Dupilumab (asthma): Injection 200 mg in 1.14 mL single use pre-filled syringe, Injection 300 mg in 2 mL single use pre-filled syringe; Dupixent® - November 2020
• Dupilumab: Injection 300 mg in 2 ml single use pre-filled syringe; Dupixent® - March 2020
• Dupilumab: Injection 300 mg in 2 mL single use pre-filled syringe; Dupixent® - July 2019
• Dupilumab: Injection 300 mg in 2 mL single dose pre-filled syringe; Dupixent® - July 2018
• Durvalumab: Solution concentrate for I.V. infusion 120 mg in 2.4 mL vial, Solution concentrate for I.V. infusion 500 mg in 10 mL vial; Imfinzi® - July 2023
• Durvalumab: Solution concentrate for I.V. infusion 120 mg in 2.4 mL vial, Solution concentrate for I.V. infusion 500 mg in 10 mL vial; Imfinzi® - March 2023
• Durvalumab: Solution concentrate for I.V. infusion 500 mg in 10 mL; Imfinzi® - March 2022
• Durvalumab: Solution concentrate for I.V. infusion 120 mg in 2.4 mL, Solution concentrate for I.V. infusion 500 mg in 10 mL; Imfinzi® - November 2020
• Durvalumab: Solution concentrate for I.V. infusion 120 mg in 2.4 mL, Solution concentrate for I.V. infusion 500 mg in 10 mL; Imfinzi® - November 2019
• Durvalumab (urothelial cancer): Solution concentrate for I.V. infusion 120 mg in 2.4 mL, Solution concentrate for I.V. infusion 500 mg in 10 mL; Imfinzi™ - July 2019
• Durvalumab (NSCLC): Solution concentrate for I.V. infusion 120 mg in 2.4 mL, Solution concentrate for I.V. infusion 500 mg in 10 mL; Imfinzi™ - July 2019
• Durvalumab: Solution for I.V. infusion 120 mg in 2.4 mL, Solution for I.V. infusion 500 mg in 10 mL; Imfinzi® - November 2018
• Dutasteride, capsule, 0.5 mg, Avodart® July 2009
• Dutasteride, capsule, 500 micrograms, Avodart®, November 2009
• Dutasteride with tamsulosin hydrochloride, capsule, 500 micrograms – 400 micrograms, Duodart®, November 2010
  Top of page

E

• Eculizumab: Solution concentrate for I.V. infusion 300 mg in 30 mL; Soliris® - November 2021
• Eculizumab: Solution concentrate for I.V. infusion 300 mg in 30 mL; Soliris® - November 2020
• Eculizumab: Solution concentrate for I.V. infusion 300 mg in 30 mL; Soliris® - March 2018
• Eculizumab: Solution concentrate for I.V.infusion 300 mg in 30 mL; Soliris® - July 2017
• Eculizumab, 300 mg/30 mL injection, 1 x 30mL vial injection, Soliris® - July 2014
• Eculizumab, concentrated solution for I.V. infusion, 300 mg in 30 mL, Soliris® - March 2014
• Eculizumab, concentrated solution for I.V. infusion, 300 mg in 30 mL, Soliris® - March 2013
• Eculizumab, solution concentrate for I.V. infusion, 300 mg in 30 mL, Soliris® July 2010
• Eculizumab, solution concentrate for I.V. infusion, 300 mg in 30 mL, Soliris®, March 2009
• Eculizumab, solution concentrate for I.V. infusion, 300 mg in 30 mL, Soliris®, July 2008
• Efalizumab, injection set containing 4 vials powder for injection 125 mg and 4 pre-filled syringes diluent 1.3 mL, Raptiva®, November 2008
• Efalizumab, injection set containing 4 vials powder for injection 125 mg and 4 pre-filled syringes solvent 1.3 mL, Raptiva®, November 2005
• Elexacaftor with Tezacaftor and with Ivacaftor, and Ivacaftor: Pack containing 56 tablets elexacaftor 100 mg with tezacaftor 50 mg and with ivacaftor 75 mg and 28 tablets ivacaftor 150 mg, Pack containing 56 tablets elexacaftor 50 mg with tezacaftor 25 mg and with ivacaftor 37.5 mg and 28 tablets ivacaftor 75 mg; Trikafta® - November 2022 - March 2023
• Elexacaftor/tezacaftor/ivacaftor: Pack containing 56 tablets of elexacaftor 100 mg with tezacaftor 50 mg and ivacaftor 75 mg and 28 tablets of ivacaftor 150 mg; Trikafta® – December 2021
• Elexacaftor/tezacaftor/ ivacaftor and ivacaftor: Pack containing 56 tablets of elexacaftor 100 mg with tezacaftor 50 mg and ivacaftor 75 mg and 28 tablets of ivacaftor 150 mg; Trikafta® - July 2021
• Elexacaftor+ tezacaftor + ivacaftor: Pack containing 56 tablets of elexacaftor 100 mg with tezacaftor 50 mg and ivacaftor 75 mg and 28 tablets of ivacaftor 150 mg; Trikafta® - May 2021
• Elexacaftor + tezacaftor + ivacaftor: Pack containing 56 tablets of elexacaftor 100 mg with tezacaftor 50 mg and ivacaftor 75 mg and 28 tablets of ivacaftor 150 mg; Trikafta®- March 2021
• Eliglustat; eliglustat tartrate 100 mg hard capsule (equivalent to 84 mg eliglustat), 56; Cerdelga®Eliglustat; eliglustat tartrate 100 mg hard capsule (equivalent to 84 mg eliglustat), 56; Cerdelga® - July 2015
• Elitriptan Hydrobromide tablet, 40 mg (base) and 80 mg (base), Relpax® - March 2010
• Elosulfase alfa: 5mg/5mL injection, 5 mL vial, Vimizim® - March 2016
• Elosulfase alfa; 1 mg/mL concentrate for solution for infusion, 5mL vial; Vimizim® - November 2014
• Elotuzumab: Powder for I.V. infusion 300 mg, Powder for I.V. infusion 400 mg; Empliciti® - July 2021
• Elotuzumab: Powder for I.V. infusion 300 mg, Powder for I.V. infusion 400 mg; Empliciti® - November 2020
• Eltrombopag and Romiplostim: eltrombopag: Tablet 25 mg (as olamine), Tablet 50 mg (as olamine); romiplostim: Powder for injection 375 micrograms, Powder for injection 625 micrograms; Revolade® and Nplate® – May 2022
• Eltrombopag tablets, 25 mg, 50 mg, 75 mg and 100 mg (as olamine), Revolade® - July 2013
• Eltrombopag, tablets, 25 mg and 50 mg, (as olamine), Revolade® - March 2011
• Eltrombopag olamine, tablets, 25 mg and 50 mg, Revolade®, November 2010
• Eltrombopag; tablets, 25 mg and 50 mg; Revolade® - November 2014
• Elvitegravir, tablet (film coated), 85 mg and 150 mg, Vitekta® - March 2013
• Elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide, fixed-dose combination tablet, 150 mg/ 150 mg/200 mg/10 mg, Genvoya® - November 2015
• Empagliflozin: Tablet 10 mg; Jardiance® – November 2022 – OOS 2022
• Empagliflozin: Tablet 10 mg; Jardiance® - November 2021
• Empagliflozin: oral tablet, 10mg, 25mg, Jardiance® (triple oral therapy) - November 2015
• Empagliflozin: oral tablet, 10mg, 25mg, Jardiance® (with insulin) - November 2015
• Empagliflozin, oral tablet, 10 mg, 25 mg, Jardiance® - July 2014
• Empagliflozin with linagliptin: Tablet containing 10 mg empagliflozin with 5 mg linagliptin; Tablet containing 25 mg empagliflozin with 5 mg linagliptin; Glyxambi® - March 2017
• Empagliflozin with metformin: oral tablet, 5mg/500mg, 5mg/850mg, 5mg/1000mg, 12.5mg/500mg, 12.5mg/850mg, 12.5mg/1000mg, Jardiancemet®/Jardiamet® - November 2015
• Empagliflozin, 2. Empagliflozin with metformin, 3. Linagliptin, 4. Linagliptin with metformin: 1. Tablet 10mg, Tablet 25 mg, 2. Tablet containing 12.5 mg empagliflozin with 500 mg metformin hydrochloride, Tablet containing 12.5 mg empagliflozin with 1 g metformin hydrochloride, Tablet containing 5 mg empagliflozin with 500 mg metformin hydrochloride, Tablet containing 5 mg empagliflozin with 1 g metformin hydrochloride, 3. Tablet 5 mg, 4. Tablet containing 2.5 mg linagliptin with 500 mg metformin hydrochloride, Tablet containing 2.5 mg linagliptin with 1 g metformin hydrochloride, Tablet containing 2.5 mg linagliptin with 850 mg metformin hydrochloride; Jardiance®, Jardiamet®, Trajenta®, Trajentamet® - November 2017 
• Empagliflozin with linagliptin: Tablet containing 10 mg empagliflozin with 5 mg linagliptin, Tablet containing 25 mg empagliflozin with 5 mg linagliptin; Glyxambi® - November 2017 
• Emtricitabine with rilpivirine and tenofovir: emtricitabine 200 mg + rilpivirine 25 mg + tenofovir alafenamide 25 mg tablet, 30, Odefsey® - July 2016
• Encorafenib Tablet 50 mg, Tablet 75 mg, Braftovi® - May 2021
• Encorafenib: Capsule 50 mg, Capsule 75 mg; Braftovi®- March 2021
• Encorafenib and Binimetinib: encorafenib: capsule 50 mg, capsule 75 mg; binimetinib: tablet 15 mg; Braftovi® and Mektovi® - November 2018
• Enfortumab Vedotin: Powder for I.V. infusion 20 mg, Powder for I.V. infusion 30 mg; Padcev® - November 2022 - OOS February 2023
• Enfortumab vedotin: Powder for I.V. infusion 20 mg, Powder for I.V. infusion 30 mg; Padcev® - March 2022

• Enoxaparin: Injection containing enoxaparin sodium 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre filled syringe, Injection containing enoxaparin sodium 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre filled syringe, Injection containing enoxaparin sodium 60 mg (6,000 I.U. anti-Xa) in 0.6 mL pre filled syringe, Injection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL pre filled syringe, Injection containing enoxaparin sodium 100 mg (10,000 I.U. anti-Xa) in 1 mL pre filled syringe, Injection containing enoxaparin sodium 120 mg (12,000 I.U. anti-Xa) in 0.8 mL pre filled syringe, Injection containing enoxaparin sodium 150 mg (15,000 I.U. anti-Xa) in 1 mL pre filled syringe; ExaraneTM Exarane ForteTM - July 2023

• Enoxaparin: Injection containing enoxaparin sodium 100 mg (10,000 I.U. anti-Xa) in 1 mL pre-filled syringe, Injection containing enoxaparin sodium 120 mg (12,000 I.U. anti-Xa) in 0.8 mL syringe, Injection containing enoxaparin sodium 150 mg (15,000 I.U. anti-Xa) in 1 mL syringe, Injection containing enoxaparin sodium 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre-filled syringe, Injection containing enoxaparin sodium 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre-filled syringe, Injection containing enoxaparin sodium 60 mg (6,000 I.U. anti-Xa) in 0.6 mL pre-filled syringe, Injection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL syringe; Enoxapo® - July 2020
• Enoxaparin: Injection containing enoxaparin sodium 120 mg (12,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe, Injection containing enoxaparin sodium 150 mg (15,000 I.U. anti-Xa) in 1 mL pre-filled syringe; Clexane Forte®, Enoxaparin Winthrop® and Clexane Forte Safety-Lock® - July 2019
• Enoxaparin sodium; 20 mg/0.2 mL injection, 10 x 0.2 mL pre-filled syringes, 40 mg/0.4 mL injection, 10 x 0.4 mL pre-filled syringes, 60 mg/0.6 mL injection, 10 x 0.6 mL pre-filled syringes, 80 mg/0.8 mL injection, 10 x 0.8 mL pre-filled syringes, 100 mg/1.0 mL injection, 10 x 1.0 mL pre-filled syringes; Clexane Safety-Lock® - November 2014
• Enoxaparin: Injection containing enoxaparin sodium 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre-filled syringe, Injection containing enoxaparin sodium 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre-filled syringe; Clexane® - March 2019
• Entecavir, tablets, 500 microgram and 1 mg, Baraclude®, July 2006
• Entrectinib: Capsule 200 mg; Rozlytrek® - March 2020
• Enzalutamide: Capsule 40 mg; Xtandi® - March 2023
• Enzalutamide and abiraterone: Enzalutamide: Capsule 40 mg; Xtandi®; Abiraterone: Tablet 500 mg, Tablet 250 mg; Zytiga® - July 2021
• Enzalutamide and abiraterone acetate: Enzalutamide: Capsule 40 mg; Xtandi®; Abiraterone: Tablet 500 mg, Tablet 250 mg; Zytiga® - March 2021
• Enzalutamide: Capsule 40 mg; Xtandi® - March 2022
• Enzalutamide: Capsule 40 mg; Xtandi® - July 2017
• Enzalutamide: Capsule 40 mg; Xtandi® - March 2017
• Enzalutamide: capsules, 40 mg, Xtandi® - November 2015
• Enzalutamide, capsule, 40 mg, Xtandi® - July 2014
• Eplerenone, film-coated tablets, 25 mg, 50 mg, Inspra®, July 2005
• Epoetin lambda: Injection 1,000 units in 0.5 mL pre-filled syringe, Injection 2,000 units in 1 mL pre-filled syringe, Injection 3,000 units in 0.3 mL pre-filled syringe, Injection 4,000 units in 0.4 mL pre-filled syringe, Injection 5,000 units in 0.5 mL pre-filled syringe, Injection 6,000 units in 0.6 mL pre-filled syringe, Injection 8,000 units in 0.8 mL pre-filled syringe, Injection 10,000 units in 1 mL pre-filled syringe; Novicrit® - July 2017
• Epoetin Lambda, injection, 1,000 units in 0.5 mL, 2,000 units in 1.0 mL, 3,000 units in 0.3 mL, 4,000 units in 0.4 mL, 5,000 units in 0.5 mL, 6,000 units in 0.6 mL, 8,000 units in 0.8 mL and 10,000 units in 1.0 mL, pre-filled syringe, Novicrit® - July 2010
• Epoprostenol, 500 microgram injection, vial; Epoprostenol 1.5 mg injection, vial; Veletri® - July 2014
• Epoprostenol: Injection 500 microgram, Injection 1.5 mg; Flolan® - November 2016
• Epoprostenol sodium, powder for I.V. infusion, 500 micrograms (base) with diluent, 1.5 mg (base) with diluent, Flolan® - November 2011
• Epoprostenol sodium, injection set containing 1 vial powder for I.V. infusion 500 micrograms and 1 vial diluent 50 mL, injection set containing 1 vial powder for I.V. infusion 1.5 mg and 2 vials diluent 50 mL, Flolan®, March 2006
• Eptinezumab: Solution concentrate for I.V infusion 100 mg in 1 mL; Vyepti® - July 2022
• Erenumab: Injection 70 mg in 1 mL single dose pre-filled pen; Aimovig® - July 2018
• Erenumab: Injection 70 mg in 1 mL single dose pre-filled pen; Aimovig® - March 2019
• Eribulin mesilate, injection in vial, 1mg/2mL Halaven® - November 2013
• Eribulin Mesilate, solution for injection, 1mg in 2mL Halaven® - March 2013
• Erlotinib, 25 mg tablet, 30, 100 mg tablet, 30 and 150 mg tablet, 30, Tarceva®, Roche Products Pty Limited - March 2014
• Erlotinib, tablets, 25 mg, 100 mg, 150 mg (as hydrochloride), Tarceva® - July 2013
• Erlotinib, tablet, 25 mg, 100 mg, 150 mg (as hydrochloride), Tarceva® - July 2012
• Erlotinib hydrochloride, film-coated tablets, 25 mg, 100 mg and 150 mg (base), Tarceva®, November 2006
• Erlotinib hydrochloride, film-coated tablets, 25 mg, 100 mg and 150 mg (base), Tarceva®, November 2007
• Erlotinib hydrochloride, tablet, 25 mg, 100 mg and 150 mg (base), Tarceva® March 2006
• Eribulin: Solution for I.V. injection containing eribulin mesilate 1 mg in 2 mL; Halaven® - November 2016
• Ertugliflozin: Tablet containing 5 mg ertugliflozin, Tablet containing 15 mg ertugliflozin; Steglatro®; ertugliflozin with metformin: Tablet containing 2.5 mg ertugliflozin with 500 mg metformin hydrochloride, Tablet containing 2.5 mg ertugliflozin with 1 g metformin hydrochloride, Tablet containing 7.5 mg ertugliflozin with 500 mg metformin hydrochloride, Tablet containing 7.5 mg ertugliflozin with 1 g metformin hydrochloride; Segluromet® - March 2018
• Ertugliflozin with sitagliptin: Tablet containing 5 mg ertugliflozin with 100 mg sitagliptin (as phosphate monohydrate); Tablet containing 15 mg ertugliflozin with 100 mg sitagliptin (as phosphate monohydrate); 2. Ertugliflozin: Ertugliflozin tablet 5 mg; Ertugliflozin tablet 15 mg; 3. Ertugliflozin + metformin: Tablet containing 2.5 mg ertugliflozin with 500 mg metformin hydrochloride; Tablet containing 2.5 mg ertugliflozin with 1 g metformin hydrochloride; Tablet containing 7.5 mg ertugliflozin with 500 mg metformin hydrochloride; Tablet containing 7.5 mg ertugliflozin with 1 g metformin hydrochloride; 4. Sitagliptin: Sitagliptin tablet 25 mg (as phosphate monohydrate); Sitagliptin tablet 50 mg (as phosphate monohydrate); Sitagliptin tablet 100 mg (as phosphate monohydrate); 5. Sitagliptin + metformin: Tablet containing 50 mg sitagliptin (as phosphate monohydrate) with 500 mg metformin hydrochloride; Tablet containing 50 mg sitagliptin (as phosphate monohydrate) with 850 mg metformin hydrochloride; Tablet (modified release) containing 50 mg sitagliptin (as phosphate monohydrate) with 1000 mg metformin hydrochloride; Tablet (modified release) containing 100 mg sitagliptin (as phosphate monohydrate) with 1000 mg metformin hydrochloride; 1. Stenglujan®, 2. Steglatro®, 3. Segluromet®, 4. Januvia®; 5. Janumet®, Janumet XR® - July 2018
• Ertugliflozin: Tablet containing 15 mg ertugliflozin; Steglatro®; Ertugliflozin with metformin: Tablet containing 7.5 mg ertugliflozin with 500 mg metformin hydrochloride; Tablet containing 7.5 mg ertugliflozin with 1 g metformin hydrochloride; Segluromet® - July 2018
• Escitalopram, 20 mg/mL oral liquid, 15 mL, Lexapro® - July 2014
• Escitalopram oxalate, tablets, 10 mg and 20 mg (base), Lexapro® - GAD, March 08
• Escitalopram oxalate, tablets, 10 mg and 20 mg (base), Lexapro® - SAD, March 2008
• Escitalopram, tablet 10 mg (base), tablet 20 mg (base), oral solution 10 mg (base) per mL, Lexapro®, March 2007
• Esketamine: Nasal spray solution 28 mg in 0.2 mL; Spravato® - July 2023
• Esketamine: Nasal spray solution 28 mg in 0.2 mL; Spravato® - July 2022
• Esketamine: Nasal spray solution 28 mg; Spravato® - July 2021
• Eslicarbazepine: Tablet 800 mg; Zebinix®- March 2021
• Esomeprazole magnesium trihydrate, tablet (enteric coated), equivalent to 20 mg esomeprazole, Nexium®, November 2005
• Essential amino acids formula with vitamins and minerals: Sachets containing oral powder 12.5 g, 50; EAA Supplement® - November 2021
• Etanercept: Injection 50 mg in 1 mL single use auto-injector, 4; Nepexto® - November 2022
• Etanercept: Injections 50 mg in 1 mL single use pre-filled syringes, 4; Rymti® - November 2021
• Etanercept: Injection 50 mg in 1 mL single use dose-dispenser cartridge, 4; Enbrel® - July 2021
• Etanercept: Injection 50 mg in 1 mL single use auto-injector, 4; Injections 50 mg in 1 mL single use pre-filled syringes, 4; Brenzys® - December 2020
• Etanercept: Injection 50 mg in 1 mL single use auto-injector, 4; Injections 50 mg in 1 mL single use pre-filled syringes, 4; Brenzys® - November 2018
• Etanercept: Injection 50 mg in 1 mL single use auto-injector, 4, Injection 50 mg in 1 mL single use pre-filled syringes, 4; Erelzi® - March 2018
• Etanercept: Injection 50mg in 1mL single use pre-filled syringes and 50mg in 1mL single use auto-injectors; Brenzys® - August 2017
• Etanercept: 50 mg/mL injection, 1 mL pre-filled syringe, 4, 50 mg/mL injection, 1 mL auto-injector, 4, Brenzys® - July 2016
• Etanercept: 25 mg injection [4 x 25 mg vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack; 50 mg in 1 mL single use pre-filled syringes, 4; 50 mg in 1 mL single use auto-injector, 4, Enbrel® - March 2016
• Etanercept; 50 mg injection in 1mL single use auto-injector, 4 pack 50 mg injection in 1 mL single use pre-filled syringes, 4 pack 25 mg injection [4 x 25 mg vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack; Enbrel® - March 2015
• Etanercept injection 50 mg in 1 mL single use auto-injector, Etanercept injection 50 mg in 1 mL single use pre-filled syringes, Enbrel® - July 2014
• Etanercept, injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL; injections 50 mg in 1 mL single use pre-filled syringes; injection 50 mg in 1 mL single use auto-injector, Enbrel® - March 2012
• Etanercept, injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL, Enbrel ®, July 2005
• Etanercept, injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL, and injection set containing 4 vials powder for injection 50 mg and 4 pre-filled syringes solvent 1 mL, Enbrel®, March 2007
• Etanercept, injection set containing 4 vials powder for injection 25 mg and 50 mg and 4 pre-filled syringes solvent 1 mL, and injection 50 mg in 1 mL single use pre-filled syringes, 4, Enbrel®, July 2008
• Etanercept, injection set containing 4 vials powder for injection 25 mg and 50 mg and 4 pre-filled syringes solvent 1 mL, and injection 50 mg in 1 mL single use pre-filled syringes, 4, Enbrel®, July 2008
• Etanercept, injection set containing 4 vials powder for injection 25 mg or 50 mg and 4 pre-filled syringes solvent 1 mL, Enbrel®, March 2006
• Etanercept, injection set containing 4 vials powder for injection, 25 mg and 4 pre-filled syringes solvent 1 mL, injection set containing 4 vials powder for injection, 50 mg and 4 pre-filled syringes solvent 1 mL, injections, 50 mg in 1 mL single use pre-filled syringes, Enbrel®, March 2009
• Etanercept, powder for injection, 25 mg, Enbrel®, November 2005
• Etoricoxib, tablet, 30 mg, 60 mg, Arcoxia®, July 2008
• Etoricoxib, tablets, 60 mg, Arcoxia®, July 2007
• Etravirine, tablet, 100 mg, Intelence® , March 2009
• Everolimus: Tablet, dispersible, 2 mg, Tablet, dispersible, 3 mg, Tablet, dispersible, 5 mg; Afinitor® - December 2017
• Everolimus: tablets, 250 mcg, 500 mcg, 750 mcg, 1 mg, Certican® - November 2015
• Everolimus (RCC), tablets, 5 mg and 10 mg, Afinitor®, Novartis Pharmaceuticals Australia Pty Ltd - March 2014
• Everolimus (pNet), tablets, 5 mg and 10 mg, Afinitor®, Novartis Pharmaceuticals Australia Pty Ltd - March 2014
• Everolimus, tablet, 5 mg and 10 mg, Afinitor® - July 2013
• Everolimus, tablet, 5 mg and 10 mg, Afinitor® - March 2013
• Everolimus, tablets, 2.5 mg, 5 mg and 10 mg, Afinitor® (in SEGA) - November 2012
• Everolimus, tablets, 2.5 mg, 5 mg and 10 mg, Afinitor® - April 2013
• Everolimus, tablets, 5 mg and 10 mg, Afinitor® (in pNET) - November 2012
• Everolimus, tablets, 5 mg and 10 mg, Afinitor® - November 2011
• Everolimus, tablets, 5 mg and 10 mg, Afinitor® - July 2010
• Everolimus, tablet, 5 mg and 10 mg, Afinitor®, November 2009
• Evolocumab: Injection 140 mg in 1 mL single use pre-filled pen, Injection 420 mg in 3.5 mL single use pre-filled cartridge; Repatha® - July 2022
• Evolocumab: Injection 420 mg in 3.5 mL single use pre-filled cartridge; Repatha®- March 2021
• Evolocumab: Injection 140 mg in 1 mL single use pre-filled pen, Injection 420 mg in 3.5 mL single use pre-filled cartridge; Repatha® - November 2020
• Evolocumab: Injection 420 mg in 3.5 mL single use pre-filled cartridge - November 2019
• Evolocumab: Injection 420 mg in 3.5 mL single use pre-filled cartridge, Injection 140 mg in 1 mL single use pre-filled pen; Repatha® - July 2019
• Evolocumab: Injection 140 mg in 1 ml single use pre-filled pen; Injection 420 mg in 3.5 ml single use pre-filled cartridge; Repatha® - July 2018
• Evolocumab: Injection 420 mg in 3.5 mL single use pre-filled cartridge, Injection 140 mg in 1 mL single use pre-filled pen; Repatha® - March 2018
• Evolocumab: Injection 420 mg in 3.5 mL single use pre-filled cartridge, Injection 140 mg in 1 mL single use pre-filled pen; Repatha® - November 2017
• Evolocumab: Injection 420 mg in 3.5 mL, single dose autoinjector; Repatha® - July 2017
• Evolocumab: 140 mg/1 mL injection, 1 mL injection device, 1, Repatha® - March 2016
• Evolocumab; 140 mg/1 mL injection, 1 x 1 mL injection device; Repatha® - March 2015
• Exemestane, tablet, 25 mg, Aromasin®, July 2006 
• Exenatide; 5 microgram/0.02 mL injection: solution, 60 unit doses 10 microgram/0.04 mL injection: solution, 60 unit doses; Byetta® – March 2015
• Exenatide: 2 mg powder for injection pre-filled pen, Bydureon® - March 2016
• Exenatide; 2 mg, powder for injection, vial; Bydureon® - July 2015
• Exenatide, powder for injection, 2 mg, Bydureon® - November 2013
• Exenatide: Injection 2 mg in 0.85 mL single dose autoinjector; Bydureon® BCise® - March 2019
• Exenatide, injection, 5 microgram per dose, 10 microgram per dose, pre-filled pen, 60 doses, Byetta®, July 2007
• Exenatide, powder for injection, 2 mg, Bydureon® - July 2011
• Exenatide, pre-filled injection pen, 5 microgram per dose, 10 microgram per dose, 60 doses, Byetta®, March 2008
• Exenatide, pre-filled injection pen, 5 microgram per dose, 10 microgram per dose, Byetta®, November 2008
• Ezetimibe and Rosuvastatin tablets, ezetimibe 10mg + rosuvastatin 5mg; ezetimibe 10mg + rosuvastatin 10mg; ezetimibe 10mg + rosuvastatin 20mg; ezetimibe 10mg + rosuvastatin 40mg, Rosuzet® - July 2014
• Ezetimibe and rosuvastatin, pack containing 30 tablets ezetimibe 10 mg, and 30 tablets rosuvastatin 5 mg, 10 mg, 20 mg or 40 mg, Rosuzet® Composite Pack - November 2013
• Ezetimibe + atorvastatin; fixed dose combination tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg; Atozet® - November 2014
• Ezetimibe and Atorvastatin, pack containing 30 tablets ezetimibe 10 mg, and 30 tablets atorvastatin (as calcium) 10 mg, 20 mg, 40 mg or 80 mg, Atozet® Composite Pack - July 2013
• Ezetimibe and Atorvastatin, pack containing 30 tablets ezetimibe 10 mg, and 30 tablets atorvastatin 10 mg (as calcium), atorvastatin 20 mg (as calcium), atorvastatin 40 mg (as calcium), Atozet Composite Pack® - November 2012
• Ezetimibe with Simvastatin, tablets, 10 mg - 20 mg, Vytorin®, March 2009
• Ezetimibe with simvastatin, tablet, 10 mg-20 mg, Vytorin® - March 2012
• Ezetimibe + simvastatin; tablets, 10 mg – 10 mg, 10 mg – 20 mg, 10 mg – 40 mg and 10 mg – 80 mg; Vytorin® - November 2014
• Ezetimibe, tablet, 10 mg, Ezetrol®, and Ezetimibe with Simvastatin, tablet, 10 mg – 10 mg, 10 mg – 40 mg and 10 mg – 80 mg, Vytorin® November 2006
• Ezetimibe, tablet, 10 mg, Ezetrol®; ezetimibe with Simvastatin, tablets, 10 mg-40 mg, 10 mg-80 mg, Vytorin® , November 2005
• Ezetimibe, tablet, 10 mg, Ezetrol®, November 2010
• Ezetimibe with Simvastatin, tablet, 10 mg-40 mg, 10 mg-80 mg, Vytorin® , July 2005
  Top of page

F

• Famciclovir, Tablet, 500 mg, Famvir®, November 2006
• Fampridine, tablet (modified release), 10 mg, Fampyra® - March 2014
• Fampridine, modified release tablet, 10 mg, Fampyra® - November 2012
• Faricimab (diabetic macular oedema): Solution for intravitreal injection 28.8 mg in 0.24 mL; Vabysmo® – May 2022
• Faricimab (neovascular (wet) age-related macular degeneration): Solution for intravitreal injection 28.8 mg in 0.24 mL; Vabysmo® – May 2022
• Febuxostat: Tablet 80 mg; Adenuric® - July 2017
• Febuxostat; 80 mg tablet 28, 120 mg tablet 28; Adenuric® – March 2015
• Febuxostat, tablet, 80 mg and 120 mg, Adenuric® - March 2014
• Fentantyl, 100 micrograms/actuation nasal spray, 8 actuations and 400 micrograms/actuation nasal spray, 8 actuations, PecFent® - March 2014
• Fentanyl citrate: 100 microgram tablet: buccal, 4, 28; 200 microgram tablet: buccal, 4, 28; 400 microgram tablet: buccal, 4, 28; 600 microgram tablet: buccal, 4, 28; 800 microgram tablet: buccal, 4, 28, Fentora® - November 2015
• Fentanyl citrate (buccal); Fentora® - July 2015
• Fentanyl: Tablet (sublingual) 100 micrograms (as citrate) Tablet (sublingual) 200 micrograms (as citrate); Abstral® - July 2017
• Fentanyl citrate (sublingual); Abstral® - July 2015
• Fentantyl, tablet: sublingual, 100 microgram, 200 microgram and 400 microgram, Abstral® - March 2014
• Fentanyl citrate, nasal spray,  6 pack of single-dose nasal spray bottles 50 microgram, 100 microgram, 200 microgram, Instanyl® - March 2013
• Fentanyl citrate, lozenge with integral applicator, 200 microgram, 400 microgram, 600 microgram, 800 microgram, 1200 microgram and 1600 microgram, Actiq® March 2006
• Fentanyl citrate, lozenge with integral applicator, 200 microgram, 400 microgram, 600 microgram, 800 microgram, 1200 microgram and 1600 microgram, Actiq®, November 2007
• Fentanyl, transdermal patch, releasing approximately 12, 25, 50, 75 or 100 micrograms per hour, Durogesic® 12/25/50/75/100 March 2006
• Ferric Derisomaltose Injection 1000 mg (iron) in 10 mL, Injection 500 mg (iron) in 5 mL, Monofer®, Pfizer Australia Pty Ltd. - August 2019
• Ferric Carboxymaltose: Injection 1 g (iron) in 20 mL; Ferinject® - November 2018
• Ferric Carboxymaltose, solution for I.V. use, 500mg in 10mL, Ferinject® - November 2013
• Ferric Carboxymaltose, solution for injection, 100 mg in 2 mL and 500 mg in 10mL, Ferinject®, March 2013
• Ferric derisomaltose: Injection 1000 mg (iron) in 10 mL, Injection 500 mg (iron) in 5 mL; Monofer ® - July 2019
• Ferric derisomaltose: Injection 500 mg (iron) in 5 mL; Monofer® - July 2018
• Ferrous fumurate with folic acid, tablet, 310 mg – 350 micrograms, Ferro-F-Tab®, March 2006
• Filgrastim: Injection 120 micrograms in 0.2 mL single use pre‑filled syringe, Injection 300 micrograms in 0.5 mL single use pre‑filled syringe, Injection 480 micrograms in 0.5 mL single use pre‑filled syringe; Nivestim® - March 2018
• Filgrastim, injection, 120 micrograms in 0.2 mL single use pre-filled syringe, 300 micrograms in 0.5 mL single use pre-filled syringe, 480 micrograms in 0.5 mL single use pre-filled syringe, Nivestim®, November 2010
• Finerenone: Tablet 10 mg, Tablet 20 mg; Kerendia® - March 2023
• Finerenone: Tablet 10 mg, Tablet 20 mg; Kerendia® - July 2022
• Fingolimod: Capsule 250 micrograms (as hydrochloride); Gilenya® - July 2019
• Fingolimod, capsule, 0.5 mg (as hydrochloride), Gilenya®, March 2011
• First-line anti-retroviral therapy (ART) - November 2013
• Flucloxacillin: 1 g injection, 10 vials, Flucloxacillin Hospira brand - November 2015
• Fludarabine phosphate, tablet 10 mg , injection 50 mg , Fludara®, March 2008

• Fluocinolone acetonide: Intravitreal injection 190 micrograms; Iluvien® - November 2020

• Fluocinolone acetonide: Intravitreal injection 190 micrograms; Iluvien® - March 2020

• Fluticasone furoate with umeclidinium and vilanterol: Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms withFluticasone furoate with umeclidinium and vilanterol: Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses; Trelegy Ellipta 200/62.5/25® - November 2021

• Fluticasone Furoate: Powder for oral inhalation in breath actuated device containing fluticasone furoate 50 micrograms per dose, 30 doses; Arnuity Ellipta® - July 2019
• Fluticasone furoate: Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms per dose; Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms per dose; Arnuity Ellipta® - March 2017
• Fluticasone Fuorate with Umeclidinium and Vilanterol: Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses; Trelegy® Ellipta® - March 2019
• Fluticasone: Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms per dose; Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms per dose; Arnuity Ellipta® - November 2015
• Fluticasone furoate with umeclidinium and vilanterol: Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose; Trelegy® Ellipta® - December 2017
• Fluticasone Furoate and Vilanterol Trifenatate, dry powder inhaler, fluticasone furoate 100 microgram/actuation + vilanterol (as trifenatate) 25 microgram/actuation, Breo® Ellipta® - July 2014
• Fluticasone Furoate and Vilanterol Trifenatate, 30 actuations Breo® Ellipta® GlaxoSmithKline Australia Pty Ltd (Asthma) - March 2014
• Fluticasone Furoate and Vilanterol Trifenatate, dry powder inhaler, fluticasone furoate 100 microgram/actuation + vilanterol trifenatate 25 microgram/actuation, Breo® Ellipta®, GlaxoSmithKline Australia Pty Ltd (COPD) - March 2014
• Fluticasone Propionate With Eformoterol: Pressurised inhalation containing fluticasone propionate 50 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses; Pressurised inhalation containing fluticasone propionate 125 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses; Pressurised inhalation containing fluticasone propionate 250 micrograms with formoterol fumarate dihydrate 10 micrograms per dose, 120 doses; Flutiform® 50/5, 125/5, 250/10 - November 2018
• Fluticasone propionate with eformoterol fumarate, inhalation pressurised, 50 micrograms-5 micrograms per actuation, 125 micrograms-5 micrograms per actuation, 250 micrograms-10 micrograms per actuation, 120 actuations, Flutiform® - July 2013
• Fluticasone propionate with salmeterol xinafoate, oral pressurised inhalation 250 micrograms-25 micrograms (base) per dose (120) doses, CFC-free formulation, powder for oral inhalation in breath actuated device 500 micrograms- 50 micrograms (base) per dose(60), Seretide MDI 250/25®, Seretide Accuhaler 500/50®, March 2007
• Fluticasone with salmeterol: Powder for oral inhalation containing fluticasone propionate 500 micrograms with salmeterol (as xinafoate) 50 micrograms per dose; Airflusal Forspiro 500/50 - November 2016
• Follitropin alfa: Injection 300 I.U. in 0.5 mL multi-dose cartridge, Injection 450 I.U. in 0.75 mL multi-dose cartridge, Injection 900 I.U. in 1.5 mL multi-dose cartridge; Gonal-f Pen® - November 2021
• Follitropin alfa: Injection 300 I.U. in 0.5 mL multi-dose cartridge, Injection 450 I.U. in 0.75 mL multi-dose cartridge, Injection 900 I.U. in 1.5 mL multi-dose cartridge; Ovaleap® - July 2021
• Follitropin Alfa With Lutropin Alfa: Injection 900 I.U., 450 I.U. in 1.44 mL multi-dose cartridge; Pergoveris® - November 2018
• Follitropin alfa: Injection 75 I.U. in 0.125 mL pre-filled pen, Injection 150 I.U. in 0.25 mL pre-filled pen, Injection 225 I.U. in 0.375 mL pre-filled pen, Injection 300 I.U. in 0.5 mL pre-filled pen, Injection 450 I.U. in 0.75 mL pre-filled pen; Bemfola® - March 2018
• Follitropin alfa: 75 units (5.5 microgram)/0.125 mL injection, 5 x 0.125 mL injection devices, 150 units (11 microgram)/0.25 mL injection, 5 x 0.25 mL injection devices 225 units (16.5 microgram)/0.375 mL injection, 5 x 0.375 mL injection devices 300 units (22 microgram)/0.5 mL injection, 5 x 0.5 mL injection devices 450 units (33 microgram)/0.75 mL injection, 5 x 0.75 mL injection devices, Bemfola® - March 2016
• Follitropin alfa: lutropin alfa 75 international units injection [1 x 75 international units vial] (&) inert substance diluent [1 x 1 mL vial], 1 follitropin alfa 150 units + lutropin alfa 75 units [1 vial] (&) inert substance diluent [1 vial],1, Luveris® Pergoveris® - March 2016
• Follitropin Alfa and Lutropin Alfa, injection, 150 IU + 75 IU, Pergoveris® - March 2014
• Follitropin alfa (rch) + lutropin alfa (rch); follitropin alfa (rch) 150 IU + lutropin alfa (rch) 75 IU injection; Pergoveris® – March 2015
• Follitropin delta: Solution for injection 12 micrograms per 0.36 mL pre-filled cartridge, Solution f: Follitropin delta: Solution for injection 12 micrograms per 0.36 mL pre-filled cartridge, Solution for injection 36 micrograms per 1.08 mL pre-filled cartridge, Solution for injection 72 micrograms per 2.16 mL pre-filled cartridge; Rekovelle® - November 2017
• Fosaprepitant: Powder for I.V. infusion 150 mg; Emend® IV - November 2016
• Fosnetupitant (as chloride hydrochloride)/palonosetron (as hydrochloride): Solution concentrate for I.V. infusion containing fosnetupitant 235 mg and palonosetron 0.25 mg in 20 mL vial; Akynzeo®IV- March 2023
• Fosnetupitant (as chloride hydrochloride)/ palonosetron (as hydrochloride): Powder for Injection containing fosnetupitant 235 mg and palonosetron 250 mg; Akynzeo IV® - July 2020
• Fremanezumab: Solution for injection 225 mg in 1.5 mL single dose pre-filled syringe, Solution for injection 225 mg in 1.5 mL single dose autoinjector; Ajovy® - November 2022 – OOS August 2023
• Fremanezumab (auto-injector): Solution for injection 225 mg in 1.5 mL single dose auto-injector; Ajovy® - March 2022
• Fremanezumab (pre-filled syringe): Injection 225 mg in 1.5 mL pre-filled syringe; Ajovy® - March 2022
• Fremanezumab: Injection 225 mg in 1.5 mL pre-filled syringe; Ajovy® - March 2020
• Fremanezumab: Injection 225 mg in 1.5 mL pre-filled syringe; Ajovy® - November 2019
• Fulvestrant: Injection 250 mg in 5 mL pre-filled syringe; Faslodex® - July 2020Top of page

G

• Galcanezumab: Injection 120 mg in 1 mL pre-filled pen; Emgality® - March 2022
• Galcanezumab (chronic migraine): Injection 120 mg in 1 mL pre-filled pen; Emgality® - November 2020
• Galcanezumab (episodic migraine): Injection 120 mg in 1 mL pre-filled pen; Emgality® - November 2020
• Galcanezumab: Injection 120 mg in 1 mL single use pre-filled pen; Emgality® - July 2019
• Galsulfase-rch, solution concentrate for I.V. infusion, 5 mg in 5 mL, Naglazyme®, July 2007
• Ganirelix, solution for injection, 250 micrograms in 0.5ml (as acetate), single use pre-filled syringe, Orgalutran®, November 2009
• Gefitinib, tablet, 250mg, Iressa® - July 2013
• Gefitinib, tablet, 250 mg, Iressa® - November 2012
• Gefitinib, tablet, 250 mg, Iressa®, November 2010
• Gemtuzumab ozogamicin: Powder for Injection 5 mg; Mylotarg® - November 2021
• Gemtuzumab ozogamicin: Powder for injection 5 mg; Mylotarg®- March 2021
• Gilteritinib: Tablet 40 mg (as fumarate); Xospata® - March 2022
• Gilteritinib: Tablet 40 mg (as fumarate); Xospata® - November 2021
• Glatiramer: Injection containing glatiramer acetate 40 mg in 1 mL single dose pre-filled pen; Copaxone® - March 2022
• Glatiramer: Injection containing glatiramer acetate 20 mg in 1 mL single dose pre-filled syringe; Injection containing glatiramer acetate 40 mg in 1 mL single dose pre-filled syringe; Glatira®- March 2021
• Glatiramer: Injection containing glatiramer acetate 20 mg in 1 mL single dose pre-filled syringe, Injection containing glatiramer acetate 40 mg in 1 mL single dose pre-filled syringe; Copaxone® - July 2017
• Glatiramer; 40 mg/mL injection, 12 x 1 mL syringes; Copaxone 40® – March 2015
• Glecaprevir and pibrentasvir: Tablet containing 100 mg glecaprevir with 40 mg pibrentasvir; Maviret®  - November 2020
• Glecaprevir with pibrentasvir: Tablet containing 100 mg glecaprevir with 40 mg pibrentasvir, Maviret® - July 2017
• Glecaprevir with pibrentasvir: Tablet containing 100 mg glecaprevir with 40 mg pibrentasvir; Maviret® - November 2017 
• Glucosamine hydrochloride, capsule, 750 mg, Arthro-Aid®, July 2006
• Glucose indicator blood: 100 strips, VivaChek Ino - March 2016
• Glucose Indicator Blood Strip: diagnostic, 50, Medissentials Diabetic Test Strips® - July 2014
• Glucose indicator blood strip: diagnostic, 50 and 100, 2in1 Smart Blood Glucose measuring test strips - November 2015
• Glucose indicator blood strip; diagnostic, 50 and 100; GluNeo® Blood Glucose Test Strip, Healthpro® Blood Glucose Test Strip - November 2014
• Glucose indicator blood strip; diagnostic, 100; Dario® Blood Glucose Test Strip - November 2014
• Glycine with Carbohydrate containing 500 mg L-glycine oral liquid: powder for, 30 x 4 g sachets, Glycine500® - July 2014
• Glycomacropeptide and essential amino acids with vitamins and minerals: Oral liquid 250 mL, 30 (Tylactin RTD); Tylactin RTD – March 2023
• Glycomacropeptide and essential amino acids with vitamins and minerals: Sachets containing oral powder 40 g, 30 (Camino Pro Bettermilk); Camino Pro Bettermilk. Oral liquid 250 mL, 30 (PKU Glytactin RTD 15); PKU Glytactin RTD 15 – March 2023
• Glycomacropeptide Formula with Long Chain Polyunsaturated Fatty Acids and Docosahexaenoic Acid and Low in Phenylalanine: Oral liquid, 237 mL, 15 (PKU Sphere Liquid); PKU Sphere Liquid - November 2022
• Glycomacropeptide formula with amino acids and low phenylalanine: Sachets containing oral powder 12.5 g, 30; PKU GMPro MIX-IN® - March 2022
• Glycomacropeptide formula with amino acids, vitamins, minerals, trace elements, carbohydrate, fat and low phenylalanine: Sachets containing oral powder 33.4 g, 30; PKU GMPro ULTRA® - March 2022
• Glycomacropeptide and essential amino acids with vitamins and minerals: Sachets containing oral powder 31 g, 30; Tylactin Build 20® - July 2020
• Glycomacropeptide and essential amino acids with vitamins and minerals: Sachets containing oral powder 16 g, 60, Sachets containing oral powder 32 g, 30; PKU Build 10®; PKU Build 20® - November 2019
• Glycomacropeptide formula with docosahexaenoic acid with low phenylalanine: Oral liquid 250 mL, 18; PKU GMPro LQ® - July 2019
• Glycomacropeptide and essential amino acids with vitamins and minerals: Sachets containing oral powder 35 g, 30; TYR Sphere 20® - July 2019
• Glycomacropeptide And Essential Amino Acids With Vitamins And Minerals: Oral liquid 250 mL, 30 (PKU Glytactin RTD 15 Lite); PKU Glytactin RTD 15 LITE® - November 2018
• Glycomacropeptide and essential amino acids with vitamins and minerals; 15 g protein oral liquid, 30 x 250 mL tetra pack; Tylactin® RTD - July 2015
• Glycomacropeptide and essential amino acids with vitamins and minerals: oral liquid: powder for, 30 × 51 g sachets, PKU Bettermilk Lite® - July 2016
• Glycomacropeptide and essential amino acids with vitamins and minerals, oral liquid: powder for, 30 x 49 g, Camino Pro® Bettermilk - November 2015
• Glycomacropeptide and essential amino acids with vitamins and minerals; oral liquid, 28 x 250 mL cartons, oral liquid, 28 x 250 mL cartons; PKU Glytactin® RTD and 10 PKU Glytactin® RTD 15 ­– March 2015
• Glycomacropeptide and essential amino acids with vitamins and minerals: Sachet containing oral powder 35 g; PKU Restore® - November 2016
• Glycomacropeptide and essential amino acids with vitamins and minerals: Sachets containing oral powder 16 g, 60 (PKU Build 10), Sachets containing oral powder 32g, 30 (PKU Build 20); PKU Build 10®, PKU Build 20® - November 2017
• Glycomacropeptide and essential amino acids with vitamins and minerals: Bars 81 g, 14; Tylactin Complete® - November 2017
• Glycomacropeptide Formula With Docosahexaenoic Acid With Low Phenylalanine: Sachets containing oral powder 33.3 g, 16 (PKU GMPro); PKU GMPro® - November 2018
• Glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low in phenylalanine: Sachets containing oral powder 27 g, 30; Sachets containing oral powder 35 g, 30; PKU Sphere® 15, PKU Sphere® 20 - July 2017
• Glycomacropeptide and essential amino acids: Sachets containing oral powder 20 g; PKU Sphere® - November 2016
• Glycopyrronium bromide: powder for inhalation, 50 microgram, Seebri®, Breezhaler® - November 2015
• Glycopyrronium bromide, powder for inhalation, 50 microgram, Seebri®, Breezhaler® - November 2013
• Golimumab: Injection 50 mg in 0.5 ml single use pre‑filled syringe (Simponi); Injection 50 mg in 0.5 ml single use pre‑filled pen (Simponi Smartject); Simponi®, Simponi Smartject® - July 2018
• Golimumab, 50 mg/0.5 mL injection, 1x 0.5 mL, syringe Simponi®;Infliximab, 100 mg injection, 1x 100 mg vial, Remicade®; Ustekinumab 45 mg/0.5 ml injection, 1x 0.5 ml vial, Stelara®; Janssen-Cilag Pty Ltd - July 2014
• Golimumab, injection, 50 mg in 0.5 mL, pre-filled syringe, single use pre-filled pen, Simponi® - March 2010 (AS)
• Golimumab, injection, 50 mg in 0.5 mL, pre-filled syringe, single use pre-filled pen, Simponi® - March 2010 (PSA)
• Golimumab, injection 50 mg in 0.5 mL, pre-filled syringe, single use pre-filled pen, Simponi® March 2010 (RA)
• Golimumab (nr-axSpA): Injection 50 mg in 0.5 mL single use pre-filled syringe ; Simponi® - November 2017
• Golimumab (ulcerative colitis): Injection 100 mg in 1 mL single use pre-filled syringe/injection device; Simponi® - November 2017
• Gondadotrophin: Powder for injection, 600 I.U, Powder for injection, 1200 I.U; Menopur® - November 2016
• Gonadotrophin : gonadotrophin-menopausal human 600 units injection [1 vial], inert substance diluent [1 mL syringe], 1 pack, Menopur® - March 2016
• Goserelin: 3.6 mg implant; Zoladex Implant® - July 2017
• Goserelin: 3.6 mg implant; Zoladex Implant® - March 2017
• Goserelin: Implant, 3.6 mg, Implant 10.8 mg; Zoladex® Implant - November 2016
• Goserelin acetate, subcutaneous implant, 3.6 mg (base) in pre-filled injection syringe, Zoladex Implant®, November 2009
• Grazoprevir with elbasvir: grazoprevir 100 mg + elbasvir 50 mg tablet, 28, Zepatier® - July 2016
• Grazoprevir with elbasvir: Tablet containing grazoprevir 100 mg with elbasvir 50 mg; Zepatier® - March 2018
• Guanfacine: Tablet containing guanfacine hydrochloride 1 mg; Tablet containing guanfacine hydrochloride 2 mg; Tablet containing guanfacine hydrochloride 3 mg; Tablet containing guanfacine hydrochloride 4 mg; Intuniv® - July 2018
• Guanfacine: Tablet containing guanfacine hydrochloride 1 mg, Tablet containing guanfacine hydrochloride 2 mg, Tablet containing guanfacine hydrochloride 3 mg,Tablet containing guanfacine hydrochloride 4 mg; Intuniv® - July 2017

• Guselkumab: Injection 100 mg in 1 mL single use pre-filled pen; Tremfya®- March 2021

• Guselkumab: Injection 100 mg in 1 mL single use pre-filled syringe, Injection 100 mg in 1 mL single use pre-filled pen; Tremfya® - November 2020
• Guselkumab: Solution for injection 100 mg in 1 mL pen device; Tremfya® - July 2020
• Guselkumab: Injection 100 mg in 1 mL single use pre-filled syringe; Tremfya® - March 2018

Top of page

H

• Haemophilus influenzae type b and group c meningococcal polysaccharide conjugate vaccine, lyophilised powder for injection, 1 vial with 0.5 mL pre-filled syringe diluent, 10 vials with 10 0.5 mL pre-filled syringe diluent, Menitorix®, November 2010
• Hepatitis B surface antigen recombinant vaccine: Injection 20 micrograms in 1 mL vial; Engerix-B® - July 2018
• Hepatitis C Antiviral Drugs - February 2014
• High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate: Oral liquid 250 mL, 30; KetoVie 3:1. Oral liquid 250 mL, 30; KetoVie 4:1. Oral liquid 250 mL, 30; KetoVie Peptide 4:1- March 2023
• High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate: Oral liquid 250 mL, 30; KetoVie® Peptide 4:1 - July 2021
• High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate: Oral semi-solid, 100 g, 36; K.Yo®- March 2021
• High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate: Oral powder 300 g; KetoCal 3:1®; KetoCal 4:1®- March 2021
• High dose inactivated trivalent Influenza vaccine (split virion): Injection 0.5 mL; Fluzone® High-Dose - November 2019
• High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate: Oral semi-solid 100 g; Keyo® - November 2016
• High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate: Oral liquid 250 mL, 30; Ketovie 4:1®; Ketovie 3:1®; Ketovie Peptide 4:1® - November 2020
• High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate (4:1 ratio long chain fat to carbohydrate plus protein) oral liquid: powder for, 300 g; KetoCal 4:1® - November 2015
• House dust mite American with house dust mite European: 100 IR tablet: sublingual, 3 + 300 IR tablet: sublingual, 28; 300 IR tablet: sublingual, 30, Actair® - July 2016
• Human menopausal gonadotrophin: Injection 600 I.U. in 0.96 mL pre-filled multi-dose pen, Injection 1200 I.U. in 1.92 mL pre-filled multi-dose pen; Menopur® - July 2022
• Human Menopuasal Gonadotrophin, powder for injection, 600 IU and 1200 IU with solvent, Menopur® - March 2012
• Human papillomavirus 9-valent vaccine: Injection 0.5 mL, pre-filled syringe; Gardasil®9 – December 2022
• Human papillomavirus 9-valent vaccine: Injection 0.5 mL, pre-filled Syringe Gardasil® 9 - July 2017
• Human Papillomavirus (HPV) types 16 18 vaccine injection, 0.5ml, Cervarix® - November 2015
• Human papillomavirus (Types 16 and 18) recombinant, AS04 adjuvanted vaccine, injection, 0.5 ml vial and pre-filled syringe, Cervarix®, July 2007
• Human Papillomavirus (Types 16 and 18) recombinant, AS04 adjuvanted vaccine, injection, 0.5 ml vial and pre-filled syringe, Cervarix®, November 2007
• Human Rotavirus Vaccine, lyophilised powder and solvent for oral administration, one mL dose, Rotarix®, November 2006
• Hyaluronic acid with polyethylene glycol 400 with propylene glycol with hydroxypropyl guar: Eye drops containing sodium hyaluronate 1.5 mg per mL with polyethylene glycol 400, propylene glycol and hydroxypropyl guar, 10 mL; Systane® Hydration – March 2023 - May 2023
• Hydrocortisone: Capsule containing granules 0.5 mg, Capsule containing granules 1 mg, Capsule containing granules 2 mg, Capsule containing granules 5 mg; Alkindi® - July 2021
• Hydromorphone hydrochloride, extended release capsules, 12 mg, 16 mg , 24 mg, and 32 mg, Palladone® XL, July 2005
• Hydromorphone hydrochloride, prolonged release tablets, 8 mg, 16 mg, 32 mg, and 64 mg Jurnista®, November 2008
• Hydromorphone hydrochloride: Oral liquid, 1 mg/mL; Dilaudid® - March 2018
• Hydroxyethyl starch 130/0.4, I.V. infusion, 60 g per L, 500 mL, Voluven® 6 %, July 2009
• Hylan G-F 20, injection, 16 mg in 2 mL, Synvisc® March 2006
• Hypromellose: Eye drops 3 mg per mL, 10 mL; Revive Tears® - July 2021
• Hypromellose: eye drops 3 mg per mL, 10 mL; In a Wink Moisturising Genteal® - November 2018

Top of page

I

• Ibandronic acid, tablet, 50 mg, Bondronat®, November 2008
• Ibandronic acid, tablet, 50 mg, Bondronat®, March 2008
• Ibandronic acid, tablet, 150 mg, Bonviva® Once Monthly, March 2007
• Ibandronic acid, tablet, 150 mg, Bonviva® Once Monthly, November 2006
• Ibandronic acid, tablet, 150 mg, Bonviva® Once Monthly, July 2006
• Ibrutinib: Capsule 140 mg; Imbruvica® – December 2022
• Ibrutinib: Tablet 140 mg, Tablet 280 mg, Tablet 420 mg, Tablet 560 mg; Imbruvica® - November 2020
• Ibrutinib: Capsule 140 mg; Imbruvica® - November 2019   
• Ibrutinib: Capsule 140 mg; Imbruvica® - March 2018
• Ibrutinib (CLL/SLL): Capsule 140 mg ; Imbruvica® - November 2017
• Ibrutinib (CLL/SLL): 140 mg capsules, 90; Imbruvica® - November 2016
• Ibrutinib (MCL): Capsule 140 mg; Imbruvica® - November 2016
• Ibrutinib (MCL): Capsule 140 mg; Imbruvica® - November 2017 
• Ibrutinib: 140 mg capsules, 90, Imbruvica® - March 2016
• Ibrutinib: oral capsule, 140 mg, Imbruvica® - November 2015
• Ibrutinib; 140 mg capsules, 90; Imbruvica® - July 2015
• Icatibant: Injection 30 mg (as acetate)in 3 mL single use pre-filled syringe; Firazyr® - July 2017
• Icatibant: Injection 30 mg (as acetate) in 3 mL single use pre-filled syringe; Firazyr® - November 2016
• Icatibant, injection, 30 mg in 3 mL (as acetate), single use pre-filled syringe, Firazyr®, July 2011
• Icatibant, injection, 30 mg in 3 mL (as acetate), single use pre-filled syringe, Firazyr®, July 2010
• Idelalisib: 100 mg tablet, 60, 150 mg tablet, 60, Zydelig®, chronic lymphocytic leukaemia - July 2016
• Idelalisib: 100 mg tablet, 60, 150 mg tablet, 60, Zydelig®, follicular lymphoma - July 2016
• Idelalisib: 100 mg tablet, 60, 150 mg tablet, 60, Zydelig® - March 2016
• Idelalisib: 100 mg tablet, 60, 150 mg tablet, 60, Zydelig® - March 2016
• Idelalisib: 100 mg tablet, 60, 150 mg tablet, 60, Zydelig® (chronic lymphocytic leukaemia) - November 2015
• Idelalisib: oral tablet, 100 mg, 150 mg, Zydelig® (follicular lymphoma) - November 2015
• Idelalisib; 100 mg tablet 60, 150 mg tablet 60; Zydelig® - March 2015
• Idelalisib; 100 mg tablet 60, 150 mg tablet 60; Zydelig® - March 2015
• Idursulfase-rhu, concentrate for intravenous solution for infusion, 6 mg/3 mL, Elaprase®, November 2007
• Imatinib: Tablet 600 mg; Imatab® - November 2021
• Imatinib: Tablet 100 mg, Capsule 100 mg, Tablet 400 mg, Capsule 400 mg; Multiple Brands – July 2018
• Imatinib; 100 mg tablet 56, 400 mg tablet 28; Glivec® - March 2015
• Imatinib, tablets, 100 mg and 400 mg, (as mesylate) Glivec® - November 2012
• Imatinib, tablets, 100 mg and 400 mg (as mesylate), Glivec®, March 2012
• Imatinib, tablet, 100 mg and 400 mg (as mesylate), Glivec®, March 2011
• Imatinib, tablets, 100 mg and 400 mg (as mesylate), Glivec® - July 2010
• Imatinib, tablet, 100 mg and 400 mg (as mesylate), Glivec®, November 2009
• Imatinib mesylate, tablets, 100 mg and 400 mg (base), Glivec®, March 2008
• Imatinib mesylate, tablet, 100 mg and 400 mg (base), Glivec®, July 2007
• Imiquimod, cream 50 mg per g (5%), 250 mg single use sachets, 12, Aldara®, March 2009
• Imiquimod, cream 50 mg per g (5%), 250 mg single use sachets, 12, Aldara®, July 2008
• Imiquimod, cream, 12.5 mg per 250 mg single use sachets (5%), 12, Aldara®, July 2006
• Imiquimod, cream, 12.5 mg per 250 mg single use sachets (5%), Aldara®, November 2005
• Imiquimod, Independent Review Report
• Imiquimod - Sponsor's response to Independent Review Report
• Inactivated quadrivalent Influenza vaccine (split virion): Injection 0.5 mL; FluQuadriTM - November 2019
• Inactivated influenza vaccine (surface antigen), adjuvanted, suspension for injection, 15mcg in 0.5mL, Fluad® - March 2018
• Inactivated Quadrivalent Influenza Vaccine (Split Virion): Injection 0.5mL in pre-filled syringe; Afluria® Quad - November 2018
• Inactivated trivalent influenza vaccine (Split Virion) suspension for injection, 180mcg single dose in 0.5mL, Fluzone® High-Dose - March 2018
• Inclisiran: Injection 284 mg in 1.5 mL single use pre-filled syringe; Leqvio® - March 2023 - May 2023
• Indacaterol with Glycopyrronium and Mometasone: Capsule containing powder for oral inhalation mometasone furoate 80 micrograms with indacaterol 150 micrograms (as acetate) with glycopyrronium 50 micrograms (as bromide) (for use in Breezhaler), Capsule containing powder for oral inhalation mometasone furoate 160 micrograms  with indacaterol 150 micrograms (as acetate) with glycopyrronium 50 micrograms (as bromide) (for use in Breezhaler); Enerzair Breezhaler® - July 2020

• Indacaterol with Mometasone: Capsule containing powder for oral inhalation mometasone furoate 80 micrograms with indacaterol 150 micrograms (as acetate) (for use in Breezhaler®), Capsule containing powder for oral inhalation mometasone furoate 160 micrograms with indacaterol 150 micrograms (as acetate) (for use in Breezhaler®), Capsule containing powder for oral inhalation mometasone furoate 320 micrograms with indacaterol 150 micrograms (as acetate) (for use in Breezhaler®); Atectura Breezhaler® - July 2020

• Indacaterol with Glycopyrronium (FDC), indacaterol 110 microgram + glycopyrronium 50 microgram, inhalation: powder for, 30 capsules, Ultibro® Breezhaler® 110/50 - July 2014
• Incobotulinumtoxin A: Lyophilised powder for injection 100 units; Xeomin® - November 2019
• Incobotulinumtoxin A, powder for solution for injection, 100LD50 units, Xeomin® - July 2014
• Indacaterol + Glycopyrronium, indacaterol 110 microgram + glycopyrronium 50 microgram inhalation: powder for, Ultibro Breezhaler 110/50®, Novartis Pharmaceuticals Australia Pty Ltd - March 2014
• Indacaterol, capsule containing powder for oral inhalation, 150 micrograms and 300 micrograms (as maleate), Onbrez®, July 2011
• Indacaterol maleate, capsules containing powder for oral inhalation, 150 microgram (base) and 300 microgram (base), Onbrez® Breezhaler®, November 2010
• Infliximab: Solution for injection 120 mg in 1 mL pre-filled pen, Solution for injection 120 mg in 1 mL pre-filled syringe; Remsima® SC - November 2022
• Infliximab: Solution for injection 120 mg in 1 mL pre-filled pen, Solution for injection 120 mg in 1 mL pre-filled syringe; Remsima® SC - March 2022
• Infliximab: Injection 120 mg in 1 mL pre-filled syringe, Injection 120 mg in 1 mL pre-filled pen: Remsima® SC - November 2020
• Infliximab; 100 mg injection vial, 1; 100 mg injection vial, 3; 100 mg injection vial, 4; Inflectra® - July 2015
• Infliximab, injection vial, 100 mg, Remicade® - July 2014
• Infliximab, 100 mg injection, 1 x 100 mg vial, Remicade® - March 2014
• Infliximab, powder for intravenous infusion, 100mg, Remicade® - November 2013
• Infliximab, powder for IV infusion, 100mg, Remicade® - March 2013
• Infliximab, powder for IV infusion, 100 mg, Remicade® - March 2010
• Infliximab, powder for IV infusion, 100 mg, Remicade®, July 2008
• Infliximab, powder for I.V. infusion, 100 mg, Remicade®, July 07
• Infliximab, powder for I.V. infusion, 100 mg, Remicade®, March 2007
• Infliximab, powder for I.V. infusion, 100 mg, Remicade®, July 2006
• Infliximab: Powder for I.V. infusion 100 mg; Renflexis® - November 2017
• Infliximab: Powder for I.V. infusion 100 mg; Inflectra® - March 2019
• Infliximab, powder for intravenous infusion, 100 mg, Remicade®, March 2006
• Infliximab (biosimilar) : Powder for I.V. infusion 100 mg; Renflexis® - November 2016
• Influenza Quadrivalent Adjuvanted Vaccine, Injection 0.5 mL Fluad® Quad, and Influenza Trivalent Adjuvanted Vaccine, Injection 0.5 mL, Fluad®, Seqirus (Australia) Pty Ltd - August 2019
• Influenza Quadrivalent Adjuvanted Vaccine, Influenza Trivalent Adjuvanted Vaccine: Injection 0.5 mL; Fluad® Quad and Fluad® - July 2019
• Influenza Quadrivalent Vaccine: Injection 0.5 mL; Vaxigrip Tetra™ - July 2019
• Influenza vaccine, injection in pre-filled syringe, 15 micrograms/strain/0.1 mL (containing A/New Caledonia/20/99, A/Wisconsin/67/2005, B/Malaysia/2506/2004 like strains), Intanza®, July 2009
• Influenza vaccine, injection, 0.5 mL, Fluarix®, Fluvax®, Influvac®, Vaxigrip®, November 2007
• Influenza Vaccine (quadrivalent); 0.5 mL pre-filled syringe; Fluarix tetra® – March 2015
• Ingenol Mebutate, gel 0.15 mg/g (0.015%), 3 x 0.47 g, Picato® - July 2014
• Ingenol Mebutate 0.015% gel, 3 x 470 mg tubes, Picato® - November 2013
• Ingenol, gel, 0.15 mg per g (0.015% ), 70 mcg ingenol mebutate in 0.47 g single use tubes, 3 Picato® - November 2012
• Inotuzumab ozogamicin: Powder for I.V. infusion, 1 mg; Besponsa® - May 2019
• Inotuzumab Ozogamicin: Powder for I.V. infusion 1 mg; Besponsa® - November 2018
• Insect allergen extract-honey bee venom: Injection set containing 550 micrograms with diluent; 2. Insect allergen extract-paper wasp venom: Injection set containing 550 micrograms with diluent, 3. Insect allergen extract-yellow jacket venom: Injection set containing 550 micrograms with diluent; 1. Hymenoptera Honey Bee Venom®, 2. Hymenoptera Paper Wasp Venom®, 3. Hymenoptera Yellow Jacket Venom® - July 2018
• Insulin aspart: Injections (human analogue), catridges, 100 units per mL, 3 mL, 5; Truvelog®;  Injections (human analogue), pre-filled pen, 100 units per mL, 3 mL, 5; Truvelog Solostar® - November 2021
• Insulin Aspart: Injections (human analogue), pre filled pen, 100 units per mL, 3mL; Injections (human analogue), vial, 100 units per mL, 10 mL; Injections (human analogue), cartridges, 100 units per mL, 3 mL; Fiasp® - November 2018
• Insulin degludec with insulin aspart: Injections, cartridges, 70 units-30 units per mL, 3 mL, 5, Injections, pre-filled pen, 70 units-30 units per mL, 3 mL, 5; Ryzodeg® - March 2018
• Insulin degludec with insulin aspart: Injections, cartridges, 70 units-30 units per mL, 3 mL, 5, Injections, pre-filled pen, 70 units-30 units per mL, 3 mL, 5; Ryzodeg FlexTouch®, Ryzodeg Penfill® - November 2017
• Insulin degludec, injection solution, 100 IU/mL and 200 IU/mL, Tresiba Flextouch® and Tresiba Penfill® - March 2013
• Insulin detemir, cartridge 3mL, prefilled device 3 mL, prefilled syringe 3 mL, 100 U/mL, Levemir® , November 2007
• Insulin detemir (rys) cartridge 3mL (Penfill® ), prefilled device 3 mL (FlexPen®), 100U/mL, Levemir ®, July 2005
• Insulin detemir (rys) cartridge 3mL (Penfill®), prefilled device 3 mL, (FlexPen®), 100 U/mL, Levemir®, March 2006
• Insulin glargine: Injections (human analogue), cartridges, 100 units per ml, 3 ml, 5; Semglee® - July 2018
• Insulin glargine: 3 ml cartridges, 100 IU/ml, Basaglar® - November 2015
• Insulin Glargine; 100 international units/mL injection, 5 x 3 mL cartridges; Basaglar®, Basaglar KwikPen® – March 2015
• Insulin glargine, injection, 100 units per mL, 10 mL vials and 3 mL x 5 cartridges, Lantus® , July 2005
• Insulin glargine, injection, 100 units per mL, 10 mL vials and 3 mL x 5 cartridges, Lantus®, March 2006
• Insulin glargine; 300 unit/mL, 1 x 1.5 mL cartridge; 300 unit/mL, 3 x 1.5 mL cartridge; 300 unit/mL, 5 x 1.5 mL cartridge; Toujeo® - July 2015
• Insulin glargine with lixisenatide: Injections (human analogue), cartridges, insulin glargine 100 units per mL with lixisenatide 50 microgram per mL, 3 mL, 5; Injections (human analogue), cartridges, insulin glargine 100 units per mL with lixisenatide 33 microgram per mL, 3 mL, 5; Soliqua® - March 2018
• Insulin Glargine with Lixisenatide: Injections (human analogue), cartridges, insulin glargine 100 units per mL with lixisenatide 50 micrograms per mL, 3 mL, 5, Injections (human analogue), cartridges, insulin glargine 100 units per mL with lixisenatide 33 micrograms per mL, 3 mL, 5; Soliqua® - March 2019
• Insulin glulisine, injection (human analogue), 100 units per mL, 3 mL, 5, Apidra®, Apidra SoloStar®, March 2007
• Insulin lispro: Injections (human analogue), cartridges, 200 units per mL, 3 mL, 5; Humalog® U200 Kwikpen® - November 2017
• Interferon beta – 1b, injection set comprising 1 vial powder for injection 8,000,000 i.u. (250 micrograms) and solvent, Betaferon®, March 2007
• Ipilimumab: 50 mg/10 mL injection, 10 mL, 200 mg/40 mL injection, 40 mL, Yervoy® - July 2016
• Ipilimumab, concentrate solution for I.V infusion, 50 mg in 10 mL, 200 mg in 40 mL, Yervoy® - November 2012
• Ipilimumab, concentrate solution for I.V. infusion, 50 mg in 10 mL, 200 mg in 40 mL, Yervoy® - March 2012
• Ipilimumab, concentrate solution for I.V. infusion, 50 mg in 10 mL, 200 mg in 40 mL, Yervoy®,July 2011
• Irinotecan (nanoliposomal): 43 mg in 10 mL Injection; Onivyde® - March 2018
• Irinotecan (nanoliposomal): Injection concentrate for I.V. infusion 43 mg (as sucrosofate) in 10 mL; Onivyde® - November 2016
• Iron chelating agents; Deferasirox, Deferiprone, Desferrioxamine - November 2014
• Iron sucrose; 100 mg/5 mL injection, 5 x 5 mL ampoules; Venofer® - November 2014
• Isotretinoin: Capsule 30 mg; Oratane® - November 2019
• Isotretinoin: Capsule 5 mg; Oratane® - November 2018
• Itraconazole:50 mg capsule, 60, Lozanoc® - November 2015
• Itraconazole; 50 mg capsule, 60; Lozanoc® - November 2014
• Ivabradine; 5 mg tablet 56, 7.5 mg tablet 56; Coralan® – March 2015
• Ivabradine, tablet, 5 mg and 7.5 mg (as hydrochloride), Coralan® - November 2012
• Ivabradine, tablet, 5 mg and 7.5 mg (as hydrochloride), Coralan® - July 2012
• Ivabradine, tablets (film-coated), 5 mg and 7.5 mg (as hydrochloride), Coralan®, November 2011
• Ivabradine hydrochloride, film coated tablets, 5 mg and 7.5 mg, Coralan®, July 2008
• Ivabradine hydrochloride, film coated tablets, 5 mg and 7.5 mg, Coralan®, July 2009
• Ivabradine hydrochloride, film coated tablets, 5 mg and 7.5 mg, Coralan®, November 2007
• Ivacaftor: Sachet containing granules 50 mg, Sachet containing granules 75 mg; Kalydeco® - November 2016
• Ivacaftor: Sachet containing granules 50 mg, Sachet containing granules 75 mg; Kalydeco® - March 2019
• Ivacaftor: tablet, 150mg, Kalydeco® - November 2015
• Ivacaftor; 150 mg tablet, 56; Kalydeco® - July 2015
• Ivacaftor, 150 mg tablet, 56, Kalydeco® - March 2014
• Ivacaftor, tablet, 150mg, Kalydeco® - November 2013
• Ivacaftor, tablet, 150mg, Kalydeco® - July 2013
• Ivacaftor; tablet, 150 mg; Kalydeco® - November 2014
• Ivermectin, 3 mg tablet, Stromectol® - March 2014
• Ixazomib: Capsule 2.3 mg, Capsule 3 mg, Capsule 4 mg; Ninlaro® - March 2022
• Ixazomib: Capsule 2.3 mg, Capsule 3 mg, Capsule 4 mg; Ninlaro® - November 2020
• Ixekizumab: Injection 80 mg in 1 mL single dose pre-filled pen; Taltz® - November 2021
• Ixekizumab: Injection 80 mg in 1 mL single dose pre-filled pen; Taltz® - July 2020
• Ixekizumab: Injection 80 mg in 1 ml single dose pre-filled pen; Injection 80 mg in 1 ml single dose pre-filled syringe; Taltz® - July 2018
• Ixekizumab: Injection 80 mg in 1 mL single dose pre-filled pen, Taltz® - July 2023
• Ixekizumab: 80 mg/mL injection 2 × 1 mL syringe, 80 mg/mL injection 2 x 1 mL injection device, Taltz® - July 2016
  Top of page

J K L

• Lacosamide: Tablet 50 mg, Tablet 100 mg, Tablet 150 mg, Tablet 200 mg, Oral solution 10 mg per mL, 200 mL; Vimpat®- March 2021
• Lacosamide: Tablet 50 mg, Tablet 100 mg, Tablet 150 mg, Tablet 200 mg, Oral liquid 10 mg per mL, 200 mL ; Vimpat® - November 2018
• Lacosamide, tablets, 50 mg, 100 mg, 150 mg and 200 mg, Vimpat® - November 2012
• Lacosamide, tablets, 50 mg, 100 mg, 150 mg and 200 mg, Vimpat® , November 2011
• Lacosamide, tablets, 50 mg, 100 mg, 150 mg and 200 mg, oral solution, 15 mg per mL, Vimpat®, November 2009
• Lacosamide; 50 mg tablet; Vimpat® – March 2015
• Lanadelumab: Solution for subcutaneous injection 300 mg in 2 mL; Takhzyro® - July 2021
• Lanadelumab: Solution for subcutaneous injection 300 mg in 2 mL; Takhzyro® - July 2020
• Lanadelumab: Solution for injection 300 mg in 2 mL; Takhzyro® - July 2019
• Lanreotide: Injection 60 mg (as acetate) in single dose pre-filled syringe, Injection 90 mg (as acetate) in single dose pre-filled syringe, Injection 120 mg (as acetate) in single dose pre-filled syringe; Mytolac® - November 2022
• Lanreotide (GEP-NETs): Injection 120 mg (as acetate) in single dose pre-filled syringe; Somatuline® Autogel® - November 2017
• Lanreotide: Injection 120 mg (as acetate) in single dose pre-filled syringe; Somatuline® and Autogel® - July 2017
• Lanreotide: Injection 120 mg (as acetate) in single dose pre-filled syringe; Somatuline®Autogel® - March 2019
• Lanreotide: Injection 60 mg (as acetate) in single dose pre-filled syringe, Injection 90 mg (as acetate) in single dose pre-filled syringe, Injection 120 mg (as acetate) in single dose pre-filled syringe; Somatuline® Autogel® - November 2016
• Lanreotide: 120 mg injection, Somatuline® - November 2015
• Lanreotide acetate, pre-filled syringe, 60 mg in 0.3mL (base), 90 mg in 0.3 mL (base) and 120 mg in 0.5 mL (base), Somatuline Autogel®, July 2005
• Lanreotide (acromegaly and functional carcinoid tumour): Injection 60 mg (as acetate) in single dose pre-filled syringe, Injection 90 mg (as acetate) in single dose pre-filled syringe, Injection 120 mg (as acetate) in single dose pre-filled syringe; Somatuline® Autogel® - November 2017
• Lanthanum carbonate hydrate, chewable tablet, 500 mg, 750 mg and 1000 mg, Fosrenol®, November 2008
• Lanthanum carbonate hydrate, chewable tablet, 500 mg (base), 750 mg (base), 1 g (base), Fosrenol®, March 2007
• Lapatinib ditosylate, tablets, 250 mg, Tykerb®, November 2007
• Lapatinib ditosylate monohydrate, tablet, 250mg (base), Tykerb®, July 2007
• Larotrectinib: Capsule 25 mg, Capsule 100 mg, Oral solution 20 mg per mL, 100 mL; Vitrakvi® - March 2022
• Larotrectinib: Capsule 25 mg, Capsule 100 mg, Oral solution 20 mg per mL, 100 mL; Vitrakvi® - November 2021
• Larotrectinib: Capsule 25 mg; Capsule 100 mg; Oral solution 20 mg per mL, 100 mL; Vitrakvi® - November 2020
• Latanoprost with Timolol maleate, eye drops, 50 micrograms-5mg (base) per mL (0.005%-0.5%), 2.5 mL Xalacom®, November 2005
• Latanoprost with Timolol maleate, eye drops, 50 micrograms-5 mg (base) per mL (0.005%-0.5%), 2.5 mL, Xalacom®. , July 2005
• Ledipasvir with sofosbuvir; ledipasvir 90 mg + sofosbuvir 400 mg tablet 28; Harvoni® – March 2015
• Leflunomide, tablet 10 mg, 20 mg, Arava®/Arabloc®; pack of 3 tablets leflunomide 100 mg and 30 tablets leflunomide 20 mg, 1, Arava®, March 2007
• Lenacapavir: Tablet 300 mg, Pack containing 2 injection sets 463.5 mg in 1.5 mL; Sunlenca® - November 2022
• Lenalidomide, 5 mg, 10 mg, 15 mg, 25 mg, Capsule, Revlimid®, Celgene Pty Ltd. - August 2019
• Lenalidomide: Capsule 5 mg, 10 mg, 15 mg; Revlimid® - July 2019
• Lenalidomide: Capsule, 5 mg, 10 mg and 15 mg; Revlimid® - March 2018
• Lenalidomide: Capsule 5 mg, Capsule 10 mg, Capsule 15 mg, Capsule 25 mg; Revlimid® - November 2017   
• Lenalidomide: 5 mg capsule, 21, 10 mg capsule, 21, 15 mg capsule, 21, 25 mg capsule, 21, Revlemid® - July 2016
• Lenalidomide: 5 mg capsule, 10 mg capsule, 15 mg capsule, 25 mg capsule, Revlimid® - March 2016
• Lenalidomide: capsules, 5 mg, 10 mg, 15 mg, 25 mg, Revlimid® - November 2015
• Lenalidomide, capsules, 5 mg and 10 mg, Revlimid®, March 2013
• Lenalidomide, capsules, 5 mg and 10 mg, Revlimid®, July 2011
• Lenalidomide, capsules, 5 mg and 10 mg, Revlimid®, March 2011
• Lenalidomide, capsules, 5 mg, 10 mg, 15 mg and 25 mg, Revlimid®, November 2008
• Lenalidomide: Capsule 5 mg, Capsule 10 mg, Capsule 15 mg, Capsule 25 mg; Revlimid® - March 2019
• Lenalidomide, capsules, 5 mg, 10 mg, 15 mg and 25 mg, Revlimid®, March 2008
• Lenvatinib: Capsule 4 mg (as mesilate); Lenvima® - November 2018
• Lenvatinib (HCC): Capsule 4 mg (as mesilate); Lenvima® - July 2018
• Lenvatinib (thyroid cancer): Capsule 4 mg (as mesilate); Capsule 10 mg (as mesilate); Lenvima® - July 2018
• Lenvatinib: Capsule 4 mg (as mesilate), Capsule 10 mg (as mesilate); Lenvima® - March 2018
• Lenvatinib : Capsule 10 mg (as mesilate), Capsule 4 mg (as mesilate); Lenvima® - November 2017
• Lenvatinib: 4 mg capsule, 30, 10 mg capsule, 30, Lenvima® - July 2016
• Lenvatinib: 4 mg capsule, 3010 mg capsule, 30, Lenvima® - March 2016
• Lenvatinib: capsule 4 mg and 10 mg, Lenvima® - November 2015
• Lercanidipine with Enalapril, tablets, 10 mg-10 mg, 10 mg-20 mg, Zan Extra®, March 2008
• Letermovir: Tablet 240 mg; Prevymis® - July 2018
• Letermovir: Tablet 240 mg; Prevymis® - March 2019
• Letrozole, tablet 2.5 mg, Femara®, March 2007
• Letrozole, tablet, 2.5 mg, Femara®, July 2006
• Letrozole, tablet, 2.5 mg, Femara®, November 2005
• Leuprorelin acetate: Suspension for subcutaneous injection (modified release) containing 45 mg of leuprorelin acetate; Eligard® 6 month - July 2022
• Leuprorelin: Subcutaneous implant 3.6 mg (as acetate) in pre-filled syringe, Subcutaneous implant 5 mg (as acetate) in pre-filled syringe; Lerin® - July 2019
• Leuprorelin and bicalutamide: leuprorelin 7.5 mg injection and bicalutamide 50 mg tablet, 28, leuprorelin 22.5 mg injection and bicalutamide 50 mg tablet, 28, leuprorelin 22.5 mg injection and bicalutamide 50 mg tablet, 84, Bi Eligard CP® - July 2016
• Leuprorelin: 22.5 mg injection: modified release [1 x 22.5 mg syringe] (&) inert substance diluent [1 x 2 mL syringe], 1 pack 30 mg injection: modified release [1 x 30 mg syringe] (&) inert substance diluent [1 x 2 mL syringe], 1 pack 7.5 mg injection: modified release [1 x 7.5 mg syringe] (&) inert substance diluent [1 x 2 mL syringe], 1 pack 45 mg injection: modified release [1 syringe] (&) inert substance diluent [1 syringe], 1 pack, Lucrin® - March 2016
• Leuprorelin; 30 mg injection: modified release [1 x 30 mg syringe] (&) inert substance diluent [1 x 2 mL syringe], 1; Lucrin® Depot - July 2015
• Leuprorelin; 30 mg injection: modified release [1 x 30 mg syringe] (&) inert substance diluent [1 x 2 ml syringe], 1 pack; Lucrin Depot Paediatric® - November 2014
• Leuprorelin; 45 mg injection: modified release [1 x 45 mg syringe] (&) inert substance diluent [1 x 2 mL syringe], 1; Lucrin® Depot 6 month PDS - July 2015
• Levetiracetam, tablets 250 mg, 500 mg, 1000 mg and 100 mg per mL, Keppra®, November 2008
• Levodopa with Carbidopa: Intestinal gel containing levodopa 20 mg with carbidopa monohydrate 5 mg per mL, 100 mL; Duodopa® - November 2019
• Levodopa with carbidopa: Intestinal gel containing levodopa 20 mg with carbidopa (as monohydrate) 5 mg in 1 mL; Duodopa® - November 2016
• Levodopa with carbidopa monohydrate, intestinal gel, 20 mg – 5 mg (base) per mL, 100 mL, Duodopa®, March 2009
• Levodopa with Carbidopa, intestinal gel, 20 mg–5 mg per mL, Duodopa®, March 2008
• Levodopa with carbidopa (as monohydrate), intestinal gel, 20 mg – 5 mg (base) per mL, 100 mL, Duodopa®, November 2010
• Levonorgestrel, intrauterine system, 13.5 mg, Jaydess® - March 2014
• Levonorgestrel, intrauterine system, 13.5 mg, Jaydess® - July 2013
• Levonorgestrel, intrauterine drug delivery system 52 mg (releasing approximately 20 micrograms per 24 hours), Mirena®, March 2007
• Levonorgestrel: Intrauterine drug delivery system 19.5 mg; Kyleena® - March 2019
• Lignocaine; 5% patch: dermal, 30; Versatis® - March 2015
• Linagliptin linagliptin and metformin: linagliptin 5 mg tablet, 30 linagliptin 2.5 mg + metformin hydrochloride 500 mg tablet, 60 linagliptin 2.5 mg + metformin hydrochloride 850 mg tablet, 60 linagliptin 2.5 mg + metformin hydrochloride 1 g tablet, 60, Trajenta® Trajentamet® - March 2016
• Linagliptin linagliptin and metformin: linagliptin 5 mg tablet, 30 linagliptin 2.5 mg + metformin hydrochloride 500 mg tablet, 60 linagliptin 2.5 mg + metformin hydrochloride 850 mg tablet, 60 linagliptin 2.5 mg + metformin hydrochloride 1 g tablet, 60, Trajenta® Trajentamet® - March 2016
• Linagliptin with metformin hydrochloride, tablets, 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/1000 mg, Trajentamet® - March 2013
• Linagliptin with metformin hydrochloride, tablets, 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/1000 mg, Trajentamet® - April 2013
• Linagliptin, tablet, 5 mg, Trajenta® - July 2012
• Linagliptin, tablet, 5 mg, Trajenta® - November 2011
• Linagliptin, tablet, 5 mg, Trajenta® - July 2011
• Linezolid, injection, 600 mg per 300 mL, tablet, 600 mg and powder for oral suspension, 20 mg per mL, Zyvox® - July 2013
• Lipegfilgrastim: 6 mg/0.6mL, 1 x 0.6 mL injection, Lonquex® - March 2016
• Liraglutide: Injection, 3 mL pre-filled, multi-dose, disposable pen, 6 mg/mL; 2 pen pack; Victoza® - March 2018
• Liraglutide: Injection 6 mg/mL, 3 mL pre-filled pen; Victoza® - July 2017
• Liraglutide, solution for injection, 6mg/mL, Victoza®, March 2013
• Liraglutide (rys), injection solution, pre-filled pen, 6 mg per mL, 3 mL, 2 and 3 pen pack, Victoza® - November 2011
• Liraglutide (rys), solution for injection, 3 mL pre-filled injection pen, 6 mg per mL, Victoza®, November 2010
• Lisdexamfetamine: Capsule containing lisdexamfetamine dimesilate 20mg, 30mg, 40mg, 50mg, 60mg, 70mg; Vyvanse® - March 2020
• Lisdexamfetamine: Capsule containing lisdexamfetamine dimesilate 20 mg, 40 mg and 60 mg; Vyvanse® - July 2019
• Lisdexamfetamine Dimesilate, capsules, 30 mg, 50 mg & 70 mg, Vyvanse® - July 2014
• Lisdexamfetamine, capsules, 30 mg, 50 mg, and 70 mg, Vyvanse® - July 2013
• Lixisenatide,10 microgram/0.2 mL injection, 14 unit doses (&) 20 microgram/0.2 mL injection, 14 unit doses, Lyxumia® treatment initiation pack, Sanofi-Aventis Australia Pty Ltd - July 2014
• Lixisenatide,10 micrograms/0.2 ml injection, 14 unit doses (&) 20 micrograms/0.2 ml injection, 14 unit doses, Lyxumia®, Sanofi-Aventis Australia Pty Ltd - July 2014
• Losartan, tablets, 25 mg and 50 mg (as potassium), Cozavan® - July 2010
• Lorlatinib: Tablet 25 mg, Tablet 100 mg; Lorviqua® - December 2021
• Lorlatinib: Tablet 25 mg, Tablet 100 mg; Lorviqua® - July 2021
• Lorlatinib: Tablet 25 mg, Tablet 100 mg; Lorviqua® - November 2019
• Lumacaftor with ivacaftor: Sachet containing granules, lumacaftor 150 mg with ivacaftor 188 mg, Sachet containing granules, lumacaftor 75 mg with ivacaftor 94 mg, Sachet containing granules, lumacaftor 100 mg with ivacaftor 125 mg; Orkambi® - July 2023
• Lumacaftor + ivacaftor: Tablet containing lumacaftor 100 mg with ivacaftor 125 mg; Orkambi® - December 2021
• Lumacaftor + ivacaftor: Tablet containing lumacaftor 100 mg with ivacaftor 125 mg; Orkambi® - July 2021
• Lumacaftor with Ivacaftor: Sachet containing granules, lumacaftor 100 mg with ivacaftor 125 mg, Sachet containing granules, lumacaftor 150 mg with ivacaftor 188 mg; Orkambi® 100/125 and Orkambi® 150/188 - July 2019
• Lumacaftor with ivacaftor (aged 6 – 11 years): Tablet containing lumacaftor 100 mg with ivacaftor 125 mg; Orkambi® - July 2018
• Lumacaftor with ivacaftor (aged 12+ years): Tablet containing lumacaftor 200 mg with ivacaftor 125 mg; Orkambi® - July 2018
• Lumacaftor with ivacaftor: Tablet containing lumacaftor 200 mg with ivacaftor 125 mg; Orkambi® - July 2017
• Lumacaftor with ivacaftor: Tablet containing lumacaftor 200 mg with ivacaftor 125 mg; Orkambi® - November 2016
• Lumacaftor + ivacaftor: lumacaftor 200 mg + ivacaftor 125 mg tablet, 4 x 28, Orkambi® - March 2016
• Lumiracoxib, tablet, 200 mg, Prexige®, November 2005
• Lurasidone hydrochloride, 40 mg tablet, 30 and 80 mg tablet, 30 Latuda® - March 2014
• Lurasidone hydrochloride; 40 mg tablet 30, 80 mg tablet 30; Latuda® – March 2015
• Lutropin alfa; 75 IU injection [1 x 75 IU vial] (&) inert substance diluent [1 x 1 mL vial], 1 pack; Luveris® – March 2015

Top of page

M

• Macitentan, tablet, 10mg, Opsumit® - March 2014
• Macrogol 3350 plus electrolytes, sachets containing powder for solution, 13.125 g and 6.563 g, Movicol®, Movicol®-Half, November 2007
• Macrogol 3350, sachet containing 13.125 g powder, 30, Movicol®, March 2007
• Macrogol 3350, sachet containing 13.125 g powder, 30, Movicol®; sachet containing 6.563 g powder, 30, Movicol-Half®, November 2005
• Mannitol: Pack containing 280 capsules containing powder for inhalation 40 mg and 2 inhalers; Bronchitol® - July 2017
• Mannitol; powder for inhalation, 40 mg capsules, 280, Bronchitol® - July 2015
• Mannitol, capsule containing powder for oral inhalation, 40 mg (for use in inhaler device), Bronchitol® - November 2011
• Mannitol, capsule containing powder for oral inhalation, 40 mg (for use in inhaler device), Bronchitol®, March 2011
• Maraviroc, tablets, 150 mg and 300 mg, Celsentri® - November 2012
• Maraviroc, tablet, 150 mg, 300 mg, Celsentri® November 2008
• Maraviroc, tablets, 150 mg and 300 mg, Celsentri®, November 2009
• Mavacamten: Capsule 2.5 mg, Capsule 5 mg, Capsule 10 mg, Capsule 15 mg; Camzyos® - July 2023
• Mavacamten: Capsule 2.5 mg, Capsule 5 mg, Capsule 10 mg, Capsule 15 mg; Camzyos® - November 2022
• Mecasermin: Solution for injection 40 mg in 4 mL vial; Increlex® - March 2022
• Mecasermin: Solution for injection 40 mg in 4 mL vial; Increlex® - November 2021
• Measles, Mumps, Rubella and Varicella Virus Vaccine Live, injection, 0.5 mL, ProQuad® - November 2012
• Measles, Mumps, Rubella and Varicella vaccine, powder for injection vial with diluent syringe, 0.5 mL, Priorix-Tetra®, November 2007
• Medium chain triglycerides, 2. Triglycerides long chain: 1. Oral liquid 225 mL (betaquik), 2. Oral liquid 225 mL (carbzero); 1. Betaquik ®, 2. Carbzero® - November 2017
• Melatonin: Tablet 1 mg, Tablet 5 mg; Slenyto® - July 2021
• Melatonin: Tablet 1 mg, Tablet 5 mg; Slenyto®- March 2021
• Memantine hydrochloride, tablet 10 mg, and oral solution 10 mg per mL, Ebixa®, March 2008
• Memantine hydrochloride, tablet, 10 mg and oral solution, 10 mg per mL, Ebixa®, March 2007
• Meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine: Injection 0.5 mL; Menquadfi® - November 2020
• Meningococcal (groups A, C, W-135 and Y) oligosaccharide CRM 197 conjugate vaccine: Pre-filled syringe, 0.5mL, Menveo®GlaxoSmithKline Australia Pty Ltd - August 2018
• Meningococcal (groups A, C, W-135 and Y) oligosaccharide CRM 197 conjugate vaccine: Injection 0.5mL combination pack; Menveo® - July 2018
• Meningococcal polysaccharide conjugate vaccine serogroups A, C, W-135 and Y Pre-filled syringe, 0.5mL, Nimenrix ®, Pfizer Australia Pty Ltd - August 2018
• Meningococcal polysaccharide conjugate vaccine serogroups A, C, W-135 and Y (infants): Pre-filled syringe, 0.5mL; Nimenrix® - March 2018
• Meningococcal polysaccharide conjugate vaccine serogroups A, C, W-135 and Y (adolescents): Pre-filled syringe, 0.5mL; Nimenrix® - March 2018
• Mepolizumab: Injection 100 mg in 1 mL single dose pre-filled pen; Nucala® - November 2022
• Mepolizumab: Injection 100 mg in 1 mL single dose pre-filled pen; Nucala® - November 2021
• Mepolizumab: Injection 100 mg in 1 ml pre-filled pen, Injection 100 mg in 1 ml pre-filled syringe; Nucala® - March 2020
• Mepolizumab: 100 mg/10 mL vial, powder for injection, 1, Nucala® - July 2016
• Mepolizumab: 100 mg/10 mL vial, powder for injection, 1, Nucala® - March 2016
• Mepolizumab: Powder for injection 100 mg; Nucala® - March 2018
• Mepolizumab: Powder for injection 100 mg; Nucala® - November 2017 
• Mercaptopurine; oral suspension 20 mg/mL, 100 mL; Allmercap® - November 2014
• Mesalazine: Tablet 1600 mg; Asacol® - November 2020
• Mesalazine: Tablet 1 g (enteric coated); Salofalk® - July 2018
• Mesalazine: Tablet (enteric coated) 800 mg ; Asacol® - March 2017
• Mesalazine; 3 g granules: modified release, 30 sachets; Salofalk® - November 2014
• Mesalazine; 4 g granules: modified release, 30 x 4 sachets; Pentasa® - November 2014
• Metformin and Saxagliptin, tablet, 1,000mg/2.5mg, 1,000mg/5mg, 500mg/5mg, Kombiglyze® XR - November 2013
• Metformin and Sitagliptin, tablet, 1000mg/50mg, 1000mg/100mg, Janumet® XR - November 2013
• Methoxsalen: Solution for blood fraction 20 microgram per mL, 10 mL; Uvadex® - July 2021
• Methotrexate: Injection 7.5 mg in 0.3 mL pre-filled syringe; Injection 10 mg in 0.4 mL pre-filled syringe; Injection 15 mg in 0.6 mL pre-filled syringe; Injection 20 mg in 0.8 mL pre-filled syringe; Injection 25 mg in 1 mL pre-filled syringe; Methoblastin® PFS - July 2018
• Methotrexate: Injection 7.5 mg in 0.15 mL pre-filled syringe, Injection 10 mg in 0.2 mL pre-filled syringe, Injection 15 mg in 0.3 mL pre-filled syringe, Injection 20 mg in 0.4 mL pre-filled syringe, Injection 25 mg in 0.5 mL pre-filled syringe; Trexject® - March 2017
• Methotrexate: solution for injection, 7.5 mg/0.15 mL solution for injection, 10 mg/0.2 mL solution for injection, 15 mg/0.3 mL solution for injection, 20 mg/0.4 mL solution for injection, 25 mg/0.5 mL, Trexject® - March 2016
• Methoxsalen: Solution for blood fraction 20 microgram per mL, 10 mL; Uvadex® - September 2021
• Methoxsalen: Solution for blood fraction, 20 microgram per mL, 10 mL; Uvadex® - May 2020
• Methoxsalen: Solution for blood fraction, 20 microgram per mL, 10 mL; Uvadex® - July 2017
• Methoxyflurane, solution, 1 x 3 mL with inhaler, Penthrox®, July 2008
• Methoxy polyethylene glycol-epoetin beta, solution for injection, 30 micrograms in 0.3 mL, 50 micrograms in 0.3 mL, 75 micrograms in 0.3 mL, 100 micrograms in 0.3 mL, 120 micrograms in 0.3 mL, 200 micrograms in 0.3 mL and 360 micrograms in 0.6 mL, single use pre-filled syringe, Mircera®, November 2009
• Methyl 5-aminolevulinate hydrochloride, cream, 160 mg/g, 2 g tube, Metvix®, March 2008
• Methyl 5-aminolevulinate hydrochloride, cream, 160 mg/g, 2 g tube, Metvix®, July 2007
• Methyl aminolevulinate, cream, 160 mg per g, 2g tube, Metvix®, November 2005
• Methylnaltrexone bromide, injection, 12 mg in 0.6 mL (base), Relistor®, March 2009
• Methylphenidate: Capsule containing methylphenidate hydrochloride 10 mg (modified release), Capsule containing methylphenidate hydrochloride 20 mg (modified release), Capsule containing methylphenidate hydrochloride 30 mg (modified release), Capsule containing methylphenidate hydrochloride 40 mg (modified release), Capsule containing methylphenidate hydrochloride 60 mg (modified release); Ritalin® LA - March 2022
• Methylphenidate: Capsule containing methylphenidate hydrochloride 60 mg (modified release); Ritalin LA® - March 2020
• Methylphenidate hydrochloride, Tablets, 18 mg, 27 mg, 36 mg, and 54 mg,(extended release) Concerta® - July 2012
• Methylphenidate hydrochloride, extended release capsules, 20 mg, 30 mg and 40 mg, Ritalin LA®, July 2007
• Methylphenidate hydrochloride, extended release tablets, 18 mg, 36 mg and 54 mg, Concerta® November 2006
• Methylphenidate hydrochloride, extended release tablets, 18 mg, 36 mg and 54 mg, Concerta® March 2006
• Mesalazine: Suppository 1g sachet containing granules, 1 g per sachet; Pentasa® - March 2020
• Mesalazine: Modified released, 1.2 g tablet, 60, Mezavant® - November 2015
• Midostaurin: Capsule 25 mg; Rydapt® - July 2018
• Midostaurin, Capsule 25 mg, Rydapt® - November 2017
• Midazolam: Oromucosal solution in pre-filled syringe 2.5 mg in 0.25 mL, Oromucosal solution in pre-filled syringe 5 mg in 0.5 mL, Oromucosal solution in pre-filled syringe 7.5 mg in 0.75 mL, Oromucosal solution in pre-filled syringe 10 mg in 1 mL; Zyamis® - November 2022
• Midazolam: Oromucosal solution in pre-filled syringe 2.5 mg in 0.25 mL, Oromucosal solution in pre-filled syringe 5 mg in 0.5 mL, Oromucosal solution in pre-filled syringe 7.5 mg in 0.75 mL, Oromucosal solution in pre-filled syringe 10 mg in 1 mL; Zyamis® - July 2022
• Mifepristone and misoprostol: Pack containing 1 tablet mifepristone 200 mg and 4 tablets misoprostol 200 micrograms; MS-2 Step® - March 2023
• Mifepristone with Misoprostol, mifepristone 200mg tablet [1 tablet] (&) misoprostol 200 microgram tablet [4 tablets], 1 pack, MS-2 step® - July 2014
• Mifepristone, tablet 200 mg, Mifepristone LinepharmaTM, and Misoprostol, tablet 200 microgram, GyMiso®, March 2013

• Migalastat: Capsule containing migalastat hydrochloride 150 mg; Galafold® – December 2022

• Migalastat: Capsule containing migalastat hydrochloride 150 mg; Galafold® - July 2017
• Migalastat: Capsule containing migalastat hydrochloride 150 mg; Galafold® - November 2017 
• Migalastat: Capsule 150 mg; Galafold® - March 2017
• Miglustat, capsule, 100 mg, Zavesca® - November 2011
• Miglustat, capsule, 100 mg, Zavesca®, July 2010
• Miglustat, capsule 100 mg, Zavesca®, March 2008
• Milk powder synthetic low calcium: Low calcium oral powder 400 g; Locasol® - July 2020
• Milk protein and fat formula with vitamins and minerals - carbohydrate free: Oral powder 225 g, Carbohydrate Free Mixture® - March 2020
• Milk powder - lactose intolerance formula: Oral liquid: powder for, 900 g, S-26 Original LI® - July 2016
• Milnacipran, capsules, 25 mg, 50 mg and 100 mg (as hydrochloride), Jonica® - November 2012
• Mirikizumab: Solution concentrate for I.V. infusion 300 mg in 15 mL, Solution for injection 100 mg in 1 mL pre filled pen; Omvoh® - July 2023
• Mobocertinib: Capsule 40 mg; Exkivity® - July 2023
• Mobocertinib: Capsule 40 mg; Exkivity® - November 2022
• Modafinil, tablet, 100 mg, Modavigil® November 2008
• Mogamulizumab; Solution concentrate for I.V. infusion 20 mg in 5 mL; Poteligeo® - July 2020
• Mogamulizumab: Solution concentrate for I.V. infusion 20 mg in 5 mL; Poteligeo® - November 2020
• Molnupiravir: Capsule 200 mg; Lagevrio® - July 2023
• Montelukast sodium, chewable tablets, 4 mg (base), chewable tablets 5 mg (base), and film coated tablet, 10 mg (base), Singulair®, July 2009
• Morphine hydrochloride: 10 mg/1 mL solution for injection, 5 x 1 mL ampoules 20 mg/1 mL solution for injection, 5 x 1 mL ampoules 50 mg/5 mL solution for injection, 5 x 5 mL ampoules 100 mg/5 mL solution for injection, 5 x 5 mL ampoules - March 2016
• Morphine: Capsule containing morphine sulfate pentahydrate 10 mg (modified release), Capsule containing morphine sulfate pentahydrate 20 mg (modified release); Kapanol® - March 2019
• Moxonidine, tablets, 200 microgram and 400 microgram, Physiotens® March 2006
• Multicomponent Meningococcal group B vaccine: Injection 0.5 mL; Bexsero® - November 2019
• Multicomponent Meningococcal Group B Vaccine (4CmenB); 0.5 mL suspension for injection pre-filled syringe; Bexsero® - July 2015
• Multicomponent Meningococcal Group B Vaccine (4CMenB), injection, 0.5mL, Bexsero® - July 2014
• Multicomponent Meningococcal Group B Vaccine, 0.5mL, injection, prefilled syringe, Bexsero® - November 2013
• Mupirocin: Nasal ointment 20 mg (as calcium) per g, 5 g; Medsurge Mupirocin Nasal Ointment® - July 2019
• Mycophenolate sodium, tablet (enteric coated), 180 mg and 360 mg (mycophenolic acid), Myfortic® - November 2011
• Mycophenolate sodium, tablet (enteric coated), 180 mg and 360 mg (mycophenolic acid), Myfortic® - July 2012
  Top of page

N

• Nabiximols: Oromucosal spray, 8 mg per dose, 90 doses; Sativex® - March 2020
• Nabiximols, oral spray, 10 mL (90 actuations of 100 microlitres), Sativex® - July 2013
• Nadroparin: Injection containing nadroparin calcium, (1,900 I.U. anti-Xa) in 0.2 m, (2,850 I.U. anti-Xa) in 0.3 mL, (3800 IU anti-Xa) in 0.4 mL , (5700 IU anti-Xa) in 0.6 mL , (7600 IU anti-Xa) in 0.8 mL , (9500 IU anti-Xa) in 1 mL , (11400 IU anti-Xa) in 0.6 mL, (15200 IU anti-Xa) in 0.8 mL, (19000 IU anti-Xa) in 1 mL - prefilled syringe; Fraxiparine® and Fraxiparine Forte® - November 2016
• Nadroparin calcium; pre-filled syringe, 1900, 2850, 3800, 5700, 7600, 9500, 11400, 15200, 19,000 IU anti-Xa/mL; Fraxiparine® and Fraxiparine Forte® - July 2015
• Nalmefene: oral tablets, 18 mg, Selincro® - November 2015
• Naloxone: 2.2 mg/actuation nasal spray, 2 x 1 actuation; Nyxoid® - March 2019
• Nandrolone decanoate: Injection 50 mg in 1 mL ampoule; Deca-Durabolin® - March 2018
• Naproxen with Esomeprazole, tablet, 500 mg – 20 mg (as magnesium trihydrate), Vimovo® - Public Summary Document, July 2013
• Naproxen with Esomeprazole, tablet, 500 mg – 20 mg (as magnesium trihydrate), Vimovo® - Independent Review, May 2013
• Naproxen with Esomeprazole, tablet, 500 mg – 20 mg (as magnesium trihydrate), Vimovo® - Review Response, May 2013
• Naproxen with Esomeprazole, tablet, 500 mg – 20 mg (as magnesium trihydrate), Vimovo® - November 2012
• Naproxen and esomeprazole, tablet, 500 mg-20 mg (as magnesium trihydrate), Vimovo® - March 2012
• Natalizumab: Injection 150 mg in 1 mL single dose pre-filled syringe; Tysabri® - March 2023
• Natalizumab: Solution concentrate for I.V. infusion 300 mg in 15 mL; Tysabri® - July 2022
• Natalizumab: Solution concentrate for I.V. infusion 300 mg in 15 mL; Tysabri® - July 2019
• Natalizumab, concentrated solution for IV infusion, 300 mg per 15 mL, Tysabri®, November 2007
• Natalizumab, concentrated solution for IV infusion, 300 mg per 15 mL, Tysabri® November 2006
• National Hepatitis C Data Collection (various) - March 2019
• Nebivolol hydrochloride, tablets, titration pack containing 42 tablets 1.25mg and 14 tablets 5 mg, 1.25 mg, 5 mg and 10 mg (base), Nebilet®, November 2009
• Neratinib: Tablet 40 mg; Nerlynx® - November 2019
• Neratinib: Tablet 40 mg; Nerlynx - March 2019
• Netupitant with palonosetron: Capsule containing netupitant 300 mg with palonosetron 500 microgram (as hydrochloride); Akynzeo® - March 2023
• Netupitant with palonosetron: Capsule containing netupitant 300 mg with palonosetron 500 microgram (as hydrochloride); Akynzeo® - November 2016
• Netupitant + palonosetron: netupitant 300 mg + palonosetron 0.5 mg, fixed-dose combination capsule; Akynzeo® - November 2015
• Netupitant and palonosetron; netupitant 300 mg + palonosetron 0.5 mg, 1; Akynzeo® - July 2015
• Netupitant with Palonosetron; netupitant 300 mg + palonosetron 500 microgram capsule 1; Akynzeo® - March 2015
• Nicotine: Gum 2 mg, Gum 4 mg, Lozenge 2 mg, Lozenge 4 mg; Nicotinell® - March 2018
• Nicotine: Gum 2 mg, Gum 4 mg, Lozenge 2 mg, Lozenge 4 mg; Nicotinell Chewing gum® and Nicotinell lozenge® - July 2017
• Nicotinic Acid, tablets (prolonged release), 500 mg, 750 mg and 1 g, Niaspan®, March 2007
• Nicotinic Acid, tablets (prolonged release), 500 mg, 750 mg and 1 g, Niaspan®, July 2006
• Nicotine, transdermal patch, releasing 15 mg per 16 hours, Nicorette® - March 2010
• Nilotinib, capsule, 150 mg, Tasigna®, July 2011
• Nilotinib, capsule, 200 mg, Tasigna®, March 2008
• Nintedanib: Capsule 100 mg, Capsule 150 mg; Ofev® - September 2021
• Nintedanib: Capsule 100 mg, Capsule 150 mg; Ofev®- March 2021
• Nintedanib: Capsule 100 mg, Capsule 150 mg; Ofev® - November 2016
• Nintedanib: 100 mg capsule, 60, 150 mg capsule, 60, Ofev® - March 2016
• Nintedanib: 100 mg capsule, 60, 150 mg capsule, 60, Ofev® - November 2015
• Nintedanib, 100 mg capsule, 60; 150 mg capsule, 60; Ofev® - March 2015
• Nintedanib, 100 mg capsule, 60; 150 mg capsule, 60; Ofev® - March 2015
• Nitisinone; 2 mg capsule, 60; 5 mg capsule, 60; 10 mg capsule, 60; Orfadin® - July 2015
• Nitisinone; 2 mg capsule, 60, 5 mg capsule, 60, 10 mg capsule, 60; Orfadin® - November 2014
• Niraparib: Capsule 100 mg; Zejula® - March 2023 - July 2023
• Niraparib: Capsule 100 mg; Zejula® - March 2022
• Niraparib: Capsule 100 mg; Zejula® - July 2021 
• Niraparib: Capsule 100 mg; Zejula®- March 2021
• Nivolumab (non-small cell lung cancer): Injection concentrate for I.V. infusion 40 mg in 4 mL vial, Injection concentrate for I.V. infusion 100 mg in 10 mL vial; Opdivo® - July 2023
• Nivolumab (for gastro-oesophageal cancer): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - July 2023
• Nivolumab (NSCLC): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - March 2023
• Nivolumab (gastro-oesophageal cancers): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - March 2023
• Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - November 2022
• Nivolumab plus Ipilimumab: Nivolumab: Injection concentrate for I.V. infusion 100 mg in 10 mL, Injection concentrate for I.V. infusion 40 mg in 4 mL; Opdivo®. Ipilimumab: Injection concentrate for I.V. infusion 200 mg in 40 mL, Injection concentrate for I.V. infusion 50 mg in 10 mL; Yervoy® - November 2022
• Nivolumab (urothelial carcinoma): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL: Opdivo® - July 2022
• Nivolumab (oesophageal carcinoma or gastroesophageal junction carcinoma): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - July 2022
• Nivolumab (HER-2-neg gastric cancer, gastroesophageal junction cancer or oesophageal adenocarcinoma): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - March 2022
• Nivolumab (Second-line squamous cell oesophageal carcinoma): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - March 2022
• Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - November 2021
• Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - July 2021
• Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®- March 2021
• Nivolumab and Ipilimumab; Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL Opdivo®; Ipilimumab: Injection concentrate for I.V. infusion 50 mg in 10 mL Yervoy®- March 2021
• Nivolumab and Ipilimumab; Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL Opdivo®; Ipilimumab: Injection concentrate for I.V. infusion 50 mg in 10 mL Yervoy® - November 2020
• Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - November 2019
• Nivolumab and Ipilimumab: Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Ipilimumab: Injection concentrate for I.V. infusion 50 mg in 10 mL, Injection concentrate for I.V. infusion 200 mg in 40 mL; Opdivo® Yervoy® - November 2019
• Nivolumab And Ipilimumab: nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion, 100 mg in 10 mL; ipilimumab: Injection concentrate for I.V. infusion, 50 mg in 10 mL, Injection concentrate for I.V. infusion, 200 mg in 40 mL; Opdivo® and Yervoy® - November 2018
• Nivolumab and ipilimumab (malignant melanoma): Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL; Injection concentrate for I.V. infusion 100 mg in 10 mL; Ipilimumab: Injection concentrate for I.V. infusion 50 mg in 10 mL; Injection concentrate for I.V. infusion 200 mg in 40 mL; Opdivo® and Yervoy® - July 2018
• Nivolumab and ipilimumab (renal cell carcinoma): Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL; Injection concentrate for I.V. infusion 100 mg in 10 mL; Ipilimumab: Injection concentrate for I.V. infusion 50 mg in 10 mL; Injection concentrate for I.V. infusion 200 mg in 40 mL; Opdivo® and Yervoy® - July 2018
• Nivolumab (malignant melanoma): Injection concentrate for I.V. infusion 40 mg in 4 mL; Injection concentrate for I.V. infusion 100 mg in 10 ml; Opdivo® - July 2018
• Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL; Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - July 2019
• Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - March 2018
• Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - November 2017
• Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - March 2017
• Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL,  Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - March 2019
• Nivolumab (non-squamous NSCLC): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - November 2016
• Nivolumab (squamous NSCLC): Injection concentrate for I.V. infusion 40 mg in 4 mL , Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - November 2016
• Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - March 2017
• Nivolumab (RCC): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - November 2016
• Nivolumab: 40 mg in 4 mL (10mg/mL concentrate for IV infusion) 1 × 4 mL vial 100 mg/10 mL injection (10mg/mL concentrate for IV infusion) 1 × 10 mL vial, Opdivo® - July 2016
• Nivolumab: 40mg in 4ml (10mg/mL concentrate for IV infusion) 100mg in 10mL (10mg/mL concentrate for IV infusion), Opdivo® - March 2016
• Nivolumab: 40mg in 4ml (10mg/mL concentrate for IV infusion) 100mg in 10mL (10mg/mL concentrate for IV infusion), Opdivo® - March 2016
• Nivolumab and Ipilimumab: Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®. Ipilimumab: Injection concentrate for I.V. infusion 50 mg in 10 mL, Injection concentrate for I.V. infusion 200 mg in 40 mL; Yervoy® - March 2017
• Nivolumab, concentrate solution for infusion: 10 mg/mL, 1 x 4 mL vial, 10 mg/mL, 1 x 10 mL vial, Opdivo®, plus Ipilimumab, concentrate solution for infusion: 5 mg/mL, 1 x 40 mL vial, 5 mg/mL, 1 x 10 mL vial, Yervoy®, Bristol Myers Squibb - November 2015
• Nivolumab, concentrate solution for infusion, 10 mg/mL, 1 x 4 mL vial, 1 x 10 mL vial, Opdivo® - November 2015
• Nivolumab (Melanoma): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®  - March 2019
• Nivolumab, concentrate solution for infusion, 10 mg/mL, 1 x 4 mL vial, concentrate solution for infusion, 10 mg/mL, 1 x 10 mL vial, Opdivo® - July 2015
• November 2019 MSAC outcomes of relevance to PBAC
• Nurse Practitioners as secondary reviewers for ongoing treatment with opioid medications – December 2020
• Nusinersen: Solution for injection 12 mg in 5 mL; Spinraza® - July 2023
• Nusinersen: Solution for injection 12 mg in 5 mL; Spinraza® - March 2022
• Nusinersen: Solution for injection 12.6 mg in 5 mL; Spinraza® - July 2021
• Nusinersen: Solution for injection 12 mg in 5 mL: Spinraza® - November 2020
• Nusinersen: Solution for injection 12 mg in 5 mL; Spinraza® - July 2020
• Nusinersen: Solution for injection 12 mg in 5 mL; Spinraza® - November 2019
• Nusinersen: Solution for injection 12 mg in 5 mL; Spinraza® - July 2019
• Nusinersen: Solution for injection 12 mg in 5 mL; Spinraza® - July 2018
• Nusinersen: Solution for injection 12 mg in 5 mL; Spinraza® - March 2018
• Nusinersen: Solution for injection 12 mg in 5 mL; Spinraza® - November 2017
  Top of page

O

• Obeticholic acid: Tablet 5 mg, Tablet 10 mg; Ocaliva®- March 2021
• Obeticholic acid: Tablet 5 mg, Tablet 10 mg; Ocaliva® - November 2020
• Obeticholic Acid: Tablet 5 mg, Tablet 10 mg; Ocaliva® - July 2019
• Obeticholic Acid: Tablet 5 mg, Tablet 10 mg; Ocaliva® - November 2018
• Obinutuzumab: Solution for I.V. infusion 1000 mg in 40 mL; Gazyva® - July 2018
• Obinutuzumab: Solution for I.V. infusion, 1000 mg in 40 mL; GAZYVA® - March 2018
• Obinutuzumab: Solution for I.V. infusion 1000 mg in 40 mL; Gazyva® - November 2017
• Obinutuzumab: Solution for I.V. infusion 1000 mg in 40 mL; Gazyva® - November 2016
• Obinutuzumab; 1 g/40 mL injection, 40 mL vial; Gazyva® – March 2015
• Obinutuzumab, solution for IV infusion, 1000 mg/40 mL, Gazyva®, Roche Products Pty Ltd - July 2014

• Ocrelizumab: Solution concentrate for I.V. infusion 300 mg in 10 mL; Ocrevus® - July 2020

• Ocrelizumab: Solution concentrate for I.V. infusion 300 mg in 10 mL; Ocrevus® - November 2017
• Ocrelizumab: Solution concentrate for I.V. infusion 300 mg in 10 mL; Ocrevus® - July 2017
• Ocriplasmin: 0.5 mg/0.2 mL injection, 1 x 0.2 mL vial, Jetrea® - March 2016
• Ocriplasmin; 0.5 mg / 0.2 mL injection, 1 x 0.2 mL vial, Jetrea® - November 2014
• Ocriplasmin: Solution for intravitreal injection 0.375 mg in 0.3 mL; Jetrea® RTU - March 2019
• Octreotide: Injection (modified release) 30 mg (as acetate), vial and diluent syringe; Sandostatin® - July 2019
• Octreotide: Injection (modified release) 10 mg (as acetate); Vial and diluent syringe injection (modified release) 20 mg (as acetate); Vial and diluent syringeinjection (modified release) 30 mg (as acetate); Vial and diluent syringe; Sandostatin LAR® - July 2018
• Ocular lubricants - November 2014
• Ofatumumab: Injection 20 mg in 0.4 mL single use pre-filled pen; Kesimpta®- March 2021
• Ofatumumab; 100 mg/5 mL injection, 5 mL vial, 1 g/50 mL injection, 50 mL vial; Arzerra® - November 2014
• Olanzapine pamoate monohydrate, powder for injection with diluent vial, 210 mg, 300 mg and 405 mg, Zyprexa Relprevv®
• Olaparib: Tablet 100 mg, Tablet 150 mg; Lynparza® - March 2023
• Olaparib: Tablet 100 mg, Tablet 150 mg; Lynparza® - November 2022 - July 2023
• Olaparib: Tablet 100 mg, Tablet 150 mg; Lynparza® - July 2022
• Olaparib: Tablet 100 mg, Tablet 150 mg; Lynparza® - November 2021
• Olaparib: Tablet 150 mg, Tablet 100 mg; Lynparza®- March 2021
• Olaparib: Tablet 100 mg, Tablet 150 mg: Lynparza® - July 2020
• Olaparib: Capsule 50 mg, Tablet 100 mg, Tablet 150 mg; Lynparza® - March 2020
• Olaparib: Tablet 100 mg, Tablet 150 mg ; Lynparza® - November 2019
• Olaparib: Capsule 50mg; Lynparza® - November 2016
• Olaparib: 50 mg capsule, 4 x 112 capsules, Lynparza™ - July 2016
• Olaparib: 50 mg capsule, 4 x 112, Lynparza® - March 2016
• Olaparib: Tablet 150 mg, Tablet 100 mg; Lynparza™ - March 2018
• Olipudase alfa: Powder for I.V. infusion 20 mg; Xenpozyme® - July 2023
• Olmesartan medoxomil and amlodipine and hydrochlorothiazide 20/5/15.5 mg, 40/5/12.5 mg, 40/5/25 mg, 40/10/12.5 mg, 40/10/25 mg, Sevikar HCT® - July 2013
• Olmesartan medoxomil with hydrochlorothiazide, tablet, 20 mg-12.5 mg, 40 g 12.5 mg, 40 mg-25 mg, Olmetec Plus®, March 2007
• Olmesartan medoxomil, tablets, 10 mg, 20 mg, and 40 mg, Olmetec®, November 2005
• Olodaterol, 2.5 microgram/actuation inhalation: solution for, 60 actuations, Striverdi® Respimat® Boehringer Ingelheim Pty Ltd - July 2014
• Omalizumab : Injection 75 mg in 0.5 mL single dose pre-filled syringe, Injection 150 mg in 1 mL single dose pre-filled syringe; Xolair® - November 2021
• Omalizumab (rch), powder for injection, 150 mg, Xolair®, November 2009
• Omalizumab (rch), powder for injection, 150 mg, Xolair®, November 2010
• Omalizumab: Injection 150 mg in 1 mL; Xolair® - November 2016
• Omalizumab: 75 mg/0.5 mL injection, 1 × 0.5 mL syringe, 150 mg/mL injection, 1 × 1 mL syringe, Xolair® - July 2016
• Omalizumab: 75 mg/0.5 mL injection, 1 x 0.5 mL syringe; 150 mg/mL injection, 1 x 1 mL syringe, 1 pack, Xolair® - November 2015
• Omalizumab; 75 mg/0.5 mL injection, 1 x 0.5 mL syringe, 150 mg/mL injection, 1 x 1 mL syringe, 150 mg injection [1 x 150 mg vial] (&) inert substance diluent [1 x 1.2 mL ampoule], 1 pack; Xolair® - November 2014
• Omalizumab: prefilled syringe, 150 mg/mL; Xolair® - March 2018
• Omalizumab: pre-filled syringe, 150 mg/mL, Xolair® - November 2015
• Omega-3-acid ethyl esters 90, soft capsule, 1,000 mg, Omacor®, November 2010
• Onasemnogene abeparvovec: Solution for injection, customised based on patient weight; Zolgensma® - July 2023
• Onasemnogene Abeparvovec: Solution for injection, customised based on patient weight; Zolgensma® - November 2022
• Onasemnogene abeparvovec: Solution for injection, customised based on patient weight; Zolgensma® - September 2021
• Onasemnogene abeparvovec: Solution for injection, customised based on patient weight; Zolgensma® - May 2021
• Onasemnogene abeparvovec: Solution for injection, customised based on patient weight; Zolgensma® - November 2020
• Ondansetron: Wafer 4 mg, 8 mg; Tablet (as hydrochloride dehydrate) 4 mg, 8 mg; Tablet (orally disintegrating) 4 mg, 8 mg; various brands - March 2020
• Olmesartan Medoxomil with Amlodipine (as besylate), tablets, 20 mg-5 mg, 20 mg-10 mg, 40 mg-5 mg and 40 mg-10 mg, Sevikar® , July 2010
• Opicapone: Capsule 50 mg; Ongentys® - July 2021
• Oseltamivir, capsules 30 mg, 45 mg and 75 mg, powder for oral suspension, 12 mg per mL, Tamiflu® November 2008
• Osilodrostat: Tablet 1 mg, Tablet 5 mg, Tablet 10 mg; Isturisa® - March 2023
• Osimertinib: Tablet 40 mg, Tablet 80 mg; Tagrisso® - July 2020
• Osimertinib: Tablet 40 mg, Tablet 80 mg; Tagrisso® - July 2019
• Osimertinib: Tablet 40 mg, Tablet 80 mg; Tagrisso® - November 2018
• Osimertinib: Tablet 40 mg, Tablet 80 mg; Tagrisso® - November 2017
• Osimertinib: Tablet 40 mg, Tablet 80 mg; Tagrisso® - July 2018
• Oxybutynin, transdermal patches, 36 mg (releasing approximately 3.9 mg per 24 hours), 8, Oxytrol® , March 2009
• Oxybutynin, transdermal patches, 36mg (releasing approximately 3.9 mg per 24 hours), Oxytrol®, November 2008
• Oxybutynin, transdermal patches, 36mg (releasing approximately 3.9 mg per 24 hours), Oxytrol®, March 2008
• Oxycodone: Tablet containing oxycodone hydrochloride 10 mg (controlled release), Tablet containing oxycodone hydrochloride 15 mg (controlled release), Tablet containing oxycodone hydrochloride 20 mg (controlled release), Tablet containing oxycodone hydrochloride 30 mg (controlled release), Tablet containing oxycodone hydrochloride 40 mg (controlled release), Tablet containing oxycodone hydrochloride 80 mg (controlled release); OxyContin® - July 2019
• Oxycodone: Capsule containing oxycodone hydrochloride 5 mg; OxyNorm® - July 2019Oxycodone: Capsule containing oxycodone hydrochloride 5 mg; OxyNorm® - July 2019
• Oxycodone with naloxone: Tablet (controlled release) containing oxycodone (as hydrochloride) 80 mg with naloxone (as hydrochloride) 40 mg, Tablet (controlled release) containing oxycodone (as hydrochloride) 60 mg with naloxone (as hydrochloride) 30 mg; Targin® - November 2016
• Oxycodone hydrochloride + naloxone hydrochloride: modified release tablet, 2.5 mg/1.25 mg, 15 mg/7.5 mg , and 30 mg/15 mg,Targin® - November 2015
• Oxycodone and Naloxone; Targin® - July 2015
• Oxycodone hydrochloride + naloxone modified release tablet, 2.5 mg/1.25 mg, 15 mg/7.5 mg, and 30mg/15 mg; Targin® - March 2015
• Oxycodone Hydrochloride and Naloxone Hydrochloride Dihydrate, tablets, 5 mg-2.5 mg, 10 mg-5 mg, 20 mg-10 mg and 40 mg-20 mg (controlled release), Targin®, July 2010
• Oxycodone hydrochloride with naloxone hydrochloride dihydrate, controlled release tablet, 5 mg-2.5 mg, 10 mg-5 mg, 20 mg-10 mg and 40 mg-20 mg, Targin®, November 2010
• Oxycodone hydrochloride; modified release tablet, 5 mg; Oxycodone Sandoz® - March 2015
• Oxycodone; modified release tablets, 10mg, 15mg, 20mg, 30mg, 40mg, 80mg, OxyContin® - November 2014
• Ozanimod: Capsule 920 micrograms, Pack containing 4 capsules 230 micrograms and 3 capsules 460 micrograms: Zeposia® - November 2022
• Ozanimod: Capsule 920 micrograms, Pack containing 4 capsules 230 micrograms and 3 capsules 460 micrograms; Zeposia® - March 2022
• Ozanimod: Capsule 230 micrograms, 460 micrograms and 920 micrograms; Zeposia®
• Ozanimod: Capsule 230 micrograms, Capsule 460 micrograms, Capsule 920 micrograms; Zeposia® - September 2020
  Top of page

P

• Paclitaxel – Nanoparticle albumin bound (Nab-Paclitaxel): nanoparticle albumin bound 100 mg injection, 1 x 100 mg vial, Abraxane® - November 2015
• Paclitaxel-Nanoparticle Albumin Bound, 100 mg injection, 1 x 100 mg vial, 250 mg injection, 1 x 250 mg vial, Abraxane® - March 2014
• Paclitaxel, Nanoparticle Albumin-Bound:  Powder for I.V. injection containing 250 mg paclitaxel; Abraxane® - March 2019
• Paclitaxel, powder for I.V. infusion (suspension), 100 mg, Abraxane® November 2008
• Paclitaxel, solution concentrate for I.V. infusion, 30 mg in 5 mL, 100mg in 16.7 mL, 150 mg in 25 mL and 300 mg in 50 mL, Anzatax®, March 2006
• Palbociclib: Tablet 75 mg, Tablet 100 mg, Tablet 125 mg; Ibrance® - March 2022
• Palbociclib: Tablet 75 mg, Tablet 100 mg, Tablet 125 mg; Ibrance® - July 2021
• Palbociclib: Capsules, 75 mg, 100 mg, 125 mg; Ibrance® - March 2018
• Palbociclib: Capsule 75 mg, Capsule 100 mg, Capsule 125 mg; Ibrance® - March 2017
• Palbociclib: Capsule 75 mg, Capsule 100 mg, Capsule 125 mg; Ibrance® - November 2017 
• Paliperidone: I.M. injection (modified release) 700 mg (as palmitate) in pre-filled syringe, I.M. injection (modified release) 1000 mg (as palmitate) in pre-filled syringe; Invega Hafyera® - March 2022
• Paliperidone: I.M. injection (modified release) 175 mg (as palmitate) in pre-filled syringe, I.M. injection (modified release) 263 mg (as palmitate) in pre-filled syringe, I.M. injection (modified release) 350 mg (as palmitate) in pre-filled syringe, I.M. injection (modified release) 525 mg (as palmitate) in pre-filled syringe; Invega® Trinza™ - November 2016
• Paliperidone, prolonged release tablets, 3mg, 6 mg, 9 mg, 12 mg, Invega®, November 2007
• Paliperidone palmitate, aqueous suspension for injection, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg, pre-filled syringe, Invega® Sustenna™, November 2010
• Palliative Care Schedule Review
• Palonosetron Hydrochloride, solution for injection vial, 250 micrograms in 5 mL, Onicit® - March 2010
• Pancreatic extract: Capsule (containing enteric coated minimicrospheres) providing not less than 20,000 bp units of lipase activity, Capsule (containing enteric coated minimicrospheres) providing not less than 35,000 bp units of lipase activity; Creon® - November 2020
• Panitumumab; 100 mg/5 mL injection, 1 x 5 mL vial, 400 mg/20 mL injection, 1 x 20 mL vial; Vectibix® – March 2015
• Panitumumab, injection, 100 mg/5 mL and 400 mg/20 mL, Vectibix® - July 2014
• Panitumumab, 100 mg/5 ml and 400 mg/20 ml injection, Vectibix® - November 2013
• Panitumumab, concentrate solution for infusion, 100 mg in 5mL & 400 mg in 20 mL, Vectibix®, March 2013
• Panitumumab, concentrated solution for infusion, 20 mg per mL, 5 mL, Vectibix® November 2008

• Paracetamol: Suppositories 500 mg, 24; Panadol® - July 2020

• Paracetamol; tablet (modified release), 665 mg; Paracetamol Osteo- Tab® - November 2014
• Paricalcitol, capsule, 1 microgram and 2 micrograms, Zemplar® - March 2011
• Paricalcitol, injection, 2 micrograms in 1 mL and 5 micrograms in 1 mL; capsules, 1 microgram, 2 micrograms, Zemplar® , March 2009
• Paricalcitol, injection, 5 micrograms in 1 mL and 10 micrograms in 2ml; capsules, 1 microgram, 2 micrograms and 4 micrograms, Zemplar®, July 2007
• Paricalcitol, capsules, 1 microgram, 2 micrograms and 4 micrograms, Zemplar®, March 2008
• Paritaprevir with ritonavir with ombitasvir: Tablet containing 75 mg paritaprevir with 50 mg ritonavir with 12.5 mg ombitasvir; Technivie® - November 2016
• Paritaprevir with ritonavir, ombitasvir and dasabuvir; paritaprevir with ritonavir, ombitasvir, dasabuvir and ribavirin; VIEKIRA PAK®; VIEKIRA PAK-RBV® - July 2015
• Pasireotide: long-acting release intramuscular injection, 20mg, 40mg, 60mg, Signifor® long-acting release (LAR) - November 2015
• Patiromer: Sachet, 8.4 g powder for oral liquid, Sachet, 16.8 g powder for oral liquid; Veltassa® - March 2023
• Patiromer: Sachet, 8.4 g powder for oral liquid, Sachet, 16.8 g powder for oral liquid; Veltassa® - November 2022
• Patiromer: Sachet, 8.4 g powder for oral liquid; Sachet, 16.8 g powder for oral liquid; Veltassa® - November 2020
• Patiromer: Powder for oral liquid 8.4 g, Powder for oral liquid 16.8 g; Veltassa® - November 2019
• Patisiran: Solution concentrate for I.V. infusion 10 mg in 5 mL; Onpattro® - July 2023
• Pazopanib, tablets, 200 mg and 400 mg (as hydrochloride), Votrient® - July 2013
• Pazopanib, tablets, 200 mg and 400 mg (as hydrochloride), Votrient®, July 2010
• Pazopanib, tablets, 200 mg and 400 mg (as hydrochloride), Votrient® - November 2012
• Pazopanib, tablet, 200 mg and 400 mg (as hydrochloride), Votrient® - March 2012
• Pegcetacoplan: Solution for subcutaneous infusion 1,080 mg in 20 mL; Empaveli™ - July 2022
• Pegcetacoplan: Solution for subcutaneous infusion 1,080 mg in 20 mL; Empaveli™ - March 2022
• Pegfilgrastim: Injection 6 mg in 0.6 ml single use pre-filled syringe; Pelgraz® - March 2020
• Pegfilgrastim: Injection 6 mg in 0.6 mL single use pre-filled syringe; Ziextenzo® - November 2019
• Pegfilgrastim: Injection 6 mg in 0.6 mL, single use pre-filled syringe; Neulasta® - March 2018
• Pegfilgrastim: Injection 6 mg in 0.6 ml single use pre-filled syringe; Fulphila® - July 2018
• Pegfilgrastim: Injection 6 mg in 0.6 mL single use pre-filled syringe; Neulasta®, Ristempa® - July 2017
• Pegfilgrastim, injection, 6 mg in 0.6 mL single use pre-filled syringe, Neulasta®, November 2008
• Pegfilgrastim, single dose pre-filled syringe, 6 mg in 0.6 mL, Neulasta®, March 2008
• Pegfilgrastim, injection, 6 mg in 0.6 mL single use pre-filled syringe, Neulasta®, July 2007
• Pegfilgrastrim, injection 6 mg in 0.6 mL single use prefilled syringe and injection 6 mg in 0.6 mL single use prefilled pen, Neulasta® and Neulasta Sureclick®November 2006
• Peginterferon alfa-2a, injection, single use pre-filled syringe, 135 micrograms and 180 micrograms, Pegasys®, November 2005
• Peginterferon alfa-2A: Injection 135 micrograms in 0.5 mL single use pre filled syringe, Injection 180 micrograms in 0.5 mL single use pre-filled syringe; Pegasys® - November 2017 
• Peginterferon alfa-2b, Single use injection pens containing powder for injection in vials of 50, 80, 100, 120 and 150 micrograms and Ribavirin capsules 200 mg, (all pack sizes), Pegatron®, and peginterferon alfa-2b, single use injection pens containing powder for injection in vials of 50, 80, 100, 120 and 150 micrograms, PEG-Intron Redipen®, November 2005
• Peginterferon beta-1a; 63 microgram/0.5 ml injection, 0.5 ml syringe + 94 microgram/0.5 ml injection, 0.5 ml syringe, 63 microgram/0.5 ml injection, 0.5 ml injection device + 94 microgram/0.5 ml injection, 0.5 ml injection device, 125 microgram/0.5 ml injection, 2 x 0.5 ml syringes, 125 microgram/0.5 ml injection, 2 x 0.5 ml injection devices; Plegridy® - November 2014
• Pegvaliase: Solution for injection 2.5 mg in 0.5 mL, Solution for injection 10 mg in 0.5 mL, Solution for injection 20 mg in 1 mL; Palynziq® - July 2022
• Pegvisomant: Powder for injection 10 mg, Powder for injection 15 mg, Powder for injection 20 mg; Somavert® - November 2016
• Pegvisomant: Injection set containing powder for injection 10 mg, 30 and diluent, 30, Injection set containing powder for injection 15 mg, 30 and diluent, 30, Injection set containing powder for injection 20 mg, 30 and diluent, 30, Injection set containing powder for injection 20 mg, 1 and diluent, 1; Somavert® - March 2019
• Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
• Pembrolizumab(early breast cancer): Solution concentrate for I.V. infusion 100 mg in 4 mL vial; Keytruda® - March 2023
• Pembrolizumab (metastatic breast cancer): Solution concentrate for I.V. infusion 100 mg in 4 mL vial; Keytruda® - March 2023
• Pembrolizumab (urothelial carcinoma): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - November 2022
• Pembrolizumab (cervical cancer): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - November 2022
• Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - July 2022
• Pembrolizumab (Renal cell carcinoma): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - March 2022
• Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® – May 2022
• Pembrolizumab (Oesophageal carcinoma or HER-2-neg gastroesophageal junction adenocarcinoma): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - March 2022
• Pembrolizumab (Endometrial cancer): Solution concentrate for I.V. infusion 100 mg in 4 mL vial; Keytruda®- March 2022- March 2023
• Pembrolizumab (SCCHN): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - March 2022
• Pembrolizumab (OAC): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - November 2021
• Pembrolizumab (SCCHN): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - November 2021
• Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®- March 2021
• Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - November 2020
• Pembrolizumab (melanoma, NSCLC): Solution concentrate for I.V. infusion 100 mg in 4 ml; Keytruda® - March 2020
• Pembrolizumab (melanoma): Solution concentrate for I.V. infusion 100 mg in 4 ml; Keytruda® - March 2020
• Pembrolizumab (melanoma resubmission): Solution concentrate for I.V. infusion 100 mg in 4 ml; Keytruda® - March 2020
• Pembrolizumab (PMBCL): Solution concentrate for I.V. infusion 100 mg in 4 ml; Keytruda® - March 2020
• Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - November 2019
• Pembrolizumab (NSCLC): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - July 2019
• Pembrolizumab (Melanoma): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - July 2019
• Pembrolizumab: Powder for injection 50 mg, Solution concentrate for I.V. infusion, 100 mg in 4 mL; Keytruda® - November 2018
• Pembrolizumab: Powder for injection 50 mg, Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®- March 2019
• Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; keytruda® - March 2019
• Pembrolizumab (melanoma): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - November 2018
• Pembrolizumab (melanoma): Powder for injection 50 mg, solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - March 2018
• Pembrolizumab (melanoma): Powder for injection 50 mg; Keytruda® - November 2016
• Pembrolizumab (NSCLC): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - November 2018
• Pembrolizumab (NSCLC): Powder for injection 50 mg; Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - July 2018
• Pembrolizumab (NSCLC): Powder for injection 50 mg, solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - March 2018
• Pembrolizumab (NSCLC): Powder for injection 50 mg , Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - November 2017
• Pembrolizumab (NSCLC): Powder for injection 50 mg; Keytruda® - November 2016
• Pembrolizumab (PMBCL): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - November 2018
• Pembrolizumab (rrcHL), powder for I.V. infusion, 50 mg and 100 mg vials, Keytruda® - August 2017
• Pembrolizumab (SCCHN): Solution concentrate for I.V. infusion 100 mg in 4 ml; Keytruda® - July 2018
• Pembrolizumab (urothelial cancer): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - July 2018
• Pembrolizumab: Powder for injection 50 mg, Solution for I.V. infusion 100 mg in 4 mL; Keytruda® - July 2017
• Pembrolizumab: Injection concentrate for I.V. infusion 100 mg in 4 mL, Powder for injection 50 mg; Keytruda® - March 2017
• Pembrolizumab (urothelial cancer): Powder for injection 50 mg, Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® - November 2017
• Pembrolizumab (additional strength): Solution for infusion 100 mg; Keytruda® - November 2016
• Pembrolizumab: 50mg injection: powder for, 1 vial, Keytruda® - March 2016
• Pembrolizumab; 50 mg injection: powder for, 1 vial, 100 mg injection: powder for, 1 vial; Keytruda® – March 2015
• Pemetrexed: Solution concentrate for I.V. infusion 100 mg in 4 mL vial, Solution concentrate for I.V. infusion 500 mg in 20 mL vial, Solution concentrate for I.V. infusion 1000 mg in 40 mL vial; Pemetrexed EVER Pharma – March 2023
• Pemetrexed: 1000 mg powder for I.V. infusion, Pemetrexed MYX™ - March 2016
• Pemetrexed: 1000 mg powder for injection, DBL Pemetrexed™ - March 2016
• Pemetrexed Disodium, powder for I.V. infusion, 100 mg (base) and 500 mg (base), Alimta® March 2010
• Pemetrexed, powder for I.V. infusion, 100 mg and 500 mg (base), Alimta® , March 2009
• Pemetrexed disodium, powder for I.V. infusion, 100 mg and 500 mg (base), Alimta®, November 2009
• Pemetrexed disodium, injection, 500 mg, Alimta®, November 2007
• Pemetrexed disodium, powder for IV infusion (base), 500 mg, Alimta® , November 2005
• Perampanel: Tablets (as hemisesquihydrate); 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg Fycompa® - July 2017
• Perampanel: 2 mg tablet, 7, 4 mg tablet, 28, 6 mg tablet, 28, 8 mg tablet, 28, 10 mg tablet, 28, 12 mg tablet, 28, Fycompa® - July 2016
• Perampanel, tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg, Fycompa® - July 2014
• Perfluorohexyloctane: Eye drops containing perfluorohexyloctane 1 mL per mL, 3 mL; NovaTears® - March 2018
• Perindopril Arginine with Amlodipine Besylate, tablet, 5 mg-5 mg, 5 mg-10 mg, 10 mg-5 mg and 10 mg-10 mg, Coveram® - March 2010
• Pertussis vaccine-acellular combined with diphtheria and tetanus toxoids (Adsorbed), 0.5 mL, Adacel® - November 2011
• Pertussis vaccine acellular with Diphtheria and Tetanus Toxoids, adsorbed, injection, 0.5 mL, Adacel®, March 2006
• Pertussis vaccine-acellular, combined with diptheria and tetanus toxoids; 0.5 ml vial, 1; Tripacel® - July 2015
• Pertuzumab: Solution for I.V. infusion 420 mg in 14 ml; Perjeta® - March 2020
• Pertuzumab, 420 mg/14 mL injection, 1 x 14 mL vial, Perjeta®, Roche Products Pty Ltd - March 2014
• Pertuzumab: Solution for I.V. infusion 420 mg in 14 ml; Perjeta® - July 2018
• Pertuzumab: Solution for I.V. infusion 420 mg in 14 mL; Perjeta® - March 2019
• Pertuzumab; 420 mg/14 mL injection, 1 x 14 mL vial; Perjeta®; Trastuzumab; 150 mg injection, 1 x 150 mg vial, 60 mg injection, 1 x 60 mg vial; Herceptin®; Trastuzumab emtansine; 100 mg injection, 1 x 100 mg vial, 160 mg injection, 1 x 160 mg vial; Kadcyla® - November 2014
• Pimecrolimus, cream, 1%, 15 g, Elidel®, July 2006Pioglitazone hydrochloride, tablet, 15 mg, 30 mg and 45 mg, Actos®, November 2007
• Pirfenidone : Capsule 267 mg; Esbriet® - November 2016
• Pirfenidone: 267 mg capsules, 270, Esbriet® - March 2016
• Pirfenidone: 267 mg capsule, 270, Esbriet® - November 2015
• Pirfenidone: Tablet 267 mg, 90, Tablet 801 mg, 90; Esbriet® - March 2018
• Plerixafor 24 mg/1.2 mL, injection, subcutaneous infusion, 1.2 mL vialMozobil® - November 2013
• Plerixafor, solution for injection, 20 mg in 1 mL, 1.2 mL, Mozobil® - July 2012
• Plerixafor, solution for injection, 20 mg in 1 mL, 1.2 mL, Mozobil® - November 2011
• Plerixafor, solution for subcutaneous injection, 20 mg per mL, 1.2 mL, Mozobil®, November 2010
• Plitidepsin: Powder for I.V infusion 2 mg with 4 ml solvent; Aplidin® - March 2020
• Plitidepsin: Powder for I.V. infusion 2 mg with 4 mL solvent; Aplidin® - July 2019
• Pneumococcal conjugate vaccine, 15 valent adsorbed: 0.5 mL pre-filled syringe; Vaxneuvance® - March 2023
• Pneumococcal Polysaccharide Conjugate Vaccine, 20-Valent Adsorbed: 0.5 mL pre-filled syringe; Prevenar 20® - November 2022
• Pneumococcal Polysaccharide Conjugate Vaccine, 15 Valent Adsorbed: 0.5 mL in pre-filled syringe; Trade name TBC - November 2021
• Pneumococcal conjugate vaccine: 13-Valent Adsorbed Pre-Filled Syringe, 0.5 mL, Prevenar 13® - July 2016
• Pneumococcal conjugate vaccine (13-valent); 0.5 mL injection; Prevenar 13® - July 2015
• Pneumococcal Polysaccharide Conjugate Vaccine, 13-Valent Adsorbed: Injection 0.5 mL in pre-filled syringe; Prevenar-13® - November 2018
• Pneumococcal polysaccharide conjugate 13-valent adsorbed vaccine: Pre-filled syringe, 0.5 mL; Prevenar 13® - March 2018
• Pneumoccal polysaccharide conjugate vaccine (13-valent), 0.5 mL injection; Prevenar 13® - March 2015
• Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent adsorbed, injection, 0.5 mL, pre-filled syringe, Prevenar-13® July 2010
• Pneumococcal polysaccharide conjugate vaccine, turbid liquid suspension for injection (0.5 mL) in pre-filled syringe or vial, Synflorix®, July 2009
• Pneumococcal polysaccharide conjugate vaccine, 13-valent adsorbed, pre-filled syringe, 0.5 mL, Prevenar 13®, November 2010
• Polyethylene glycol 400 with propylene glycol: Eye drops 4 mg-3 mg per mL, 15 mL; Optix® - July 2022
• Polyethylene glycol 400 with propylene glycol: Eye drops 4mg-3mg per mL, single dose units 0.8 mL, 30; Systane® - November 2021
• Poly-l-lactic acid, powder for injection, 150 mg, Sculptra®, March 2009
• Poly-l-lactic acid, powder for intradermal injection, 150 mg, Sculptra®, November 2008
• Polatuzumab Vedotin: Powder for I.V. infusion 30 mg, Powder for I.V. infusion 140 mg; Polivy® - November 2022
• Polatuzumab vedotin: Powder for I.V. infusion 140 mg; Polivy® - November 2019
• Pomalidomide: Capsule 1 mg, Capsule 2 mg; PomolideTM - July 2023
• Pomalidomide: Capsule 3 mg, Capsule 4 mg; Pomalyst® - November 2019
• Pomalidomide: Capsule 3 mg, Capsule 4 mg; Pomalyst® - July 2019
• Pomalidomide: Capsule 3 mg, Capsule 4 mg; Pomalyst® - November 2017 
• Pomalidomide: Capsule 3 mg, Capsule 4 mg; Pomalyst® - March 2017
• Pomalidomide: 3 mg capsule, 214 mg capsule, 21, Pomalyst® - March 2016
• Pomalidomide,capsules, 3 mg and 4 mg, Pomalyst®, Celgene Pty Ltd - July 2014
• Pomalidomide; capsules, 3 mg and 4 mg; Pomalyst® - November 2014
• Ponatinib: Tablet 15 mg (as hydrochloride), Tablet 45 mg (as hydrochloride); Iclusig® - November 2018
• Ponatinib: Tablet 15 mg (as hydrochloride), Tablet 45 mg (as hydrochloride); Iclusig® - November 2017 
• Ponatinib; 15 mg tablet, 60; 45 mg tablet, 30; Iclusig® - July 2015
• Ponatinib; tablets; 15 mg and 45 mg; Iclusig® - November 2014
• Posaconazole; 100 mg modified release tablet; Noxafil® – March 2015
• Posaconazole, oral suspension, 40 mg per mL, 105 mL, Noxafil®, March 2008
• Posaconazole, oral suspension, 40 mg per mL, 105 mL, Noxafil®, July 2006
• Pralatrexate: Solution for I.V. infusion 20 mg in 1mL; Folotyn® - July 2017
• Pralatrexate: Solution for I.V. infusion 20 mg in 1 mL; Folotyn® - November 2017 
• Pralatrexate: 20 mg/mL injection, 1 mL vial, Folotyn® - March 2016
• Pralatrexate: solution for infusion, 1 mL vial, 20 mg, Folotyn® - November 2015
• Pramipexole hydrochloride, tablets, 125 micrograms, 250 micrograms, 1mg, Sifrol®
• Pramipexole hydrochloride, tablets, 125 micrograms, 250 micrograms, 1mg, Sifrol®, July 2009
• Pramipexole hydrochloride, tablet, 125 micrograms and 250 micrograms, Sifrol®, November 2008
• Pramipexole hydrochloride, tablet, 125 micrograms, 250 micrograms and 1 mg, Sifrol®, July 2008
• Pramipexole hydrochloride, tablet, 125 micrograms and 250 micrograms, Sifrol®, July 2007
• Pramipexole hydrochloride, tablet, 125 micrograms and 250 micrograms, Sifrol® November 2006
• Prasugrel hydrochloride, tablets, 5 mg (base) and 10 mg (base), Effient®, July 2009
• Prednisolone with Phenylephrine: Eye drops containing prednisolone acetate 10 mg with phenylephrine hydrochloride 1.2 mg per mL, 10 mL; Prednefrin® Forte - November 2019
• Pregabalin: Oral solution 20 mg per mL, 473 mL; Pregabalin AFT® - May 2022
• Pregabalin: Tablet 82.5 mg, Tablet 165 mg, Tablet 330 mg; Lyrica® CR – May 2022
• Pregabalin: Oral solution 20 mg per mL, 473 mL; Pregabalin-AFT® - November 2021
• Pregabalin: Tablet 82.5 mg, Tablet 165 mg, Tablet 330 mg; Lyrica CR® - November 2021
• Pregabalin, capsules, 25 mg, 75 mg, 150 mg and 300 mg, Lyrica® - March 2012
• Pregabalin, capsule, 25 mg, 75 mg, 150 mg and 300 mg, Lyrica®, March 2011
• Primidone: Tablet 250 mg; APO Primidone® - November 2019
• Progesterone: Pessary 400 mg; Cyclogest® - July 2022
• Progesterone: Pessary 200 mg; Oripro® - November 2021
• Progesterone: Pessary 200 mg; Oripro® - November 2020
• Progesterone, pessary, 100 mg, Endometrin® - March 2014
• Progesterone: Capsule 200 mg; Utrogestan® - November 2020
• Progesterone: 200 mg capsule, 42, Utrogestan® - July 2016
• Progesterone: 200 mg capsule, 42, Utrogestan® - March 2016
• Propranolol: Oral liquid 3.75 mg per mL, 120 mL; Hemangiol® - July 2017
• Propranolol: oral liquid, 3.75 mg/mL, 120 mL x 2, Hemangiol® - November 2015
• Propanolol; 3.75 mg/mL oral liquid,2 x 120 mL; Hemangiol® – March 2015

• Protein formula  with vitamins and minerals, low in potassium, phosphorus, calcium, chloride and vitamin A: Oral liquid 125 mL, 24; Renastep® - July 2020

• Protein formula with carbohydrate, fat, vitamins, minerals and transforming growth factor beta-2: Powder for oral liquid, 400 g, 12; Modulen® IBD - March 2020
• Protein formula with vitamins and minerals, and low in potassium, phosphorus, calcium, chloride and vitamin A: Oral liquid 125 mL, 24; Renastep® - November 2019
• Protein formula with carbohydrate, fat, fibre, vitamins and minerals: 8 x 500 mL, Nutrini Low Energy Multi Fibre® - November 2015
• Protein hydrosylate formula with medium chain triglycerides: Oral powder 450 g (Aptamil Gold + Pepti-Junior); Aptamil Gold + Pepti-Junior® - March 2018
• Prucalopride, tablets, 1 mg and 2 mg (as succinate), Resotrans® - July 20